

WEBVTT

NOTE duration:"01:15:58"

NOTE recognizability:0.815

NOTE language:en-us

NOTE Confidence: 0.75584751375

00:00:00.000 --> 00:00:02.510 For joining this is Yale.

NOTE Confidence: 0.75584751375

00:00:02.510 --> 00:00:05.241 Highlights of ASH 2021 presented by

NOTE Confidence: 0.75584751375

00:00:05.241 --> 00:00:07.276 Yale Hematology and today's seminar

NOTE Confidence: 0.75584751375

00:00:07.276 --> 00:00:09.526 is presented by the program for

NOTE Confidence: 0.75584751375

00:00:09.526 --> 00:00:10.898 multiple myeloma and Gammopathy's,

NOTE Confidence: 0.75584751375

00:00:10.898 --> 00:00:12.926 and we have really fantastic set

NOTE Confidence: 0.75584751375

00:00:12.926 --> 00:00:14.505 of speaker presentations. Today.

NOTE Confidence: 0.75584751375

00:00:14.505 --> 00:00:17.895 Our program presented by Doctor Gore,

NOTE Confidence: 0.75584751375

00:00:17.900 --> 00:00:20.120 Shine our expert clinical expert

NOTE Confidence: 0.75584751375

00:00:20.120 --> 00:00:22.340 in hematology doctor Terry Parker,

NOTE Confidence: 0.75584751375

00:00:22.340 --> 00:00:24.626 who's the clinical leader of our

NOTE Confidence: 0.75584751375

00:00:24.626 --> 00:00:26.150 program with extensive experience

NOTE Confidence: 0.75584751375

00:00:26.213 --> 00:00:28.118 and expertise in clinical trials.

NOTE Confidence: 0.75584751375

00:00:28.120 --> 00:00:29.404 Doctor no far bar.  
NOTE Confidence: 0.75584751375

00:00:29.404 --> 00:00:31.009 Who's our expert in cellular?  
NOTE Confidence: 0.75584751375

00:00:31.010 --> 00:00:32.906 Therapies and transplantation in  
NOTE Confidence: 0.75584751375

00:00:32.906 --> 00:00:35.276 myeloma and doctor Sabrina Browning,  
NOTE Confidence: 0.75584751375

00:00:35.280 --> 00:00:37.485 who has expertise in preclinical  
NOTE Confidence: 0.75584751375

00:00:37.485 --> 00:00:39.249 studies and alloyed doses.  
NOTE Confidence: 0.75584751375

00:00:39.250 --> 00:00:41.679 And I just like to share this  
NOTE Confidence: 0.75584751375

00:00:41.679 --> 00:00:43.350 structure of today's seminar.  
NOTE Confidence: 0.75584751375

00:00:43.350 --> 00:00:45.865 First, Doctor Gore Shine will present  
NOTE Confidence: 0.75584751375

00:00:45.865 --> 00:00:47.445 updates in smoldering multiple  
NOTE Confidence: 0.75584751375

00:00:47.445 --> 00:00:49.870 myeloma and newly diagnosed myeloma.  
NOTE Confidence: 0.75584751375

00:00:49.870 --> 00:00:51.940 This will be followed by Doctor  
NOTE Confidence: 0.75584751375

00:00:51.940 --> 00:00:53.800 Terry Parker with updates in  
NOTE Confidence: 0.75584751375

00:00:53.800 --> 00:00:55.448 relapse and refractory myeloma.  
NOTE Confidence: 0.75584751375

00:00:55.450 --> 00:00:55.858 Later,  
NOTE Confidence: 0.75584751375

00:00:55.858 --> 00:00:58.306 Doctor Barr will present updates on

NOTE Confidence: 0.75584751375  
00:00:58.306 --> 00:01:00.688 cellular therapies in myeloma and.  
NOTE Confidence: 0.75584751375  
00:01:00.688 --> 00:01:03.078 Some followed by Doctor Browning,  
NOTE Confidence: 0.75584751375  
00:01:03.080 --> 00:01:04.720 who will present updates on  
NOTE Confidence: 0.75584751375  
00:01:04.720 --> 00:01:06.825 basic signs in myeloma and some  
NOTE Confidence: 0.75584751375  
00:01:06.825 --> 00:01:08.845 clinical updates on AL Amyloidosis,  
NOTE Confidence: 0.75584751375  
00:01:08.850 --> 00:01:10.274 and we will devote.  
NOTE Confidence: 0.75584751375  
00:01:10.274 --> 00:01:13.326 Devote a few minutes in the end for the  
NOTE Confidence: 0.75584751375  
00:01:13.326 --> 00:01:15.294 question and answer and discussion session.  
NOTE Confidence: 0.75584751375  
00:01:15.300 --> 00:01:16.110 So again,  
NOTE Confidence: 0.75584751375  
00:01:16.110 --> 00:01:16.920 welcome everyone.  
NOTE Confidence: 0.75584751375  
00:01:16.920 --> 00:01:18.945 Thank you all for joining  
NOTE Confidence: 0.75584751375  
00:01:18.945 --> 00:01:20.710 and Doctor Gore Shine.  
NOTE Confidence: 0.75584751375  
00:01:20.710 --> 00:01:21.838 Please you may proceed.  
NOTE Confidence: 0.830706213846154  
00:01:55.340 --> 00:01:57.860 We can see our slides if you just can  
NOTE Confidence: 0.830706213846154  
00:01:57.860 --> 00:02:00.610 project in the slide view. On the bottom  
NOTE Confidence: 0.898583405

00:02:01.580 --> 00:02:03.615 there you go, got it OK, perfect.  
NOTE Confidence: 0.898583405

00:02:03.615 --> 00:02:08.330 Can you hear me now? Yes, OK alright,  
NOTE Confidence: 0.898583405

00:02:08.330 --> 00:02:09.890 so thank you Talia hello everyone.  
NOTE Confidence: 0.898583405

00:02:09.890 --> 00:02:12.854 So as Natalia mentioned, I'm going  
NOTE Confidence: 0.898583405

00:02:12.854 --> 00:02:16.520 to rehash ash from a perspective of.  
NOTE Confidence: 0.898583405

00:02:16.520 --> 00:02:18.495 Updates on smaller multiple myeloma  
NOTE Confidence: 0.898583405

00:02:18.495 --> 00:02:20.470 and newly diagnosed multiple myeloma.  
NOTE Confidence: 0.9265111125

00:02:23.680 --> 00:02:25.460 Here are my disclosures.  
NOTE Confidence: 0.861213724

00:02:29.860 --> 00:02:32.265 Alright, so multiple myeloma is  
NOTE Confidence: 0.861213724

00:02:32.265 --> 00:02:34.189 consistently preceded by precursor  
NOTE Confidence: 0.861213724

00:02:34.189 --> 00:02:36.445 states of monoclonal gammopathy  
NOTE Confidence: 0.861213724

00:02:36.445 --> 00:02:38.146 of undetermined significance  
NOTE Confidence: 0.861213724

00:02:38.146 --> 00:02:40.414 and smoldering multiple myeloma.  
NOTE Confidence: 0.861213724

00:02:40.420 --> 00:02:43.210 And these essentially represent a continuum  
NOTE Confidence: 0.861213724

00:02:43.210 --> 00:02:46.079 of progression of the tumor burden,  
NOTE Confidence: 0.861213724

00:02:46.080 --> 00:02:50.230 with clonal evolution and heterogeneity.

NOTE Confidence: 0.861213724

00:02:50.230 --> 00:02:52.730 Now we understand the heterogeneity

NOTE Confidence: 0.861213724

00:02:52.730 --> 00:02:54.730 of smoldering multiple myeloma.

NOTE Confidence: 0.861213724

00:02:54.730 --> 00:02:56.260 In clinical practice,

NOTE Confidence: 0.861213724

00:02:56.260 --> 00:03:01.430 we often rely and apply on the 20 to 20 rule,

NOTE Confidence: 0.861213724

00:03:01.430 --> 00:03:04.160 which is 20% bone marrow plasma cells,

NOTE Confidence: 0.861213724

00:03:04.160 --> 00:03:05.702 a monoclonal protein of greater than

NOTE Confidence: 0.861213724

00:03:05.702 --> 00:03:07.808 or equal to 2 grams per deciliter,

NOTE Confidence: 0.861213724

00:03:07.810 --> 00:03:10.074 and a free light chain ratio of greater

NOTE Confidence: 0.861213724

00:03:10.074 --> 00:03:12.824 than 20 patients with two or more of

NOTE Confidence: 0.861213724

00:03:12.824 --> 00:03:15.518 these risk factors or components are

NOTE Confidence: 0.861213724

00:03:15.518 --> 00:03:17.846 essentially considered high risk,

NOTE Confidence: 0.861213724

00:03:17.850 --> 00:03:20.778 and this subset of patient population.

NOTE Confidence: 0.861213724

00:03:20.780 --> 00:03:24.420 Has been evaluated for early

NOTE Confidence: 0.861213724

00:03:24.420 --> 00:03:25.876 therapeutic intervention.

NOTE Confidence: 0.861213724

00:03:25.880 --> 00:03:27.835 Now, with respect to early

NOTE Confidence: 0.861213724

00:03:27.835 --> 00:03:28.617 therapeutic intervention,  
NOTE Confidence: 0.861213724

00:03:28.620 --> 00:03:34.044 we know that Lenalidomide can be  
NOTE Confidence: 0.861213724

00:03:34.044 --> 00:03:36.370 beneficial for patients with high risk,  
NOTE Confidence: 0.861213724

00:03:36.370 --> 00:03:37.462 smoldering myeloma.  
NOTE Confidence: 0.861213724

00:03:37.462 --> 00:03:40.738 So the rationale here is that  
NOTE Confidence: 0.861213724

00:03:40.738 --> 00:03:43.771 triplet therapy which we use for  
NOTE Confidence: 0.861213724

00:03:43.771 --> 00:03:46.496 multiple myeloma may yield a deeper  
NOTE Confidence: 0.861213724

00:03:46.496 --> 00:03:48.292 responses and improved outcomes  
NOTE Confidence: 0.861213724

00:03:48.292 --> 00:03:50.980 for the smoldering population,  
NOTE Confidence: 0.861213724

00:03:50.980 --> 00:03:52.768 and I'm just going to highlight  
NOTE Confidence: 0.861213724

00:03:52.768 --> 00:03:54.618 one study on the combination of  
NOTE Confidence: 0.861213724

00:03:54.618 --> 00:03:57.310 X as a proteasome inhibitor.  
NOTE Confidence: 0.861213724

00:03:57.310 --> 00:03:59.410 Lenalidomide and immunomodulator.  
NOTE Confidence: 0.861213724

00:03:59.410 --> 00:04:01.370 Agent and dexamethasone in high  
NOTE Confidence: 0.861213724

00:04:01.370 --> 00:04:02.938 risk smoldering multiple myeloma.  
NOTE Confidence: 0.812214176666667

00:04:05.000 --> 00:04:06.398 Now, in the interest of time,

NOTE Confidence: 0.812214176666667  
00:04:06.400 --> 00:04:08.940 I'm going to essentially only  
NOTE Confidence: 0.812214176666667  
00:04:08.940 --> 00:04:10.972 discuss the conclusion slide,  
NOTE Confidence: 0.812214176666667  
00:04:10.980 --> 00:04:14.065 but this triple therapy regimen  
NOTE Confidence: 0.812214176666667  
00:04:14.065 --> 00:04:17.150 in high risk smoldering disease,  
NOTE Confidence: 0.812214176666667  
00:04:17.150 --> 00:04:19.135 and all oral regimen demonstrated  
NOTE Confidence: 0.812214176666667  
00:04:19.135 --> 00:04:21.461 a very high overall response rate  
NOTE Confidence: 0.812214176666667  
00:04:21.461 --> 00:04:23.419 of more than 90% with deep response  
NOTE Confidence: 0.812214176666667  
00:04:23.419 --> 00:04:25.177 rates of greater than I'm sorry,  
NOTE Confidence: 0.812214176666667  
00:04:25.180 --> 00:04:28.312 deep remission rates of greater than  
NOTE Confidence: 0.812214176666667  
00:04:28.312 --> 00:04:30.910 40% now there were notable Grade  
NOTE Confidence: 0.812214176666667  
00:04:30.910 --> 00:04:32.980 3 toxicities for these patients,  
NOTE Confidence: 0.812214176666667  
00:04:32.980 --> 00:04:34.172 but importantly.  
NOTE Confidence: 0.812214176666667  
00:04:34.172 --> 00:04:36.556 No patients discontinued therapy  
NOTE Confidence: 0.812214176666667  
00:04:36.556 --> 00:04:39.630 due to these adverse events,  
NOTE Confidence: 0.812214176666667  
00:04:39.630 --> 00:04:43.056 so so this is encouraging data.  
NOTE Confidence: 0.812214176666667

00:04:43.060 --> 00:04:43.966 You know,  
NOTE Confidence: 0.812214176666667

00:04:43.966 --> 00:04:45.778 suggesting they potentially more  
NOTE Confidence: 0.812214176666667

00:04:45.778 --> 00:04:47.590 biologically sensitive phase of  
NOTE Confidence: 0.812214176666667

00:04:47.660 --> 00:04:49.620 the disease to treatment and  
NOTE Confidence: 0.812214176666667

00:04:49.620 --> 00:04:51.188 really highlighting an ongoing  
NOTE Confidence: 0.812214176666667

00:04:51.188 --> 00:04:53.752 area of research in the smoldering  
NOTE Confidence: 0.812214176666667

00:04:53.752 --> 00:04:55.015 multiple myeloma disease.  
NOTE Confidence: 0.674787556

00:04:57.770 --> 00:05:01.780 Now a couple words on multiple myeloma,  
NOTE Confidence: 0.674787556

00:05:01.780 --> 00:05:04.540 so we're going to transition out to multiple  
NOTE Confidence: 0.674787556

00:05:04.599 --> 00:05:06.659 myeloma symptomatic multiple myeloma.  
NOTE Confidence: 0.674787556

00:05:06.660 --> 00:05:08.785 We're all familiar with VRD  
NOTE Confidence: 0.674787556

00:05:08.785 --> 00:05:10.910 as our backbone to therapy.  
NOTE Confidence: 0.674787556

00:05:10.910 --> 00:05:12.160 Bortezomib, Lenalidomide,  
NOTE Confidence: 0.674787556

00:05:12.160 --> 00:05:14.035 and dexamethasone proteasome  
NOTE Confidence: 0.674787556

00:05:14.035 --> 00:05:16.450 inhibitor imid, and steroid.  
NOTE Confidence: 0.674787556

00:05:16.450 --> 00:05:20.222 This is a very efficacious treatment regimen.



NOTE Confidence: 0.674787556

00:05:20.222 --> 00:05:21.094 Very durable,

NOTE Confidence: 0.674787556

00:05:21.094 --> 00:05:23.710 has a well established track record.

NOTE Confidence: 0.674787556

00:05:23.710 --> 00:05:24.208 Historically,

NOTE Confidence: 0.674787556

00:05:24.208 --> 00:05:27.196 neurotoxicity was a major concern here.

NOTE Confidence: 0.674787556

00:05:27.200 --> 00:05:29.330 But this has become significantly

NOTE Confidence: 0.674787556

00:05:29.330 --> 00:05:31.460 significantly less of an issue

NOTE Confidence: 0.674787556

00:05:31.533 --> 00:05:33.398 with the once weekly dosing,

NOTE Confidence: 0.674787556

00:05:33.400 --> 00:05:35.440 as opposed to twice weekly dosing

NOTE Confidence: 0.674787556

00:05:35.440 --> 00:05:37.980 as well as with the subcutaneous

NOTE Confidence: 0.674787556

00:05:37.980 --> 00:05:40.296 version as opposed to the Ivy.

NOTE Confidence: 0.674787556

00:05:40.300 --> 00:05:42.267 So VRD is are suitable backbone and

NOTE Confidence: 0.674787556

00:05:42.267 --> 00:05:45.155 that has been sort of the impetus for

NOTE Confidence: 0.674787556

00:05:45.155 --> 00:05:46.739 developing quadruplet based therapies.

NOTE Confidence: 0.674787556

00:05:46.740 --> 00:05:49.920 We know from some data that quadruplet

NOTE Confidence: 0.674787556

00:05:49.920 --> 00:05:53.680 regimens can be very active in the upfront

NOTE Confidence: 0.674787556

00:05:53.763 --> 00:05:56.599 treatment naive patient population,  
NOTE Confidence: 0.674787556

00:05:56.600 --> 00:05:57.653 but there are.  
NOTE Confidence: 0.674787556

00:05:57.653 --> 00:05:59.057 There are unanswered questions  
NOTE Confidence: 0.674787556

00:05:59.057 --> 00:06:01.229 and we need more information.  
NOTE Confidence: 0.674787556

00:06:01.230 --> 00:06:03.900 How does this regimen impact the  
NOTE Confidence: 0.674787556

00:06:03.900 --> 00:06:05.680 high risk patient population?  
NOTE Confidence: 0.674787556

00:06:05.680 --> 00:06:08.403 What about those that are stem cell  
NOTE Confidence: 0.674787556

00:06:08.403 --> 00:06:10.330 transplant eligible versus ineligible?  
NOTE Confidence: 0.674787556

00:06:10.330 --> 00:06:13.130 And clearly we need more long term  
NOTE Confidence: 0.674787556

00:06:13.130 --> 00:06:16.162 results that we currently have for VRD,  
NOTE Confidence: 0.674787556

00:06:16.162 --> 00:06:18.198 but you know it is not quite  
NOTE Confidence: 0.674787556

00:06:18.198 --> 00:06:19.250 not quite there yet.  
NOTE Confidence: 0.674787556

00:06:19.250 --> 00:06:22.438 For the quadruple therapy.  
NOTE Confidence: 0.674787556

00:06:22.440 --> 00:06:24.924 So moving onto the updated Griffin  
NOTE Confidence: 0.674787556

00:06:24.924 --> 00:06:27.940 analysis so this was published in Ash.  
NOTE Confidence: 0.674787556

00:06:27.940 --> 00:06:30.440 Looking at the 24 month

NOTE Confidence: 0.674787556

00:06:30.440 --> 00:06:31.710 follow follow up for Gray.

NOTE Confidence: 0.930611713333333

00:06:47.020 --> 00:06:48.736 Just a brief background on this,

NOTE Confidence: 0.930611713333333

00:06:48.740 --> 00:06:52.375 so induction therapy followed by

NOTE Confidence: 0.930611713333333

00:06:52.375 --> 00:06:55.364 high dose therapy with autologous

NOTE Confidence: 0.930611713333333

00:06:55.364 --> 00:06:57.374 stem cell transplant and lend.

NOTE Confidence: 0.930611713333333

00:06:57.380 --> 00:06:59.879 My maintenance therapy is a standard of

NOTE Confidence: 0.930611713333333

00:06:59.879 --> 00:07:02.580 care regiment for newly diagnosed patients.

NOTE Confidence: 0.930611713333333

00:07:02.580 --> 00:07:05.754 The phase two Griffin study that was

NOTE Confidence: 0.930611713333333

00:07:05.754 --> 00:07:08.706 initially presented well over a year

NOTE Confidence: 0.930611713333333

00:07:08.706 --> 00:07:11.620 ago evaluated the efficacy and safety

NOTE Confidence: 0.930611713333333

00:07:11.620 --> 00:07:15.320 of Dara plus RVD versus RVD induction,

NOTE Confidence: 0.930611713333333

00:07:15.320 --> 00:07:16.610 followed by AUTOTRANSPLANT

NOTE Confidence: 0.930611713333333

00:07:16.610 --> 00:07:17.900 for newly diagnosed.

NOTE Confidence: 0.930611713333333

00:07:17.900 --> 00:07:19.262 Transplant eligible patients.

NOTE Confidence: 0.930611713333333

00:07:19.262 --> 00:07:21.532 The primary analysis after almost

NOTE Confidence: 0.930611713333333

00:07:21.532 --> 00:07:24.108 14 months of therapy showed that  
NOTE Confidence: 0.9306117133333333

00:07:24.108 --> 00:07:25.839 the quadruplet therapy significantly  
NOTE Confidence: 0.9306117133333333

00:07:25.839 --> 00:07:29.013 improved the stringent CR rates versus  
NOTE Confidence: 0.9306117133333333

00:07:29.013 --> 00:07:32.208 the triplet therapy by the end of  
NOTE Confidence: 0.9306117133333333

00:07:32.208 --> 00:07:34.123 the post auto consolidation phase  
NOTE Confidence: 0.9306117133333333

00:07:34.130 --> 00:07:37.708 with response rates of 42 versus 32%.  
NOTE Confidence: 0.9306117133333333

00:07:37.708 --> 00:07:40.456 We also saw that this quadruplet  
NOTE Confidence: 0.9306117133333333

00:07:40.456 --> 00:07:42.650 treatment deepened their responses,  
NOTE Confidence: 0.9306117133333333

00:07:42.650 --> 00:07:45.105 improved MRD negativity rates after  
NOTE Confidence: 0.9306117133333333

00:07:45.105 --> 00:07:48.000 one year of maintenance therapy when.  
NOTE Confidence: 0.9306117133333333

00:07:48.000 --> 00:07:50.178 The standard of care lanolin amide  
NOTE Confidence: 0.9306117133333333

00:07:50.180 --> 00:07:52.045 when daratumumab was added to  
NOTE Confidence: 0.9306117133333333

00:07:52.045 --> 00:07:53.537 the standard of care.  
NOTE Confidence: 0.9306117133333333

00:07:53.540 --> 00:07:56.330 Importantly there were no new safety  
NOTE Confidence: 0.9306117133333333

00:07:56.330 --> 00:07:59.416 concerns and daratumumab did not  
NOTE Confidence: 0.9306117133333333

00:07:59.416 --> 00:08:02.686 impact the ability to mobilize

NOTE Confidence: 0.930611713333333

00:08:02.686 --> 00:08:04.812 themselves and patients who received

NOTE Confidence: 0.930611713333333

00:08:04.812 --> 00:08:07.020 their induction were actually able to

NOTE Confidence: 0.930611713333333

00:08:07.085 --> 00:08:09.249 successfully complete the transplant.

NOTE Confidence: 0.930611713333333

00:08:09.250 --> 00:08:11.752 So here in Asheville they reported

NOTE Confidence: 0.930611713333333

00:08:11.752 --> 00:08:13.855 the updated efficacy and safety

NOTE Confidence: 0.930611713333333

00:08:13.855 --> 00:08:16.015 from Griffin after 24 months or

NOTE Confidence: 0.930611713333333

00:08:16.015 --> 00:08:18.589 two years of maintenance therapy.

NOTE Confidence: 0.930611713333333

00:08:18.590 --> 00:08:21.018 An overview of the treatment design,

NOTE Confidence: 0.930611713333333

00:08:21.018 --> 00:08:24.066 so again patients were transplant eligible,

NOTE Confidence: 0.930611713333333

00:08:24.070 --> 00:08:26.122 newly diagnosed disease.

NOTE Confidence: 0.930611713333333

00:08:26.122 --> 00:08:30.226 They received 4 induction cycles of

NOTE Confidence: 0.930611713333333

00:08:30.230 --> 00:08:32.600 they were randomized to either the

NOTE Confidence: 0.930611713333333

00:08:32.600 --> 00:08:35.428 quadruple it or the triplet with RV.

NOTE Confidence: 0.930611713333333

00:08:35.430 --> 00:08:37.334 They subsequently underwent stem

NOTE Confidence: 0.930611713333333

00:08:37.334 --> 00:08:38.286 cell transplant,

NOTE Confidence: 0.930611713333333

00:08:38.290 --> 00:08:41.080 followed by two cycles of consolidation  
NOTE Confidence: 0.9306117133333333

00:08:41.080 --> 00:08:44.166 treatment and then patients under work  
NOTE Confidence: 0.9306117133333333

00:08:44.166 --> 00:08:47.844 continue to darreft maintenance or lanolin.  
NOTE Confidence: 0.9306117133333333

00:08:47.850 --> 00:08:49.950 Maintenance for up to two years.  
NOTE Confidence: 0.9306117133333333

00:08:49.950 --> 00:08:54.038 The primary endpoint here was a stringent CR.  
NOTE Confidence: 0.9306117133333333

00:08:54.040 --> 00:08:56.020 Secondary endpoints included various  
NOTE Confidence: 0.9306117133333333

00:08:56.020 --> 00:08:58.122 response rates, MRD, negativity,  
NOTE Confidence: 0.9306117133333333

00:08:58.122 --> 00:08:59.790 progression, free survival,  
NOTE Confidence: 0.9306117133333333

00:08:59.790 --> 00:09:01.746 and overall survival on the bottom  
NOTE Confidence: 0.9306117133333333

00:09:01.746 --> 00:09:03.050 half of the slide.  
NOTE Confidence: 0.9306117133333333

00:09:03.050 --> 00:09:04.920 You note that the patient  
NOTE Confidence: 0.9306117133333333

00:09:04.920 --> 00:09:06.416 characteristics were were fairly  
NOTE Confidence: 0.9306117133333333

00:09:06.416 --> 00:09:08.580 well balanced between both groups.  
NOTE Confidence: 0.9137729833333333

00:09:11.600 --> 00:09:13.480 Now highlighted here is what's  
NOTE Confidence: 0.9137729833333333

00:09:13.480 --> 00:09:16.362 important to note here is that these  
NOTE Confidence: 0.9137729833333333

00:09:16.362 --> 00:09:18.218 responses deepened overtime after

NOTE Confidence: 0.9137729833333333

00:09:18.218 --> 00:09:20.680 two years of maintenance therapy.

NOTE Confidence: 0.9137729833333333

00:09:20.680 --> 00:09:22.720 For the DRVD, the complete response

NOTE Confidence: 0.9137729833333333

00:09:22.720 --> 00:09:25.450 rates were 82% versus 61% for the

NOTE Confidence: 0.9137729833333333

00:09:25.450 --> 00:09:28.100 triplet therapy and on the right

NOTE Confidence: 0.9137729833333333

00:09:28.100 --> 00:09:30.680 here for the subgroup analysis,

NOTE Confidence: 0.9137729833333333

00:09:30.680 --> 00:09:34.726 you can appreciate that the that these

NOTE Confidence: 0.9137729833333333

00:09:34.726 --> 00:09:37.776 improved durable responses were seen

NOTE Confidence: 0.9137729833333333

00:09:37.776 --> 00:09:40.826 irrespective of the various subgroups.

NOTE Confidence: 0.9137729833333333

00:09:40.830 --> 00:09:43.070 Described.

NOTE Confidence: 0.9137729833333333

00:09:43.070 --> 00:09:44.589 In the lower half of the slide,

NOTE Confidence: 0.9137729833333333

00:09:44.590 --> 00:09:47.320 we note that there were more

NOTE Confidence: 0.9137729833333333

00:09:47.320 --> 00:09:49.140 significant MRD negativity rates

NOTE Confidence: 0.9137729833333333

00:09:49.140 --> 00:09:50.970 with increased treatment as well.

NOTE Confidence: 0.9137729833333333

00:09:50.970 --> 00:09:53.130 Again for the quadruplet therapy,

NOTE Confidence: 0.9137729833333333

00:09:53.130 --> 00:09:55.832 64% relative to 30% in the triplet

NOTE Confidence: 0.9137729833333333

00:09:55.832 --> 00:09:58.395 therapy and when we look at  
NOTE Confidence: 0.9137729833333333

00:09:58.395 --> 00:10:00.167 the various subgroup analysis,  
NOTE Confidence: 0.9137729833333333

00:10:00.170 --> 00:10:02.500 this finding was also observed  
NOTE Confidence: 0.9137729833333333

00:10:02.500 --> 00:10:05.420 for patients over the age of 65.  
NOTE Confidence: 0.9137729833333333

00:10:05.420 --> 00:10:08.675 Advanced ISS High Risk center  
NOTE Confidence: 0.9137729833333333

00:10:08.675 --> 00:10:10.628 genetic analysis and.  
NOTE Confidence: 0.9137729833333333

00:10:10.630 --> 00:10:12.074 And then revised higher,  
NOTE Confidence: 0.9137729833333333

00:10:12.074 --> 00:10:13.518 so genetic risk profile.  
NOTE Confidence: 0.849201155454546

00:10:16.240 --> 00:10:18.475 The median progression free survival  
NOTE Confidence: 0.849201155454546

00:10:18.475 --> 00:10:21.080 was not reached in either arm,  
NOTE Confidence: 0.849201155454546

00:10:21.080 --> 00:10:22.725 although what's important to note  
NOTE Confidence: 0.849201155454546

00:10:22.725 --> 00:10:25.481 here is that we do see a separation  
NOTE Confidence: 0.849201155454546

00:10:25.481 --> 00:10:27.221 of the curves beginning one  
NOTE Confidence: 0.849201155454546

00:10:27.221 --> 00:10:29.249 year after maintenance therapy,  
NOTE Confidence: 0.849201155454546

00:10:29.250 --> 00:10:31.959 so this suggests a benefit for the  
NOTE Confidence: 0.849201155454546

00:10:31.959 --> 00:10:34.623 Daerah 2 Mettler Toledo my maintenance



NOTE Confidence: 0.849201155454546  
00:10:34.623 --> 00:10:37.176 arm and although it was not powered  
NOTE Confidence: 0.849201155454546  
00:10:37.176 --> 00:10:39.580 again not powered for progression free  
NOTE Confidence: 0.849201155454546  
00:10:39.580 --> 00:10:41.960 survival in the subgroup analysis,  
NOTE Confidence: 0.849201155454546  
00:10:41.960 --> 00:10:45.520 but you can also note here a generally  
NOTE Confidence: 0.849201155454546  
00:10:45.520 --> 00:10:48.228 a positive trend for darylenn.  
NOTE Confidence: 0.849201155454546  
00:10:48.230 --> 00:10:50.285 Maintenance versus Lenalidomide  
NOTE Confidence: 0.849201155454546  
00:10:50.285 --> 00:10:52.340 monotherapy as maintenance.  
NOTE Confidence: 0.905601434  
00:10:55.120 --> 00:10:56.900 So the summarize these conclusions,  
NOTE Confidence: 0.905601434  
00:10:56.900 --> 00:10:59.735 so the quadruple therapy as induction post,  
NOTE Confidence: 0.905601434  
00:10:59.740 --> 00:11:01.965 auto consolidation and barev maintenance  
NOTE Confidence: 0.905601434  
00:11:01.965 --> 00:11:04.844 is an effective regimen for newly  
NOTE Confidence: 0.905601434  
00:11:04.844 --> 00:11:07.200 diagnosed transplant eligible patients.  
NOTE Confidence: 0.905601434  
00:11:07.200 --> 00:11:09.110 The MRD negativity rates were  
NOTE Confidence: 0.905601434  
00:11:09.110 --> 00:11:10.638 highest for the quadruplet,  
NOTE Confidence: 0.905601434  
00:11:10.640 --> 00:11:12.608 followed by darreff maintenance.  
NOTE Confidence: 0.905601434

00:11:12.608 --> 00:11:14.576 These patients had deeper  
NOTE Confidence: 0.905601434

00:11:14.576 --> 00:11:16.720 levels of MRD negativity,  
NOTE Confidence: 0.905601434

00:11:16.720 --> 00:11:18.580 greater deepening of the negativity  
NOTE Confidence: 0.905601434

00:11:18.580 --> 00:11:20.995 over time as we saw approaching  
NOTE Confidence: 0.905601434

00:11:20.995 --> 00:11:23.420 the two year maintenance phase.  
NOTE Confidence: 0.905601434

00:11:23.420 --> 00:11:25.430 Similarly, their rates of sustained.  
NOTE Confidence: 0.905601434

00:11:25.430 --> 00:11:29.852 MRMR D negativity and the subset  
NOTE Confidence: 0.905601434

00:11:29.852 --> 00:11:32.950 analysis also trended favorably in  
NOTE Confidence: 0.905601434

00:11:32.950 --> 00:11:36.730 for the high risk population as well.  
NOTE Confidence: 0.905601434

00:11:36.730 --> 00:11:40.349 In terms of the progression free survival.  
NOTE Confidence: 0.905601434

00:11:40.350 --> 00:11:43.266 Again, also this two year maintenance  
NOTE Confidence: 0.905601434

00:11:43.266 --> 00:11:45.903 was well tolerated for those who  
NOTE Confidence: 0.905601434

00:11:45.903 --> 00:11:47.467 received the daratumumab combination.  
NOTE Confidence: 0.873774954285714

00:11:49.510 --> 00:11:51.708 So moving on to the Maia study.  
NOTE Confidence: 0.873774954285714

00:11:51.710 --> 00:11:53.770 Now this these results were  
NOTE Confidence: 0.873774954285714

00:11:53.770 --> 00:11:55.006 actually originally published

NOTE Confidence: 0.873774954285714  
00:11:55.006 --> 00:11:57.030 last summer at the FAP meeting,  
NOTE Confidence: 0.873774954285714  
00:11:57.030 --> 00:11:59.864 but I'm gonna review it here also,  
NOTE Confidence: 0.873774954285714  
00:11:59.864 --> 00:12:02.655 within the context of this  
NOTE Confidence: 0.873774954285714  
00:12:02.655 --> 00:12:07.065 presentation by Doctor Usmania at MSK.  
NOTE Confidence: 0.873774954285714  
00:12:07.070 --> 00:12:09.350 Who essentially wanted to determine  
NOTE Confidence: 0.873774954285714  
00:12:09.350 --> 00:12:12.532 the effects of the Maya on patients  
NOTE Confidence: 0.873774954285714  
00:12:12.532 --> 00:12:14.344 with impaired renal function,  
NOTE Confidence: 0.873774954285714  
00:12:14.350 --> 00:12:15.910 which is relevant here?  
NOTE Confidence: 0.873774954285714  
00:12:15.910 --> 00:12:18.250 Because really up to up to  
NOTE Confidence: 0.873774954285714  
00:12:18.336 --> 00:12:20.530 50% of patients can have some  
NOTE Confidence: 0.873774954285714  
00:12:20.530 --> 00:12:22.490 baseline renal compromise that can  
NOTE Confidence: 0.873774954285714  
00:12:22.562 --> 00:12:24.587 impact our choice of treatment.  
NOTE Confidence: 0.873774954285714  
00:12:24.590 --> 00:12:26.630 So the the Maya the mitral.  
NOTE Confidence: 0.873774954285714  
00:12:26.630 --> 00:12:27.970 As you may know,  
NOTE Confidence: 0.873774954285714  
00:12:27.970 --> 00:12:30.528 evaluated the addition of Dara to Rev  
NOTE Confidence: 0.873774954285714

00:12:30.528 --> 00:12:32.928 Dex and transplant ineligible patients.  
NOTE Confidence: 0.873774954285714

00:12:32.930 --> 00:12:34.814 Newly diagnosed median follow-up  
NOTE Confidence: 0.873774954285714

00:12:34.814 --> 00:12:37.640 of four and a half years.  
NOTE Confidence: 0.873774954285714

00:12:37.640 --> 00:12:40.808 The Dara Rev Dex prolonged PFS  
NOTE Confidence: 0.873774954285714

00:12:40.808 --> 00:12:44.130 and OS versus Rev Dex alone,  
NOTE Confidence: 0.873774954285714

00:12:44.130 --> 00:12:46.314 and this was despite the fact that  
NOTE Confidence: 0.873774954285714

00:12:46.314 --> 00:12:49.376 almost half the patients in the Rev Dex  
NOTE Confidence: 0.873774954285714

00:12:49.376 --> 00:12:51.628 population received subsequent therapy,  
NOTE Confidence: 0.873774954285714

00:12:51.630 --> 00:12:53.499 including a dare to Matt based regimen.  
NOTE Confidence: 0.9099361675

00:12:55.680 --> 00:12:59.130 So so important for for  
NOTE Confidence: 0.9099361675

00:12:59.130 --> 00:13:01.200 this patient population.  
NOTE Confidence: 0.9099361675

00:13:01.200 --> 00:13:03.216 When we look at the study design,  
NOTE Confidence: 0.9099361675

00:13:03.220 --> 00:13:05.300 Somaiya trial again included  
NOTE Confidence: 0.9099361675

00:13:05.300 --> 00:13:06.340 transplant ineligible,  
NOTE Confidence: 0.9099361675

00:13:06.340 --> 00:13:08.720 newly diagnosed multiple myeloma patients,  
NOTE Confidence: 0.9099361675

00:13:08.720 --> 00:13:12.744 randomized to Dara Rev Dex or Rev Dex

NOTE Confidence: 0.9099361675  
00:13:12.744 --> 00:13:16.548 and important here to note is that  
NOTE Confidence: 0.9099361675  
00:13:16.548 --> 00:13:21.200 this treatment was continued until.  
NOTE Confidence: 0.9099361675  
00:13:21.200 --> 00:13:22.716 I told disease progression.  
NOTE Confidence: 0.9099361675  
00:13:22.716 --> 00:13:24.990 The primary endpoint for this study  
NOTE Confidence: 0.9099361675  
00:13:25.053 --> 00:13:27.098 was the progression free survival.  
NOTE Confidence: 0.9099361675  
00:13:27.100 --> 00:13:28.402 Various secondary endpoints,  
NOTE Confidence: 0.9099361675  
00:13:28.402 --> 00:13:31.440 again looking at the the response rates,  
NOTE Confidence: 0.9099361675  
00:13:31.440 --> 00:13:33.388 MRD negativity, overall survival.  
NOTE Confidence: 0.910410601428571  
00:13:36.130 --> 00:13:38.657 And here we note the updated results.  
NOTE Confidence: 0.910410601428571  
00:13:38.660 --> 00:13:40.850 So with respect to the  
NOTE Confidence: 0.910410601428571  
00:13:40.850 --> 00:13:43.297 updated five year analysis,  
NOTE Confidence: 0.910410601428571  
00:13:43.297 --> 00:13:47.311 the progression free survival was not  
NOTE Confidence: 0.910410601428571  
00:13:47.311 --> 00:13:51.386 reached for the Dara Rev Dex combination  
NOTE Confidence: 0.910410601428571  
00:13:51.390 --> 00:13:56.510 and was 30-4 months for the Rev decks.  
NOTE Confidence: 0.910410601428571  
00:13:56.510 --> 00:13:59.030 Cohort in terms of the overall  
NOTE Confidence: 0.910410601428571

00:13:59.030 --> 00:13:59.870 survival benefit,  
NOTE Confidence: 0.910410601428571

00:13:59.870 --> 00:14:01.994 we do really important here to  
NOTE Confidence: 0.910410601428571

00:14:01.994 --> 00:14:04.782 note is that there is an overall  
NOTE Confidence: 0.910410601428571

00:14:04.782 --> 00:14:07.554 survival benefit for Dara Rev Dex,  
NOTE Confidence: 0.910410601428571

00:14:07.554 --> 00:14:10.862 which is documented as a 32% reduction.  
NOTE Confidence: 0.910410601428571

00:14:10.862 --> 00:14:14.840 The risk of death relative to Rev Dex alone.  
NOTE Confidence: 0.9064067075

00:14:17.410 --> 00:14:19.370 And if you see here on the  
NOTE Confidence: 0.9064067075

00:14:19.370 --> 00:14:21.060 right side of the screen,  
NOTE Confidence: 0.9064067075

00:14:21.060 --> 00:14:23.718 regardless of whether patients received a  
NOTE Confidence: 0.9064067075

00:14:23.718 --> 00:14:27.710 Lenalidomide dose of 25 or a lower dose,  
NOTE Confidence: 0.9064067075

00:14:27.710 --> 00:14:30.146 there was a progression free survival  
NOTE Confidence: 0.9064067075

00:14:30.146 --> 00:14:32.387 benefit and an overall survival  
NOTE Confidence: 0.9064067075

00:14:32.387 --> 00:14:35.080 benefit for Darryl Rev Dex relative  
NOTE Confidence: 0.9064067075

00:14:35.080 --> 00:14:38.512 to Rev Dex and the figure on the left  
NOTE Confidence: 0.9064067075

00:14:38.512 --> 00:14:40.862 here really just highlights that this  
NOTE Confidence: 0.9064067075

00:14:40.862 --> 00:14:42.558 progression free survival benefit

NOTE Confidence: 0.9064067075

00:14:42.558 --> 00:14:45.821 that we're seeing in Maya is quite

NOTE Confidence: 0.9064067075

00:14:45.821 --> 00:14:47.696 remarkable and really superior to.

NOTE Confidence: 0.9064067075

00:14:47.700 --> 00:14:49.884 Some of the other recent phase

NOTE Confidence: 0.9064067075

00:14:49.884 --> 00:14:52.084 three trials published in transplant

NOTE Confidence: 0.9064067075

00:14:52.084 --> 00:14:53.430 ineligible patients.

NOTE Confidence: 0.868880455652174

00:14:56.170 --> 00:14:58.186 To summarize, so after five years of

NOTE Confidence: 0.868880455652174

00:14:58.186 --> 00:15:00.238 follow up the progression free and

NOTE Confidence: 0.868880455652174

00:15:00.238 --> 00:15:02.113 overall survival benefit for Darrell

NOTE Confidence: 0.868880455652174

00:15:02.113 --> 00:15:04.910 Rev Dex versus Rev Dex was observed

NOTE Confidence: 0.868880455652174

00:15:04.910 --> 00:15:07.270 and importantly relevant here.

NOTE Confidence: 0.868880455652174

00:15:07.270 --> 00:15:10.042 This was also observed in patients with

NOTE Confidence: 0.868880455652174

00:15:10.042 --> 00:15:12.020 compromised renal function at baseline,

NOTE Confidence: 0.868880455652174

00:15:12.020 --> 00:15:14.225 irrespective of the starting dose

NOTE Confidence: 0.868880455652174

00:15:14.225 --> 00:15:16.873 of Lenalidomide was a little bit

NOTE Confidence: 0.868880455652174

00:15:16.873 --> 00:15:19.051 less pronounced than those that had

NOTE Confidence: 0.868880455652174

00:15:19.051 --> 00:15:21.568 had a lower dose lower than 25.  
NOTE Confidence: 0.868880455652174

00:15:21.570 --> 00:15:25.550 But really, highlighting the impressive,  
NOTE Confidence: 0.868880455652174

00:15:25.550 --> 00:15:27.182 you know, practice changing.  
NOTE Confidence: 0.868880455652174

00:15:27.182 --> 00:15:29.222 Results of Maya for transplant  
NOTE Confidence: 0.868880455652174

00:15:29.222 --> 00:15:30.870 and eligible patients.  
NOTE Confidence: 0.829630117727273

00:15:33.200 --> 00:15:34.600 Any interest of time,  
NOTE Confidence: 0.829630117727273

00:15:34.600 --> 00:15:36.700 I'm just going to briefly review  
NOTE Confidence: 0.829630117727273

00:15:36.767 --> 00:15:38.555 another quadruplet based treatment  
NOTE Confidence: 0.829630117727273

00:15:38.555 --> 00:15:41.237 regimen presented at ASH just back  
NOTE Confidence: 0.829630117727273

00:15:41.307 --> 00:15:43.264 in December involving ISATUXIMAB,  
NOTE Confidence: 0.829630117727273

00:15:43.264 --> 00:15:46.996 which is another CD 38 monoclonal  
NOTE Confidence: 0.829630117727273

00:15:46.996 --> 00:15:50.349 antibody and hear the IT evolved  
NOTE Confidence: 0.829630117727273

00:15:50.349 --> 00:15:52.864 isatuximab with RVD or RVD  
NOTE Confidence: 0.829630117727273

00:15:52.864 --> 00:15:55.476 relative to RVD in transplant  
NOTE Confidence: 0.829630117727273

00:15:55.476 --> 00:15:58.494 eligible patients and this was the  
NOTE Confidence: 0.829630117727273

00:15:58.500 --> 00:16:01.530 phase three GMMG HD seven study.



NOTE Confidence: 0.794222217

00:16:04.530 --> 00:16:08.046 And this phase three trial demonstrated

NOTE Confidence: 0.794222217

00:16:08.046 --> 00:16:11.516 a improvement or superiority in MRD

NOTE Confidence: 0.794222217

00:16:11.516 --> 00:16:14.618 negativity rates after induction with the

NOTE Confidence: 0.794222217

00:16:14.618 --> 00:16:18.157 addition of the aesthetics mab antibody.

NOTE Confidence: 0.794222217

00:16:18.160 --> 00:16:21.120 2 RVD with the MRD response rate of

NOTE Confidence: 0.794222217

00:16:21.120 --> 00:16:24.130 50 point 1% relative to 35% and on the

NOTE Confidence: 0.794222217

00:16:24.130 --> 00:16:26.749 right side of the screen. You can also.

NOTE Confidence: 0.876426585384615

00:16:40.990 --> 00:16:43.678 Is the highest described to date in a

NOTE Confidence: 0.876426585384615

00:16:43.678 --> 00:16:47.310 randomized phase three trial at 50.1%?

NOTE Confidence: 0.876426585384615

00:16:47.310 --> 00:16:49.675 Importantly, the addition of Isatuximab

NOTE Confidence: 0.876426585384615

00:16:49.675 --> 00:16:52.543 had no significant impact on the

NOTE Confidence: 0.876426585384615

00:16:52.543 --> 00:16:54.688 safety profile or dose intensity,

NOTE Confidence: 0.876426585384615

00:16:54.690 --> 00:16:56.865 and there are ongoing studies

NOTE Confidence: 0.876426585384615

00:16:56.865 --> 00:16:58.605 evaluating this combination of

NOTE Confidence: 0.876426585384615

00:16:58.605 --> 00:17:00.680 treatment for transplant eligible

NOTE Confidence: 0.876426585384615

00:17:00.680 --> 00:17:02.776 and transplant ineligible patients.

NOTE Confidence: 0.911890994

00:17:05.500 --> 00:17:08.074 And finally, I think it's also

NOTE Confidence: 0.911890994

00:17:08.074 --> 00:17:10.500 important to discuss the master

NOTE Confidence: 0.911890994

00:17:10.500 --> 00:17:13.000 trial which involved daratumumab,

NOTE Confidence: 0.911890994

00:17:13.000 --> 00:17:14.426 carfilzomib, Lenalidomide,

NOTE Confidence: 0.911890994

00:17:14.426 --> 00:17:16.565 and dexamethasone togus

NOTE Confidence: 0.911890994

00:17:16.565 --> 00:17:19.417 transplant and MRD response.

NOTE Confidence: 0.911890994

00:17:19.420 --> 00:17:22.650 Adaptive consolidation.

NOTE Confidence: 0.911890994

00:17:22.650 --> 00:17:24.939 We know that there are two have

NOTE Confidence: 0.911890994

00:17:24.939 --> 00:17:26.415 improves outcomes when combined

NOTE Confidence: 0.911890994

00:17:26.415 --> 00:17:28.540 with a proteasome inhibitor and

NOTE Confidence: 0.911890994

00:17:28.540 --> 00:17:30.240 or an immunomodulator agents.

NOTE Confidence: 0.911890994

00:17:30.240 --> 00:17:33.648 We also know that MRD negativity

NOTE Confidence: 0.911890994

00:17:33.648 --> 00:17:35.352 has prognostic implications.

NOTE Confidence: 0.911890994

00:17:35.360 --> 00:17:38.275 Now, this study incorporated a

NOTE Confidence: 0.911890994

00:17:38.275 --> 00:17:41.190 response adopted therapy to achieve

NOTE Confidence: 0.911890994

00:17:41.282 --> 00:17:43.600 MRD negativity and really aimed

NOTE Confidence: 0.911890994

00:17:43.600 --> 00:17:46.486 to evaluate the Natural History of

NOTE Confidence: 0.911890994

00:17:46.486 --> 00:17:49.350 patients with sustained MRD negativity.

NOTE Confidence: 0.800925246875

00:17:51.830 --> 00:17:53.810 Now, the treatment included Dara

NOTE Confidence: 0.800925246875

00:17:53.810 --> 00:17:56.234 KRD and carfilzomib was dosed at

NOTE Confidence: 0.800925246875

00:17:56.234 --> 00:17:58.099 56 milligrams per meter squared.

NOTE Confidence: 0.800925246875

00:17:58.100 --> 00:18:00.998 Weekly patients received 4 induction cycles

NOTE Confidence: 0.800925246875

00:18:00.998 --> 00:18:04.118 of Derek KRD followed by a colleague.

NOTE Confidence: 0.800925246875

00:18:04.120 --> 00:18:06.040 A stem cell transplant.

NOTE Confidence: 0.800925246875

00:18:06.040 --> 00:18:10.327 And up to 8 cycles of Dara KRD MRD

NOTE Confidence: 0.800925246875

00:18:10.327 --> 00:18:13.456 was assessed at each of these blocks.

NOTE Confidence: 0.800925246875

00:18:13.460 --> 00:18:17.373 Now, patients who had two consecutive MRD

NOTE Confidence: 0.800925246875

00:18:17.373 --> 00:18:20.225 negativity findings were transitioned

NOTE Confidence: 0.800925246875

00:18:20.225 --> 00:18:24.550 to this phase called MRD Shore,

NOTE Confidence: 0.800925246875

00:18:24.550 --> 00:18:28.846 which was a treatment free interval.

NOTE Confidence: 0.800925246875

00:18:28.850 --> 00:18:32.000 Observation and surveillance.  
NOTE Confidence: 0.800925246875

00:18:32.000 --> 00:18:34.856 Those patients who did not achieve MRD  
NOTE Confidence: 0.800925246875

00:18:34.856 --> 00:18:37.215 shirt continued to receive Lenalidomide  
NOTE Confidence: 0.800925246875

00:18:37.215 --> 00:18:40.383 maintenance as their standard of care.  
NOTE Confidence: 0.800925246875

00:18:40.390 --> 00:18:41.550 And here are the results.  
NOTE Confidence: 0.800925246875

00:18:41.550 --> 00:18:43.310 You can appreciate that.  
NOTE Confidence: 0.800925246875

00:18:43.310 --> 00:18:46.150 Overall, the majority of patients at  
NOTE Confidence: 0.800925246875

00:18:46.150 --> 00:18:49.660 80% achieved MRD negativity and the  
NOTE Confidence: 0.800925246875

00:18:49.660 --> 00:18:53.545 depth of response and MRD negativity  
NOTE Confidence: 0.800925246875

00:18:53.545 --> 00:18:57.265 improved at each therapy phase.  
NOTE Confidence: 0.800925246875

00:18:57.270 --> 00:19:00.108 As you can appreciate with these  
NOTE Confidence: 0.800925246875

00:19:00.108 --> 00:19:02.000 blocks and became compareable  
NOTE Confidence: 0.800925246875

00:19:02.078 --> 00:19:04.746 among the groups with no high risk,  
NOTE Confidence: 0.800925246875

00:19:04.746 --> 00:19:06.836 cytogenetic anomalies 1 high risk  
NOTE Confidence: 0.800925246875

00:19:06.836 --> 00:19:09.455 genetic anomaly or two or more  
NOTE Confidence: 0.800925246875

00:19:09.455 --> 00:19:11.179 high risk genetic abnormalities.

NOTE Confidence: 0.800925246875

00:19:11.180 --> 00:19:14.295 When we assess when they assessed MRD

NOTE Confidence: 0.800925246875

00:19:14.295 --> 00:19:18.950 to at level of  $1 \times 10^{-6}$

NOTE Confidence: 0.800925246875

00:19:18.950 --> 00:19:21.806 66% of patients achieved MRD negativity.

NOTE Confidence: 0.800925246875

00:19:21.810 --> 00:19:25.650 Their proportion here in the various

NOTE Confidence: 0.800925246875

00:19:25.650 --> 00:19:28.080 cytogenetic abnormality populations was

NOTE Confidence: 0.800925246875

00:19:28.080 --> 00:19:31.650 somewhat lower and it did take longer

NOTE Confidence: 0.800925246875

00:19:31.650 --> 00:19:34.490 to achieve for those with ultra high risk.

NOTE Confidence: 0.800925246875

00:19:34.490 --> 00:19:36.538 As you can see here in the two

NOTE Confidence: 0.800925246875

00:19:36.538 --> 00:19:38.659 plus high risk surgical abilities.

NOTE Confidence: 0.56494648

00:19:41.150 --> 00:19:44.326 In terms of MRD shore, so about 71 or

NOTE Confidence: 0.56494648

00:19:44.326 --> 00:19:46.370 72% achieve of patients achieve them.

NOTE Confidence: 0.56494648

00:19:46.370 --> 00:19:48.554 Are these sure and this was

NOTE Confidence: 0.56494648

00:19:48.554 --> 00:19:50.010 relatively similar across the

NOTE Confidence: 0.56494648

00:19:50.074 --> 00:19:51.990 three cytogenetic risk groups.

NOTE Confidence: 0.56494648

00:19:51.990 --> 00:19:54.818 The median follow up time here was

NOTE Confidence: 0.56494648

00:19:54.818 --> 00:19:57.630 about 14 months and the risk of MRD,  
NOTE Confidence: 0.56494648

00:19:57.630 --> 00:20:01.710 resurgence or clinical progression was  
NOTE Confidence: 0.56494648

00:20:01.710 --> 00:20:06.198 40 and 27% among the standard high risk  
NOTE Confidence: 0.56494648

00:20:06.198 --> 00:20:10.110 and ultra high risk patient groups,  
NOTE Confidence: 0.56494648

00:20:10.110 --> 00:20:12.570 respectively. And importantly,  
NOTE Confidence: 0.56494648

00:20:12.570 --> 00:20:14.796 none of the patients who entered this  
NOTE Confidence: 0.56494648

00:20:14.796 --> 00:20:17.089 phase of MRD sure ultimately died  
NOTE Confidence: 0.56494648

00:20:17.090 --> 00:20:20.658 from multiple myeloma progression.  
NOTE Confidence: 0.56494648

00:20:20.660 --> 00:20:21.839 So, in conclusion,  
NOTE Confidence: 0.56494648

00:20:21.839 --> 00:20:23.018 next generation sequencing,  
NOTE Confidence: 0.56494648

00:20:23.020 --> 00:20:23.850 MRD response,  
NOTE Confidence: 0.56494648

00:20:23.850 --> 00:20:26.340 adaptive therapy is feasible in the  
NOTE Confidence: 0.56494648

00:20:26.340 --> 00:20:28.238 overwhelming majority of patients in  
NOTE Confidence: 0.56494648

00:20:28.238 --> 00:20:30.762 multicenter settings with 70 to 72% of  
NOTE Confidence: 0.56494648

00:20:30.762 --> 00:20:33.288 patients or she reaching MRD shore.  
NOTE Confidence: 0.56494648

00:20:33.290 --> 00:20:36.209 Patients who have standard and high risk,

NOTE Confidence: 0.56494648

00:20:36.210 --> 00:20:38.400 newly diagnosed myeloma had similar

NOTE Confidence: 0.56494648

00:20:38.400 --> 00:20:41.528 depth of response and low risk of MRD,

NOTE Confidence: 0.56494648

00:20:41.530 --> 00:20:43.182 resurgence or clinical progression

NOTE Confidence: 0.56494648

00:20:43.182 --> 00:20:45.247 when they were treated with

NOTE Confidence: 0.56494648

00:20:45.247 --> 00:20:47.298 the master trial quadruplets.

NOTE Confidence: 0.56494648

00:20:47.300 --> 00:20:49.430 Stem cell transplant and MRD,

NOTE Confidence: 0.56494648

00:20:49.430 --> 00:20:51.418 adaptive treatment cessation and

NOTE Confidence: 0.56494648

00:20:51.418 --> 00:20:53.406 quadruple therapy achievement of

NOTE Confidence: 0.56494648

00:20:53.406 --> 00:20:55.660 confirmed MRD negative responses.

NOTE Confidence: 0.56494648

00:20:55.660 --> 00:20:58.282 Enables us to explore stopping treatment

NOTE Confidence: 0.56494648

00:20:58.282 --> 00:21:01.247 as an alternative to continuous MRD

NOTE Confidence: 0.56494648

00:21:01.247 --> 00:21:03.539 therapy to continuous indefinite.

NOTE Confidence: 0.56494648

00:21:03.540 --> 00:21:05.566 Treatment importantly,

NOTE Confidence: 0.56494648

00:21:05.566 --> 00:21:07.030 here again, novel therapy,

NOTE Confidence: 0.56494648

00:21:07.030 --> 00:21:07.711 novel,

NOTE Confidence: 0.56494648

00:21:07.711 --> 00:21:10.435 effective consolidation treatments should  
NOTE Confidence: 0.56494648

00:21:10.435 --> 00:21:13.168 be explored to improve outcomes and  
NOTE Confidence: 0.56494648

00:21:13.168 --> 00:21:16.100 clear MRD to a negative state in these  
NOTE Confidence: 0.56494648

00:21:16.100 --> 00:21:18.130 ultra high risk patient population.  
NOTE Confidence: 0.934961033846154

00:21:20.930 --> 00:21:22.806 Thank you and I will welcome questions  
NOTE Confidence: 0.934961033846154

00:21:22.806 --> 00:21:24.818 at the end of this presentation.  
NOTE Confidence: 0.932449442857143

00:21:29.910 --> 00:21:31.737 And I'll transfer it over to Terry.  
NOTE Confidence: 0.8006976475

00:21:38.850 --> 00:21:41.265 Thank you, I will be focusing on  
NOTE Confidence: 0.8006976475

00:21:41.265 --> 00:21:43.629 updates in relapsed refractory myeloma.  
NOTE Confidence: 0.831720452941176

00:21:46.860 --> 00:21:49.812 I have no disclosures and I will be  
NOTE Confidence: 0.831720452941176

00:21:49.812 --> 00:21:51.530 specifically focusing on treatment  
NOTE Confidence: 0.831720452941176

00:21:51.530 --> 00:21:53.800 of triple class refractory patients.  
NOTE Confidence: 0.831720452941176

00:21:53.800 --> 00:21:55.676 This is defined as those patients that  
NOTE Confidence: 0.831720452941176

00:21:55.676 --> 00:21:57.714 are refractory to anime, no modulatory,  
NOTE Confidence: 0.831720452941176

00:21:57.714 --> 00:21:59.949 a Jack, a proteasome inhibitor,  
NOTE Confidence: 0.831720452941176

00:21:59.950 --> 00:22:03.205 and STD 38 monoclonal antibody currently



NOTE Confidence: 0.831720452941176  
00:22:03.205 --> 00:22:05.980 approved agents for this classification  
NOTE Confidence: 0.831720452941176  
00:22:05.980 --> 00:22:08.200 includes standard chemotherapeutic regimens,  
NOTE Confidence: 0.831720452941176  
00:22:08.200 --> 00:22:09.180 selinexor combinations,  
NOTE Confidence: 0.831720452941176  
00:22:09.180 --> 00:22:11.630 fanatical axe for patients who  
NOTE Confidence: 0.831720452941176  
00:22:11.630 --> 00:22:13.100 harbor a translocation.  
NOTE Confidence: 0.831720452941176  
00:22:13.100 --> 00:22:16.824 1114 and two BCM a targeted therapies.  
NOTE Confidence: 0.831720452941176  
00:22:16.830 --> 00:22:19.074 Mentioned at Matthew Gelatin and antibody  
NOTE Confidence: 0.831720452941176  
00:22:19.074 --> 00:22:22.085 drug conjugate and I do sell a car T therapy.  
NOTE Confidence: 0.831720452941176  
00:22:22.090 --> 00:22:23.322 Fortunately for our patients,  
NOTE Confidence: 0.831720452941176  
00:22:23.322 --> 00:22:24.554 there are many agents  
NOTE Confidence: 0.831720452941176  
00:22:24.554 --> 00:22:25.950 currently in clinical trial,  
NOTE Confidence: 0.831720452941176  
00:22:25.950 --> 00:22:27.732 many of which were updated at  
NOTE Confidence: 0.831720452941176  
00:22:27.732 --> 00:22:28.623 this year's ASH.  
NOTE Confidence: 0.831720452941176  
00:22:28.630 --> 00:22:29.767 These include BCM,  
NOTE Confidence: 0.831720452941176  
00:22:29.767 --> 00:22:33.125 a targeted therapies in the form of PCM a  
NOTE Confidence: 0.831720452941176

00:22:33.125 --> 00:22:35.890 CD3 bispecific T cell engager's non BCMA,  
NOTE Confidence: 0.831720452941176

00:22:35.890 --> 00:22:38.890 targeted therapies and Carty or cellular  
NOTE Confidence: 0.831720452941176

00:22:38.890 --> 00:22:41.283 therapies which will be discussed by  
NOTE Confidence: 0.831720452941176

00:22:41.283 --> 00:22:43.750 doctor Bark later in the session.  
NOTE Confidence: 0.831720452941176

00:22:43.750 --> 00:22:45.832 First, we'll start with a presentation  
NOTE Confidence: 0.831720452941176

00:22:45.832 --> 00:22:47.597 by Doctor Moreau entitled updated  
NOTE Confidence: 0.831720452941176

00:22:47.597 --> 00:22:49.823 results from Majestic One at phase one,  
NOTE Confidence: 0.831720452941176

00:22:49.830 --> 00:22:52.371 two study of Palestine Map Ciclista Mob  
NOTE Confidence: 0.831720452941176

00:22:52.371 --> 00:22:55.434 is at BCM a CD3 bispecific antibody here.  
NOTE Confidence: 0.831720452941176

00:22:55.434 --> 00:22:58.490 Phase one and two data from the  
NOTE Confidence: 0.831720452941176

00:22:58.490 --> 00:23:01.610 1.5 MB perchik dose was presented.  
NOTE Confidence: 0.831720452941176

00:23:01.610 --> 00:23:03.775 He eligibility criteria included that  
NOTE Confidence: 0.831720452941176

00:23:03.775 --> 00:23:06.323 patient be triple class exposed have  
NOTE Confidence: 0.831720452941176

00:23:06.323 --> 00:23:08.883 three or more lines of prior therapy and,  
NOTE Confidence: 0.831720452941176

00:23:08.890 --> 00:23:09.395 importantly,  
NOTE Confidence: 0.831720452941176

00:23:09.395 --> 00:23:12.524 no prior PC may therapy patients

NOTE Confidence: 0.831720452941176

00:23:12.524 --> 00:23:13.732 receive stubborn.

NOTE Confidence: 0.831720452941176

00:23:13.732 --> 00:23:17.395 Testing at 0.06 and 0.3 makes per

NOTE Confidence: 0.831720452941176

00:23:17.395 --> 00:23:19.850 kig subcutaneously followed by weekly

NOTE Confidence: 0.831720452941176

00:23:19.937 --> 00:23:22.708 treatment of 1.5 mix perchik subcutaneously.

NOTE Confidence: 0.831720452941176

00:23:22.708 --> 00:23:25.907 The primary endpoint for the trial was

NOTE Confidence: 0.831720452941176

00:23:25.907 --> 00:23:27.984 overall response rates 40 patients

NOTE Confidence: 0.831720452941176

00:23:27.984 --> 00:23:30.684 were accrued in phase one on 125.

NOTE Confidence: 0.831720452941176

00:23:30.684 --> 00:23:31.986 In phase two.

NOTE Confidence: 0.831720452941176

00:23:31.986 --> 00:23:35.090 The median treatment duration was 5.9 months.

NOTE Confidence: 0.831720452941176

00:23:35.090 --> 00:23:37.880 38 patients had high rossetto genetics,

NOTE Confidence: 0.831720452941176

00:23:37.880 --> 00:23:40.560 20 with ISS three disease,

NOTE Confidence: 0.831720452941176

00:23:40.560 --> 00:23:42.588 and this is a heavily pretreated

NOTE Confidence: 0.831720452941176

00:23:42.588 --> 00:23:43.264 patient population.

NOTE Confidence: 0.831720452941176

00:23:43.270 --> 00:23:45.706 With five medium prior lines of therapy,

NOTE Confidence: 0.831720452941176

00:23:45.710 --> 00:23:47.270 again,

NOTE Confidence: 0.831720452941176

00:23:47.270 --> 00:23:49.766 165 patients were triple class exposed,  
NOTE Confidence: 0.831720452941176

00:23:49.770 --> 00:23:53.238 with 128 being considered triple class  
NOTE Confidence: 0.831720452941176

00:23:53.238 --> 00:23:57.139 refractory and 50 penta drug refractory.  
NOTE Confidence: 0.831720452941176

00:23:57.140 --> 00:23:59.250 Median follow-up with 7.8 months  
NOTE Confidence: 0.831720452941176

00:23:59.250 --> 00:24:01.968 and overall response rate was 62%,  
NOTE Confidence: 0.831720452941176

00:24:01.968 --> 00:24:04.400 with 58% achieving Avicii,  
NOTE Confidence: 0.831720452941176

00:24:04.400 --> 00:24:06.820 PR or better and 28.7%.  
NOTE Confidence: 0.831720452941176

00:24:06.820 --> 00:24:09.126 Achieving the CR, or better importantly,  
NOTE Confidence: 0.831720452941176

00:24:09.126 --> 00:24:11.768 the overall response rate of 62%  
NOTE Confidence: 0.831720452941176

00:24:11.768 --> 00:24:13.800 was consistent across clinically  
NOTE Confidence: 0.831720452941176

00:24:13.800 --> 00:24:14.816 relevant subgroups,  
NOTE Confidence: 0.831720452941176

00:24:14.820 --> 00:24:16.800 including those patients that had  
NOTE Confidence: 0.831720452941176

00:24:16.800 --> 00:24:18.780 high risk cytogenetics and those  
NOTE Confidence: 0.831720452941176

00:24:18.840 --> 00:24:20.760 that were penta drug refractory.  
NOTE Confidence: 0.831720452941176

00:24:20.760 --> 00:24:22.626 The median time to first response  
NOTE Confidence: 0.831720452941176

00:24:22.626 --> 00:24:23.708 was 1.2 months,

NOTE Confidence: 0.831720452941176

00:24:23.708 --> 00:24:25.628 with a progression free survival

NOTE Confidence: 0.831720452941176

00:24:25.628 --> 00:24:27.729 rate at nine months of 58.

NOTE Confidence: 0.831720452941176

00:24:27.730 --> 00:24:30.060 Lakeside percent in patients who

NOTE Confidence: 0.831720452941176

00:24:30.060 --> 00:24:32.810 did achieve a CR better MRD.

NOTE Confidence: 0.831720452941176

00:24:32.810 --> 00:24:36.618 Negativity rate was 41.9%.

NOTE Confidence: 0.831720452941176

00:24:36.620 --> 00:24:38.060 I'm looking at the safety data.

NOTE Confidence: 0.831720452941176

00:24:38.060 --> 00:24:40.010 The most common hematologic treatment.

NOTE Confidence: 0.831720452941176

00:24:40.010 --> 00:24:42.860 Emergent adverse event was neutropenia

NOTE Confidence: 0.831720452941176

00:24:42.860 --> 00:24:45.520 occurring in 65.5% of patients with the

NOTE Confidence: 0.831720452941176

00:24:45.520 --> 00:24:47.670 most common non unity logic treatment.

NOTE Confidence: 0.831720452941176

00:24:47.670 --> 00:24:50.185 Emergent Adverse bank was cytokine

NOTE Confidence: 0.831720452941176

00:24:50.185 --> 00:24:52.854 release syndrome occurring in 71.5% of

NOTE Confidence: 0.831720452941176

00:24:52.854 --> 00:24:55.470 patients and taking a closer look at CRS.

NOTE Confidence: 0.831720452941176

00:24:55.470 --> 00:24:57.528 The meeting time to onset was two

NOTE Confidence: 0.831720452941176

00:24:57.528 --> 00:24:59.747 days with the meeting duration of

NOTE Confidence: 0.831720452941176

00:24:59.747 --> 00:25:01.830 today's 60 patients did require  
NOTE Confidence: 0.831720452941176

00:25:01.830 --> 00:25:03.490 supportive care with tocilizumab.  
NOTE Confidence: 0.7125666455

00:25:05.740 --> 00:25:07.655 The conclusions from this presentation  
NOTE Confidence: 0.7125666455

00:25:07.655 --> 00:25:10.178 was that the overall response rate with  
NOTE Confidence: 0.7125666455

00:25:10.178 --> 00:25:12.776 tip list amount was 62% with responses  
NOTE Confidence: 0.7125666455

00:25:12.776 --> 00:25:15.788 that were durable and deepened overtime.  
NOTE Confidence: 0.7125666455

00:25:15.790 --> 00:25:17.374 Treatment was well tolerated  
NOTE Confidence: 0.7125666455

00:25:17.374 --> 00:25:18.958 with no dose reductions.  
NOTE Confidence: 0.7125666455

00:25:18.960 --> 00:25:21.510 The most common adverse events again  
NOTE Confidence: 0.7125666455

00:25:21.510 --> 00:25:23.750 were CRS and hematological events.  
NOTE Confidence: 0.7125666455

00:25:23.750 --> 00:25:26.888 The CRS for all low grade and 97%  
NOTE Confidence: 0.7125666455

00:25:26.888 --> 00:25:28.616 occurred during the step of dosing  
NOTE Confidence: 0.7125666455

00:25:28.616 --> 00:25:30.872 or cycle one of treatment and there  
NOTE Confidence: 0.7125666455

00:25:30.872 --> 00:25:33.154 was only one grade three event which  
NOTE Confidence: 0.7125666455

00:25:33.154 --> 00:25:35.580 resolved I can events were rare.  
NOTE Confidence: 0.7125666455

00:25:35.580 --> 00:25:36.603 If they occurred,

NOTE Confidence: 0.7125666455

00:25:36.603 --> 00:25:39.700 were all grade one and two and resolved,

NOTE Confidence: 0.7125666455

00:25:39.700 --> 00:25:43.436 moving on to another PC MA targeted fights.

NOTE Confidence: 0.7125666455

00:25:43.440 --> 00:25:45.900 And doctors and represented early,

NOTE Confidence: 0.7125666455

00:25:45.900 --> 00:25:46.641 deep and durable.

NOTE Confidence: 0.7125666455

00:25:46.641 --> 00:25:48.123 Response to this with low rates

NOTE Confidence: 0.7125666455

00:25:48.123 --> 00:25:49.659 of cytokine release syndrome.

NOTE Confidence: 0.7125666455

00:25:49.660 --> 00:25:52.180 With Regina on 5458.

NOTE Confidence: 0.7125666455

00:25:52.180 --> 00:25:55.160 Regenerx on 5458 again as ABC made.

NOTE Confidence: 0.7125666455

00:25:55.160 --> 00:25:56.396 CD3 bispecific antibody.

NOTE Confidence: 0.7125666455

00:25:56.396 --> 00:25:58.456 This is a phase one,

NOTE Confidence: 0.7125666455

00:25:58.460 --> 00:26:01.015 two first in human study with key

NOTE Confidence: 0.7125666455

00:26:01.015 --> 00:26:02.477 eligibility criteria including three

NOTE Confidence: 0.7125666455

00:26:02.477 --> 00:26:04.289 or more lines of prior therapy,

NOTE Confidence: 0.7125666455

00:26:04.290 --> 00:26:06.342 and these patients had to be

NOTE Confidence: 0.7125666455

00:26:06.342 --> 00:26:07.368 triple class refractory.

NOTE Confidence: 0.7125666455

00:26:07.370 --> 00:26:09.542 Part One was a dose escalation  
NOTE Confidence: 0.7125666455

00:26:09.542 --> 00:26:12.179 utilizing a modified 4 + 3 design with  
NOTE Confidence: 0.7125666455

00:26:12.179 --> 00:26:14.680 dose ranges from 3 to 800 milligrams.  
NOTE Confidence: 0.7125666455

00:26:14.680 --> 00:26:17.095 Part 2 will be adjust expansion at  
NOTE Confidence: 0.7125666455

00:26:17.095 --> 00:26:18.991 the recommended phase two dose step  
NOTE Confidence: 0.7125666455

00:26:18.991 --> 00:26:21.098 up dosing was utilized for week one  
NOTE Confidence: 0.7125666455

00:26:21.098 --> 00:26:23.589 and two followed by weekly dosing and  
NOTE Confidence: 0.7125666455

00:26:23.589 --> 00:26:26.419 then every other week dosing after 16 weeks.  
NOTE Confidence: 0.7125666455

00:26:26.420 --> 00:26:27.911 Primary endpoints included.  
NOTE Confidence: 0.7125666455

00:26:27.911 --> 00:26:28.408 Safety,  
NOTE Confidence: 0.7125666455

00:26:28.408 --> 00:26:30.893 tolerability and to determine the  
NOTE Confidence: 0.7125666455

00:26:30.893 --> 00:26:33.508 recommended phase two dose data for 73  
NOTE Confidence: 0.7125666455

00:26:33.508 --> 00:26:35.884 patients in phase one were presented.  
NOTE Confidence: 0.7125666455

00:26:35.890 --> 00:26:37.666 The median number of prior lens  
NOTE Confidence: 0.7125666455

00:26:37.666 --> 00:26:40.006 was five and 38% of patients  
NOTE Confidence: 0.7125666455

00:26:40.006 --> 00:26:42.318 were pentag wreck refractory.



NOTE Confidence: 0.7125666455

00:26:42.320 --> 00:26:44.216 And looking at the safety data,

NOTE Confidence: 0.7125666455

00:26:44.220 --> 00:26:46.060 the most common hematologic treatment,

NOTE Confidence: 0.7125666455

00:26:46.060 --> 00:26:47.556 emergent adverse event was

NOTE Confidence: 0.7125666455

00:26:47.556 --> 00:26:50.201 anemia seen in 32% of patients,

NOTE Confidence: 0.7125666455

00:26:50.201 --> 00:26:52.736 followed by lymphopenia and neutropenia.

NOTE Confidence: 0.7125666455

00:26:52.740 --> 00:26:55.062 The most common non hematological treatment

NOTE Confidence: 0.7125666455

00:26:55.062 --> 00:26:57.369 of urgent adverse event was fatigue.

NOTE Confidence: 0.7125666455

00:26:57.370 --> 00:26:57.803 Interestingly,

NOTE Confidence: 0.7125666455

00:26:57.803 --> 00:26:59.535 cytokine release syndrome was

NOTE Confidence: 0.7125666455

00:26:59.535 --> 00:27:01.923 only seen in 38% of patients.

NOTE Confidence: 0.7125666455

00:27:01.923 --> 00:27:04.089 This was question in the presentation

NOTE Confidence: 0.7125666455

00:27:04.089 --> 00:27:06.986 I ask and there was not a good reason

NOTE Confidence: 0.7125666455

00:27:06.986 --> 00:27:09.313 available as to why the rates of

NOTE Confidence: 0.7125666455

00:27:09.313 --> 00:27:11.360 serous were lower here compared with

NOTE Confidence: 0.7125666455

00:27:11.360 --> 00:27:13.360 other bispecific T cell engagers.

NOTE Confidence: 0.7125666455

00:27:13.360 --> 00:27:15.761 It was postulated that it may have  
NOTE Confidence: 0.7125666455

00:27:15.761 --> 00:27:18.659 to do with the step up dosing  
NOTE Confidence: 0.7125666455

00:27:18.659 --> 00:27:20.000 and or premedications.  
NOTE Confidence: 0.7125666455

00:27:20.000 --> 00:27:21.540 And looking at the efficacy,  
NOTE Confidence: 0.7125666455

00:27:21.540 --> 00:27:24.100 the overall response rates.  
NOTE Confidence: 0.7125666455

00:27:24.100 --> 00:27:25.444 Was 51%.  
NOTE Confidence: 0.7125666455

00:27:25.444 --> 00:27:29.598 This increased to 75% when you look  
NOTE Confidence: 0.7125666455

00:27:29.598 --> 00:27:32.720 at doses of 200 to 800 milligrams  
NOTE Confidence: 0.7125666455

00:27:32.823 --> 00:27:35.120 with a VGPR better at 58.5%.  
NOTE Confidence: 0.7125666455

00:27:35.120 --> 00:27:36.920 The mean time to response was  
NOTE Confidence: 0.7125666455

00:27:36.920 --> 00:27:38.250 less than one month,  
NOTE Confidence: 0.7125666455

00:27:38.250 --> 00:27:40.040 with 70% of responses occurring  
NOTE Confidence: 0.7125666455

00:27:40.040 --> 00:27:41.830 within the first two months.  
NOTE Confidence: 0.7125666455

00:27:41.830 --> 00:27:44.266 The duration of Response was not reached,  
NOTE Confidence: 0.7125666455

00:27:44.270 --> 00:27:46.646 and in patients who achieved a CR or  
NOTE Confidence: 0.7125666455

00:27:46.646 --> 00:27:49.426 stringent CR who had available data for Dove,

NOTE Confidence: 0.7125666455

00:27:49.426 --> 00:27:51.236 10 patients were MRD negative

NOTE Confidence: 0.7125666455

00:27:51.236 --> 00:27:53.118 at 10 to the minus 5.

NOTE Confidence: 0.626279934444444

00:27:59.310 --> 00:28:01.560 So in conclusion, the author showed

NOTE Confidence: 0.626279934444444

00:28:01.560 --> 00:28:03.848 that regenerate in 5458 yielded early,

NOTE Confidence: 0.626279934444444

00:28:03.848 --> 00:28:05.778 deepened Drabble responses as seen

NOTE Confidence: 0.626279934444444

00:28:05.778 --> 00:28:08.605 as an overall response rate is 75%.

NOTE Confidence: 0.626279934444444

00:28:08.605 --> 00:28:11.650 Fifty 8% of cheated BGR are better,

NOTE Confidence: 0.626279934444444

00:28:11.650 --> 00:28:13.760 again at the higher doses

NOTE Confidence: 0.626279934444444

00:28:13.760 --> 00:28:15.870 of 200 to 800 milligrams.

NOTE Confidence: 0.626279934444444

00:28:15.870 --> 00:28:17.520 86% of responders achieved VGPR

NOTE Confidence: 0.626279934444444

00:28:17.520 --> 00:28:20.547 better with a C or better rate of 43%.

NOTE Confidence: 0.626279934444444

00:28:20.547 --> 00:28:22.809 The probability of responders being invented

NOTE Confidence: 0.626279934444444

00:28:22.809 --> 00:28:25.667 free at 8 months was reported as 90.

NOTE Confidence: 0.626279934444444

00:28:25.670 --> 00:28:28.160 22% they showed an acceptable and

NOTE Confidence: 0.626279934444444

00:28:28.160 --> 00:28:30.649 manageable safety profile as the maximum

NOTE Confidence: 0.626279934444444

00:28:30.649 --> 00:28:33.316 tolerated dose was not reached with CRS  
NOTE Confidence: 0.6262799344444444

00:28:33.316 --> 00:28:35.938 being reported in only 38% of patients,  
NOTE Confidence: 0.6262799344444444

00:28:35.938 --> 00:28:37.768 the majority events were grade  
NOTE Confidence: 0.6262799344444444

00:28:37.768 --> 00:28:39.903 one occurred within the first two  
NOTE Confidence: 0.6262799344444444

00:28:39.903 --> 00:28:41.913 weeks and resolved within one day.  
NOTE Confidence: 0.6262799344444444

00:28:41.920 --> 00:28:44.554 The phase two portion of the  
NOTE Confidence: 0.6262799344444444

00:28:44.554 --> 00:28:46.310 study is currently recruiting.  
NOTE Confidence: 0.6262799344444444

00:28:46.310 --> 00:28:47.846 And moving away from a BCM,  
NOTE Confidence: 0.6262799344444444

00:28:47.850 --> 00:28:49.092 a target doctor,  
NOTE Confidence: 0.6262799344444444

00:28:49.092 --> 00:28:50.748 Krishnan presented updated Phase  
NOTE Confidence: 0.6262799344444444

00:28:50.748 --> 00:28:53.067 one results from monumental one at  
NOTE Confidence: 0.6262799344444444

00:28:53.067 --> 00:28:55.095 first in human study of Calcutta  
NOTE Confidence: 0.6262799344444444

00:28:55.095 --> 00:28:57.869 Mad so till catnip is a G protein  
NOTE Confidence: 0.6262799344444444

00:28:57.869 --> 00:28:58.883 coupled receptor family.  
NOTE Confidence: 0.6262799344444444

00:28:58.890 --> 00:29:02.272 See Group 5D Member D as also  
NOTE Confidence: 0.6262799344444444

00:29:02.272 --> 00:29:04.127 known as GPRC 5D CD.

NOTE Confidence: 0.626279934444444

00:29:04.130 --> 00:29:06.422 3 bispecific antibody she presented updated

NOTE Confidence: 0.626279934444444

00:29:06.422 --> 00:29:09.149 data at the first recommended phase.

NOTE Confidence: 0.626279934444444

00:29:09.150 --> 00:29:11.096 Two dose and initial results for patients

NOTE Confidence: 0.626279934444444

00:29:11.096 --> 00:29:12.829 treated as second recommended phase.

NOTE Confidence: 0.626279934444444

00:29:12.830 --> 00:29:14.885 Two dose of 800 micrograms

NOTE Confidence: 0.626279934444444

00:29:14.885 --> 00:29:16.940 per kilogram Q 2 weeks.

NOTE Confidence: 0.626279934444444

00:29:16.940 --> 00:29:18.670 Patients had to be relapsed

NOTE Confidence: 0.626279934444444

00:29:18.670 --> 00:29:20.400 refractory or intolerant to all

NOTE Confidence: 0.626279934444444

00:29:20.459 --> 00:29:22.584 established my limit therapies and

NOTE Confidence: 0.626279934444444

00:29:22.584 --> 00:29:24.257 have measurable disease previously.

NOTE Confidence: 0.626279934444444

00:29:24.257 --> 00:29:25.448 A recommended phase.

NOTE Confidence: 0.626279934444444

00:29:25.448 --> 00:29:28.820 Two dose of 405 micrograms per kilogram

NOTE Confidence: 0.626279934444444

00:29:28.820 --> 00:29:31.000 weekly subcutaneously was identified.

NOTE Confidence: 0.626279934444444

00:29:31.000 --> 00:29:32.836 Step up testing was utilized and

NOTE Confidence: 0.626279934444444

00:29:32.836 --> 00:29:34.698 premedication was given before all step up,

NOTE Confidence: 0.626279934444444

00:29:34.700 --> 00:29:37.100 dusting and the first full dose.  
NOTE Confidence: 0.6262799344444444

00:29:37.100 --> 00:29:38.552 The primary end point was to  
NOTE Confidence: 0.6262799344444444

00:29:38.552 --> 00:29:39.520 identify the recommended phase.  
NOTE Confidence: 0.6262799344444444

00:29:39.520 --> 00:29:41.698 Two dose is 30 patients received  
NOTE Confidence: 0.6262799344444444

00:29:41.698 --> 00:29:43.978 weekly dosing and 25 at the key.  
NOTE Confidence: 0.6262799344444444

00:29:43.980 --> 00:29:45.324 Two weekly schedule.  
NOTE Confidence: 0.6262799344444444

00:29:45.324 --> 00:29:46.668 Three patients in.  
NOTE Confidence: 0.6262799344444444

00:29:46.670 --> 00:29:49.208 Each cohort had high risk genetics.  
NOTE Confidence: 0.6262799344444444

00:29:49.210 --> 00:29:50.710 The meeting number of pirate  
NOTE Confidence: 0.6262799344444444

00:29:50.710 --> 00:29:52.210 therapies was six and five,  
NOTE Confidence: 0.6262799344444444

00:29:52.210 --> 00:29:53.610 and eight and four patients,  
NOTE Confidence: 0.6262799344444444

00:29:53.610 --> 00:29:54.271 respectively,  
NOTE Confidence: 0.6262799344444444

00:29:54.271 --> 00:29:58.237 had prior be CMA directed therapy.  
NOTE Confidence: 0.6262799344444444

00:29:58.240 --> 00:30:00.015 And looking at the hematological  
NOTE Confidence: 0.6262799344444444

00:30:00.015 --> 00:30:01.435 treatment emergent adverse events,  
NOTE Confidence: 0.6262799344444444

00:30:01.440 --> 00:30:04.080 the most common was neutropenia and

NOTE Confidence: 0.626279934444444

00:30:04.080 --> 00:30:06.864 67 and 44% of patients followed

NOTE Confidence: 0.626279934444444

00:30:06.864 --> 00:30:08.768 by anemia and lymphopenia.

NOTE Confidence: 0.626279934444444

00:30:08.770 --> 00:30:11.260 The most common nonhematologic treatment

NOTE Confidence: 0.626279934444444

00:30:11.260 --> 00:30:13.750 emergent adverse event was cytokine

NOTE Confidence: 0.626279934444444

00:30:13.825 --> 00:30:16.316 release syndrome seen in 77 and 72%.

NOTE Confidence: 0.626279934444444

00:30:16.316 --> 00:30:19.960 It should be noted that 75% of patients did

NOTE Confidence: 0.626279934444444

00:30:19.960 --> 00:30:22.700 have skin and or nail related findings.

NOTE Confidence: 0.626279934444444

00:30:22.700 --> 00:30:23.966 In the study,

NOTE Confidence: 0.626279934444444

00:30:23.966 --> 00:30:26.076 the most common being skin

NOTE Confidence: 0.626279934444444

00:30:26.076 --> 00:30:28.558 exfoliation in 37 and 36% of patients.

NOTE Confidence: 0.626279934444444

00:30:28.558 --> 00:30:31.970 And taking a closer look at the CRS again,

NOTE Confidence: 0.626279934444444

00:30:31.970 --> 00:30:34.410 it was 77 and 72%.

NOTE Confidence: 0.626279934444444

00:30:34.410 --> 00:30:36.210 The median onset was two days,

NOTE Confidence: 0.626279934444444

00:30:36.210 --> 00:30:39.647 with the median duration of two days

NOTE Confidence: 0.626279934444444

00:30:39.650 --> 00:30:42.471 63.3% and 60% of patients in the

NOTE Confidence: 0.626279934444444

00:30:42.471 --> 00:30:44.978 two cohorts did require Tuscaloosa  
NOTE Confidence: 0.6262799344444444

00:30:44.978 --> 00:30:47.390 Mab for supportive care.  
NOTE Confidence: 0.6262799344444444

00:30:47.390 --> 00:30:48.735 And looking at overall response  
NOTE Confidence: 0.6262799344444444

00:30:48.735 --> 00:30:50.310 data at the median follow-up was  
NOTE Confidence: 0.6262799344444444

00:30:50.310 --> 00:30:51.604 nine and 4.8 months.  
NOTE Confidence: 0.6262799344444444

00:30:51.604 --> 00:30:54.406 They shouldn't overall response rate of  
NOTE Confidence: 0.6262799344444444

00:30:54.410 --> 00:30:59.230 70% and 67.7% for the Q2 week dosing.  
NOTE Confidence: 0.6262799344444444

00:30:59.230 --> 00:31:02.853 With Fiji, Fiji PR rates of 53.3 and 52.4.  
NOTE Confidence: 0.6262799344444444

00:31:02.853 --> 00:31:05.240 The trial also showed that the overall  
NOTE Confidence: 0.6262799344444444

00:31:05.308 --> 00:31:07.738 response rate held in patients who  
NOTE Confidence: 0.6262799344444444

00:31:07.738 --> 00:31:10.295 were triple class refractory at 65.2  
NOTE Confidence: 0.6262799344444444

00:31:10.295 --> 00:31:13.694 and 66.7% and in patients who are  
NOTE Confidence: 0.6262799344444444

00:31:13.694 --> 00:31:15.830 penta directory factory at 83.3%.  
NOTE Confidence: 0.6262799344444444

00:31:15.830 --> 00:31:17.630 Although the numbers are low.  
NOTE Confidence: 0.565365134

00:31:17.630 --> 00:31:20.120 Five out of 6 patients.  
NOTE Confidence: 0.565365134

00:31:20.120 --> 00:31:21.776 The median time to response was



NOTE Confidence: 0.565365134

00:31:21.776 --> 00:31:23.540 zero point 9 and 1.2 months,

NOTE Confidence: 0.565365134

00:31:23.540 --> 00:31:25.190 and the median duration of

NOTE Confidence: 0.565365134

00:31:25.190 --> 00:31:26.720 response was not reached.

NOTE Confidence: 0.565365134

00:31:26.720 --> 00:31:28.010 So in conclusion,

NOTE Confidence: 0.565365134

00:31:28.010 --> 00:31:31.020 the until catnip 800 microgram per KQ,

NOTE Confidence: 0.565365134

00:31:31.020 --> 00:31:32.916 two week dosing appeared to have

NOTE Confidence: 0.565365134

00:31:32.916 --> 00:31:34.180 comparable efficacy and safety

NOTE Confidence: 0.565365134

00:31:34.233 --> 00:31:35.568 compared to the weekly dosing

NOTE Confidence: 0.565365134

00:31:35.568 --> 00:31:37.760 at 405 micrograms per kilogram.

NOTE Confidence: 0.565365134

00:31:37.760 --> 00:31:40.640 No new safety signals were reported.

NOTE Confidence: 0.565365134

00:31:40.640 --> 00:31:42.560 Overall response rates range from

NOTE Confidence: 0.565365134

00:31:42.560 --> 00:31:45.465 67 to 70% across triple class and

NOTE Confidence: 0.565365134

00:31:45.465 --> 00:31:47.380 pencil drug refractory patients

NOTE Confidence: 0.565365134

00:31:47.380 --> 00:31:48.658 and a phase two expansion study

NOTE Confidence: 0.565365134

00:31:48.658 --> 00:31:50.090 of both of these recommended.

NOTE Confidence: 0.565365134

00:31:50.090 --> 00:31:53.260 Ways to Jesse is ongoing.  
NOTE Confidence: 0.565365134

00:31:53.260 --> 00:31:56.080 And moving away from the bispecific  
NOTE Confidence: 0.565365134

00:31:56.080 --> 00:31:58.230 antibodies and a presentation  
NOTE Confidence: 0.565365134

00:31:58.230 --> 00:32:00.470 was done on loaded,  
NOTE Confidence: 0.565365134

00:32:00.470 --> 00:32:03.508 loaded excuse me alpha which is immuno  
NOTE Confidence: 0.565365134

00:32:03.508 --> 00:32:05.520 cytokine shows clinical activity.  
NOTE Confidence: 0.565365134

00:32:05.520 --> 00:32:07.160 Updated results from my first  
NOTE Confidence: 0.565365134

00:32:07.160 --> 00:32:08.800 in human phase one study.  
NOTE Confidence: 0.565365134

00:32:08.800 --> 00:32:10.893 So Mataka Alpha is a first in  
NOTE Confidence: 0.565365134

00:32:10.893 --> 00:32:13.223 class in unison in you know  
NOTE Confidence: 0.565365134

00:32:13.223 --> 00:32:15.035 cytokine designed to deliver  
NOTE Confidence: 0.565365134

00:32:15.035 --> 00:32:16.860 attenuated interferon alpha to CD.  
NOTE Confidence: 0.565365134

00:32:16.860 --> 00:32:18.450 38 positive cells patients were  
NOTE Confidence: 0.565365134

00:32:18.450 --> 00:32:20.425 eligible if they had three or  
NOTE Confidence: 0.565365134

00:32:20.425 --> 00:32:22.399 more prior lines of therapy were  
NOTE Confidence: 0.565365134

00:32:22.399 --> 00:32:24.099 refractory or intolerant to at least.

NOTE Confidence: 0.565365134  
00:32:24.100 --> 00:32:27.687 One P&M and and could have prior  
NOTE Confidence: 0.565365134  
00:32:27.687 --> 00:32:28.854 daratumumab exposure within  
NOTE Confidence: 0.565365134  
00:32:28.854 --> 00:32:30.959 a washout period of 90 days.  
NOTE Confidence: 0.565365134  
00:32:30.960 --> 00:32:32.300 For patients who had received  
NOTE Confidence: 0.565365134  
00:32:32.300 --> 00:32:34.028 more than five months of therapy  
NOTE Confidence: 0.565365134  
00:32:34.028 --> 00:32:35.376 in the escalation portion,  
NOTE Confidence: 0.565365134  
00:32:35.380 --> 00:32:38.338 the primary objective was determine the  
NOTE Confidence: 0.565365134  
00:32:38.338 --> 00:32:40.516 maximum tolerated dose and the dose  
NOTE Confidence: 0.565365134  
00:32:40.516 --> 00:32:42.659 escalation phase at 3 + 3 design was used.  
NOTE Confidence: 0.565365134  
00:32:42.660 --> 00:32:44.272 Looking at four different  
NOTE Confidence: 0.565365134  
00:32:44.272 --> 00:32:46.287 schedules in the expansion phase,  
NOTE Confidence: 0.565365134  
00:32:46.290 --> 00:32:48.160 they looked at a dose of 0.4 and  
NOTE Confidence: 0.565365134  
00:32:48.160 --> 00:32:49.540 makes per cake every three weeks,  
NOTE Confidence: 0.565365134  
00:32:49.540 --> 00:32:51.284 with or without dexamethasone.  
NOTE Confidence: 0.565365134  
00:32:51.284 --> 00:32:53.900 Data was presented in 29 patients,  
NOTE Confidence: 0.565365134

00:32:53.900 --> 00:32:55.046 7 of 20.  
NOTE Confidence: 0.565365134

00:32:55.046 --> 00:32:57.338 Five patients were that had cytogenetic  
NOTE Confidence: 0.565365134

00:32:57.338 --> 00:33:00.109 data were considered to be high risk.  
NOTE Confidence: 0.565365134

00:33:00.110 --> 00:33:02.644 The meeting number of prior lines with  
NOTE Confidence: 0.565365134

00:33:02.644 --> 00:33:05.154 therapy was 728 patients had prior  
NOTE Confidence: 0.565365134

00:33:05.154 --> 00:33:07.384 CD 38 monoclonal antibody treatment.  
NOTE Confidence: 0.565365134

00:33:07.390 --> 00:33:09.982 26 of those patients were considered  
NOTE Confidence: 0.565365134

00:33:09.982 --> 00:33:12.157 to be monoclonal antibody refractory  
NOTE Confidence: 0.565365134

00:33:12.157 --> 00:33:14.413 and 15 patients had prior anti  
NOTE Confidence: 0.565365134

00:33:14.413 --> 00:33:16.659 PC and major active therapy.  
NOTE Confidence: 0.565365134

00:33:16.660 --> 00:33:18.315 The maximum tolerated dose was  
NOTE Confidence: 0.565365134

00:33:18.315 --> 00:33:20.678 exceeded at six weeks per kid Q4  
NOTE Confidence: 0.565365134

00:33:20.678 --> 00:33:22.278 week dosing due to disciplining  
NOTE Confidence: 0.565365134

00:33:22.278 --> 00:33:24.408 toxicities of a Grade 3 infusion  
NOTE Confidence: 0.565365134

00:33:24.408 --> 00:33:26.192 reaction and prolonged grade.  
NOTE Confidence: 0.565365134

00:33:26.192 --> 00:33:28.696 4 thrombocytopenia and neutropenia.

NOTE Confidence: 0.565365134  
00:33:28.700 --> 00:33:30.578 As a 1.5 mix per KQ,  
NOTE Confidence: 0.565365134  
00:33:30.580 --> 00:33:31.462 four week dosing,  
NOTE Confidence: 0.565365134  
00:33:31.462 --> 00:33:33.226 one patient did have a great  
NOTE Confidence: 0.565365134  
00:33:33.226 --> 00:33:35.116 treat bleeding event but was able  
NOTE Confidence: 0.565365134  
00:33:35.116 --> 00:33:37.064 to remain on treatment and three  
NOTE Confidence: 0.565365134  
00:33:37.064 --> 00:33:38.859 patients had grade 3 infections.  
NOTE Confidence: 0.565365134  
00:33:38.860 --> 00:33:40.455 The most commonly seen treatment  
NOTE Confidence: 0.565365134  
00:33:40.455 --> 00:33:42.050 emergent adverse events at the  
NOTE Confidence: 0.565365134  
00:33:42.050 --> 00:33:44.234 1.5 MB per kid Q4 week dosing,  
NOTE Confidence: 0.565365134  
00:33:44.240 --> 00:33:46.500 where hematologic with thrombocytopenia  
NOTE Confidence: 0.565365134  
00:33:46.500 --> 00:33:49.130 and current 76% of patients and  
NOTE Confidence: 0.565365134  
00:33:49.130 --> 00:33:51.293 neutropenia and 69% all grades.  
NOTE Confidence: 0.565365134  
00:33:51.293 --> 00:33:52.706 Infusion related reactions  
NOTE Confidence: 0.565365134  
00:33:52.706 --> 00:33:55.221 did occur in 31% of patients.  
NOTE Confidence: 0.565365134  
00:33:55.221 --> 00:33:58.170 Most of these were grade one and two.  
NOTE Confidence: 0.565365134

00:33:58.170 --> 00:34:00.879 The median follow-up was 4.2 months and  
NOTE Confidence: 0.565365134

00:34:00.879 --> 00:34:03.838 the overall response rate was 38% of note.  
NOTE Confidence: 0.565365134

00:34:03.838 --> 00:34:05.868 The overall response rate held  
NOTE Confidence: 0.565365134

00:34:05.868 --> 00:34:09.088 at 38% in patients who were CD  
NOTE Confidence: 0.565365134

00:34:09.088 --> 00:34:10.960 38 monoclonal antibody factory.  
NOTE Confidence: 0.565365134

00:34:10.960 --> 00:34:12.920 The median time to response was one month.  
NOTE Confidence: 0.565365134

00:34:12.920 --> 00:34:14.887 In those patients who achieved a PR  
NOTE Confidence: 0.565365134

00:34:14.887 --> 00:34:16.800 or better with a median duration  
NOTE Confidence: 0.565365134

00:34:16.800 --> 00:34:18.485 of response not being reached,  
NOTE Confidence: 0.565365134

00:34:18.490 --> 00:34:19.962 the median progression free  
NOTE Confidence: 0.565365134

00:34:19.962 --> 00:34:22.950 survival was 5.7 months.  
NOTE Confidence: 0.565365134

00:34:22.950 --> 00:34:24.225 So in conclusion,  
NOTE Confidence: 0.565365134

00:34:24.225 --> 00:34:25.925 Modaco Alpha showed promising  
NOTE Confidence: 0.565365134

00:34:25.925 --> 00:34:27.200 single agent activity  
NOTE Confidence: 0.7402168875

00:34:27.264 --> 00:34:29.790 and patients who were heavily pretreated,  
NOTE Confidence: 0.7402168875

00:34:29.790 --> 00:34:31.209 including patients who

NOTE Confidence: 0.7402168875

00:34:31.209 --> 00:34:32.628 were refractory toasty.

NOTE Confidence: 0.7402168875

00:34:32.630 --> 00:34:34.538 38 monoclonal antibody had

NOTE Confidence: 0.7402168875

00:34:34.538 --> 00:34:36.446 a manageable safety profile.

NOTE Confidence: 0.7402168875

00:34:36.450 --> 00:34:38.886 Q For Weeks was identified as the

NOTE Confidence: 0.7402168875

00:34:38.886 --> 00:34:40.838 optimal dosing interval and further

NOTE Confidence: 0.7402168875

00:34:40.838 --> 00:34:42.522 enrollment identified the maximum

NOTE Confidence: 0.7402168875

00:34:42.522 --> 00:34:45.070 tolerated dose as three mics per keg.

NOTE Confidence: 0.7402168875

00:34:45.070 --> 00:34:47.296 A randomized phase two trial is

NOTE Confidence: 0.7402168875

00:34:47.296 --> 00:34:49.363 planned in order to determine

NOTE Confidence: 0.7402168875

00:34:49.363 --> 00:34:51.908 the optimal single agent dosing.

NOTE Confidence: 0.7402168875

00:34:51.910 --> 00:34:54.225 Lastly, Dr Lonial presented herbicide

NOTE Confidence: 0.7402168875

00:34:54.225 --> 00:34:56.540 in combination with dexamethasone in

NOTE Confidence: 0.7402168875

00:34:56.602 --> 00:34:59.227 patients with relapsed refractory myeloma.

NOTE Confidence: 0.7402168875

00:34:59.230 --> 00:35:00.819 Results from the district expansion of the

NOTE Confidence: 0.703098704545455

00:35:03.050 --> 00:35:03.860 CC-220MM-001 trial.

NOTE Confidence: 0.703098704545455

00:35:03.860 --> 00:35:05.885 Roberta Mine is a novel  
NOTE Confidence: 0.703098704545455

00:35:05.885 --> 00:35:07.652 cereblon E3 lig is modulator,  
NOTE Confidence: 0.703098704545455

00:35:07.652 --> 00:35:09.704 also known as the cell Mod.  
NOTE Confidence: 0.703098704545455

00:35:09.710 --> 00:35:11.198 This was a phase one two study that,  
NOTE Confidence: 0.703098704545455

00:35:11.200 --> 00:35:13.490 evaluated at EBR with different  
NOTE Confidence: 0.703098704545455

00:35:13.490 --> 00:35:14.864 combinations of treatment.  
NOTE Confidence: 0.703098704545455

00:35:14.870 --> 00:35:16.976 Previously, the recommended phase two dose  
NOTE Confidence: 0.703098704545455

00:35:16.976 --> 00:35:19.116 was identified as 1.6 milligrams days,  
NOTE Confidence: 0.703098704545455

00:35:19.116 --> 00:35:21.288 one through 21 every 28 days.  
NOTE Confidence: 0.703098704545455

00:35:21.290 --> 00:35:22.870 When given in combination  
NOTE Confidence: 0.703098704545455

00:35:22.870 --> 00:35:24.004 with dexamethasone here,  
NOTE Confidence: 0.703098704545455

00:35:24.004 --> 00:35:25.724 she reported safety and efficacy  
NOTE Confidence: 0.703098704545455

00:35:25.724 --> 00:35:27.610 and the dose expansion cohorts.  
NOTE Confidence: 0.703098704545455

00:35:27.610 --> 00:35:29.787 Cohort D, which is Eber plus tax  
NOTE Confidence: 0.703098704545455

00:35:29.787 --> 00:35:32.142 and cohort I which was Eber plus  
NOTE Confidence: 0.703098704545455

00:35:32.142 --> 00:35:34.660 tax in patients who had prior BC



NOTE Confidence: 0.703098704545455  
00:35:34.660 --> 00:35:36.390 made treatments for both cohorts.  
NOTE Confidence: 0.703098704545455  
00:35:36.390 --> 00:35:38.847 Patients had to have three or more lines  
NOTE Confidence: 0.703098704545455  
00:35:38.847 --> 00:35:41.207 of prior therapy and again for cohort I.  
NOTE Confidence: 0.703098704545455  
00:35:41.210 --> 00:35:43.778 All patients had treatment with her  
NOTE Confidence: 0.703098704545455  
00:35:43.778 --> 00:35:46.318 prior PC may targeted Agent 107.  
NOTE Confidence: 0.703098704545455  
00:35:46.318 --> 00:35:48.964 In patients were treated in cohort D  
NOTE Confidence: 0.703098704545455  
00:35:48.964 --> 00:35:52.090 and 26 in poker I 32 patients and six.  
NOTE Confidence: 0.703098704545455  
00:35:52.090 --> 00:35:52.840 Patients respectively,  
NOTE Confidence: 0.703098704545455  
00:35:52.840 --> 00:35:54.540 had high risk cytogenetics in  
NOTE Confidence: 0.703098704545455  
00:35:54.540 --> 00:35:55.560 the two cohorts.  
NOTE Confidence: 0.703098704545455  
00:35:55.560 --> 00:35:57.396 The median number of pirate therapies  
NOTE Confidence: 0.703098704545455  
00:35:57.396 --> 00:35:59.601 was six and seven in Cohort I6.  
NOTE Confidence: 0.703098704545455  
00:35:59.601 --> 00:36:01.563 Patients had prior card T 18  
NOTE Confidence: 0.703098704545455  
00:36:01.563 --> 00:36:03.680 and antibody drug conjugate,  
NOTE Confidence: 0.703098704545455  
00:36:03.680 --> 00:36:05.768 and eight bispecific T cell engager.  
NOTE Confidence: 0.832980580769231

00:36:07.990 --> 00:36:10.185 The most common adverse events  
NOTE Confidence: 0.832980580769231

00:36:10.185 --> 00:36:11.941 working talajic with neutropenia  
NOTE Confidence: 0.832980580769231

00:36:11.941 --> 00:36:13.170 occurring in 59 point,  
NOTE Confidence: 0.832980580769231

00:36:13.170 --> 00:36:18.198 8% in cohort D and 42.3% in cohort I.  
NOTE Confidence: 0.832980580769231

00:36:18.200 --> 00:36:20.808 Infections were common at  
NOTE Confidence: 0.832980580769231

00:36:20.808 --> 00:36:22.561 57.9% AL grading Health,  
NOTE Confidence: 0.832980580769231

00:36:22.561 --> 00:36:26.538 Part D and 50% in Coker I.  
NOTE Confidence: 0.832980580769231

00:36:26.540 --> 00:36:28.340 I'm looking at the response data.  
NOTE Confidence: 0.832980580769231

00:36:28.340 --> 00:36:30.500 The overall response was 26.24,  
NOTE Confidence: 0.832980580769231

00:36:30.500 --> 00:36:33.475 cohort D and 25% in cohort I.  
NOTE Confidence: 0.832980580769231

00:36:33.480 --> 00:36:35.290 Again this year they post  
NOTE Confidence: 0.832980580769231

00:36:35.290 --> 00:36:36.738 be CMA treated patients.  
NOTE Confidence: 0.832980580769231

00:36:36.740 --> 00:36:38.370 Additional data was presented for  
NOTE Confidence: 0.832980580769231

00:36:38.370 --> 00:36:40.383 Cohort D with a median duration  
NOTE Confidence: 0.832980580769231

00:36:40.383 --> 00:36:42.303 of response of seven months and  
NOTE Confidence: 0.832980580769231

00:36:42.303 --> 00:36:44.249 median time to respond to 4.21

NOTE Confidence: 0.832980580769231

00:36:44.249 --> 00:36:45.944 weeks and a median progression

NOTE Confidence: 0.832980580769231

00:36:45.944 --> 00:36:47.770 free survival of three months.

NOTE Confidence: 0.832980580769231

00:36:47.770 --> 00:36:49.280 The authors concluded that in

NOTE Confidence: 0.832980580769231

00:36:49.280 --> 00:36:50.186 heavily pretreated patients,

NOTE Confidence: 0.832980580769231

00:36:50.190 --> 00:36:52.890 again 97% were Triple Classic factory.

NOTE Confidence: 0.832980580769231

00:36:52.890 --> 00:36:54.690 The combination of ever, ever,

NOTE Confidence: 0.832980580769231

00:36:54.690 --> 00:36:56.554 and Dex demonstrated clinically

NOTE Confidence: 0.832980580769231

00:36:56.554 --> 00:36:58.418 meaningful and durable responses.

NOTE Confidence: 0.832980580769231

00:36:58.420 --> 00:37:00.390 The treatment was well tolerated

NOTE Confidence: 0.832980580769231

00:37:00.390 --> 00:37:02.927 with adverse events that were deemed

NOTE Confidence: 0.832980580769231

00:37:02.927 --> 00:37:04.931 manageable with dose reductions

NOTE Confidence: 0.832980580769231

00:37:04.931 --> 00:37:06.935 and interruptions and treatment.

NOTE Confidence: 0.832980580769231

00:37:06.940 --> 00:37:08.986 Authority of grade three or four

NOTE Confidence: 0.832980580769231

00:37:08.986 --> 00:37:10.350 treatment emergent adverse events

NOTE Confidence: 0.832980580769231

00:37:10.410 --> 00:37:12.432 were primarily hematological and this

NOTE Confidence: 0.832980580769231

00:37:12.432 --> 00:37:13.576 supported the future development.  
NOTE Confidence: 0.832980580769231

00:37:13.580 --> 00:37:15.855 Iber based regimens including combination  
NOTE Confidence: 0.832980580769231

00:37:15.855 --> 00:37:18.380 studies with PRISM inhibitors and CD.  
NOTE Confidence: 0.832980580769231

00:37:18.380 --> 00:37:21.650 38 monoclonal antibodies.  
NOTE Confidence: 0.832980580769231

00:37:21.650 --> 00:37:23.010 I will stop there.  
NOTE Confidence: 0.832980580769231

00:37:23.010 --> 00:37:24.030 As previously stated,  
NOTE Confidence: 0.832980580769231

00:37:24.030 --> 00:37:25.620 all questions will be answered  
NOTE Confidence: 0.832980580769231

00:37:25.620 --> 00:37:27.810 at the end of the program.  
NOTE Confidence: 0.832980580769231

00:37:27.810 --> 00:37:29.600 Please encourage you to submit  
NOTE Confidence: 0.832980580769231

00:37:29.600 --> 00:37:32.319 this in the Q&A portion and now I  
NOTE Confidence: 0.832980580769231

00:37:32.319 --> 00:37:34.314 will turn it over to Doctor Barr.  
NOTE Confidence: 0.9398939

00:37:47.810 --> 00:37:52.259 Thank you Terry so. Let's get started.  
NOTE Confidence: 0.9398939

00:37:52.259 --> 00:37:55.547 I'm focusing on car T cell therapy in  
NOTE Confidence: 0.9398939

00:37:55.547 --> 00:37:58.197 the relapsed refractory myeloma patients.  
NOTE Confidence: 0.9398939

00:37:58.200 --> 00:38:00.510 I want to highlight that patients  
NOTE Confidence: 0.9398939

00:38:00.510 --> 00:38:02.968 who are refractory to image produce

NOTE Confidence: 0.9398939

00:38:02.968 --> 00:38:05.488 them inhibitors and anti CD 38

NOTE Confidence: 0.9398939

00:38:05.488 --> 00:38:07.598 antibodies have a poor prognosis.

NOTE Confidence: 0.9398939

00:38:07.600 --> 00:38:09.265 These are triple class refractory

NOTE Confidence: 0.9398939

00:38:09.265 --> 00:38:11.262 patients and when these patients if

NOTE Confidence: 0.9398939

00:38:11.262 --> 00:38:12.906 they get another line of treatment,

NOTE Confidence: 0.9398939

00:38:12.910 --> 00:38:14.920 the chance that they will respond

NOTE Confidence: 0.9398939

00:38:14.920 --> 00:38:17.090 to another agent is roughly 30%.

NOTE Confidence: 0.9398939

00:38:17.090 --> 00:38:18.035 If they respond,

NOTE Confidence: 0.9398939

00:38:18.035 --> 00:38:19.610 the median progression free survival

NOTE Confidence: 0.9398939

00:38:19.610 --> 00:38:21.368 is often less than six months,

NOTE Confidence: 0.9398939

00:38:21.370 --> 00:38:23.054 with median overall survival

NOTE Confidence: 0.9398939

00:38:23.054 --> 00:38:25.159 often less than one year.

NOTE Confidence: 0.9398939

00:38:25.160 --> 00:38:27.015 Now I want to show you how

NOTE Confidence: 0.9398939

00:38:27.015 --> 00:38:29.029 this is no longer the case,

NOTE Confidence: 0.9398939

00:38:29.030 --> 00:38:33.086 as most of you already know that in

NOTE Confidence: 0.9398939

00:38:33.090 --> 00:38:35.253 2021 the FDA approved the first car  
NOTE Confidence: 0.9398939

00:38:35.253 --> 00:38:38.032 T cell product in myeloma this is.  
NOTE Confidence: 0.9398939

00:38:38.032 --> 00:38:41.948 Called either sell formerly known as BB  
NOTE Confidence: 0.9398939

00:38:41.948 --> 00:38:45.666 2121 and now the train name is a Beckman.  
NOTE Confidence: 0.9398939

00:38:45.666 --> 00:38:48.530 This is a car T cell product that  
NOTE Confidence: 0.9398939

00:38:48.616 --> 00:38:50.848 has four one BB costimulatory  
NOTE Confidence: 0.9398939

00:38:50.848 --> 00:38:54.078 domain and it binds to BCMA on the  
NOTE Confidence: 0.9398939

00:38:54.078 --> 00:38:55.554 cell surface of the tumor cell.  
NOTE Confidence: 0.9398939

00:38:55.560 --> 00:38:57.865 It's approved for patients who  
NOTE Confidence: 0.9398939

00:38:57.865 --> 00:39:00.170 are refractory to image PRISM  
NOTE Confidence: 0.9398939

00:39:00.255 --> 00:39:03.191 inhibitor and anti CD 38 antibody's.  
NOTE Confidence: 0.9398939

00:39:03.191 --> 00:39:06.464 76% of the patients responded about a  
NOTE Confidence: 0.9398939

00:39:06.464 --> 00:39:08.858 third of the patients achieve deep responses.  
NOTE Confidence: 0.9398939

00:39:08.860 --> 00:39:11.880 CR and stringent complete response.  
NOTE Confidence: 0.9398939

00:39:11.880 --> 00:39:14.160 Most of those patients were emordi  
NOTE Confidence: 0.9398939

00:39:14.160 --> 00:39:15.680 negative potential negative 5th

NOTE Confidence: 0.9398939

00:39:15.746 --> 00:39:17.650 using next generation sequencing.

NOTE Confidence: 0.9398939

00:39:17.650 --> 00:39:18.104 Now,

NOTE Confidence: 0.9398939

00:39:18.104 --> 00:39:20.828 these patients had initially dose escalation,

NOTE Confidence: 0.9398939

00:39:20.830 --> 00:39:24.268 so not all of them received the same dose.

NOTE Confidence: 0.9398939

00:39:24.270 --> 00:39:25.845 If you look at the total population,

NOTE Confidence: 0.9398939

00:39:25.850 --> 00:39:27.830 the median progression free survival,

NOTE Confidence: 0.9398939

00:39:27.830 --> 00:39:30.380 survival was 8.8 months,

NOTE Confidence: 0.9398939

00:39:30.380 --> 00:39:32.310 but if you hone in on the target dose,

NOTE Confidence: 0.9398939

00:39:32.310 --> 00:39:33.446 the patients that received

NOTE Confidence: 0.9398939

00:39:33.446 --> 00:39:34.866 the target FDA approved dose.

NOTE Confidence: 0.9398939

00:39:34.870 --> 00:39:36.490 It is about one year.

NOTE Confidence: 0.9398939

00:39:36.490 --> 00:39:39.740 All the population median overall

NOTE Confidence: 0.9398939

00:39:39.740 --> 00:39:41.690 survival 24 months.

NOTE Confidence: 0.9398939

00:39:41.690 --> 00:39:43.524 Now we also know that deep responses

NOTE Confidence: 0.9398939

00:39:43.524 --> 00:39:45.448 lead to longer duration of response,

NOTE Confidence: 0.9398939

00:39:45.450 --> 00:39:47.490 and here I show you a graph where  
NOTE Confidence: 0.9398939

00:39:47.490 --> 00:39:49.300 patients who have a CR complete  
NOTE Confidence: 0.9398939

00:39:49.300 --> 00:39:50.540 response or higher exemplified  
NOTE Confidence: 0.9398939

00:39:50.540 --> 00:39:52.489 by the light blue line compared  
NOTE Confidence: 0.9398939

00:39:52.489 --> 00:39:54.385 to very good partial response by  
NOTE Confidence: 0.9398939

00:39:54.390 --> 00:39:56.388 the Purple line and the partial  
NOTE Confidence: 0.9398939

00:39:56.388 --> 00:39:58.529 response by the dotted purple line.  
NOTE Confidence: 0.9398939

00:39:58.530 --> 00:40:00.383 Clearly you see that these curves  
NOTE Confidence: 0.9398939

00:40:00.383 --> 00:40:02.038 spread out and the meaning  
NOTE Confidence: 0.9398939

00:40:02.038 --> 00:40:04.010 of two years of follow up.  
NOTE Confidence: 0.9398939

00:40:04.010 --> 00:40:06.215 Those patients who have a CR or higher had  
NOTE Confidence: 0.9398939

00:40:06.215 --> 00:40:08.638 a median duration of response 21 months.  
NOTE Confidence: 0.9398939

00:40:08.640 --> 00:40:11.320 So that's almost two years now.  
NOTE Confidence: 0.890803468823529

00:40:14.460 --> 00:40:16.434 I've showed you before that only  
NOTE Confidence: 0.890803468823529

00:40:16.434 --> 00:40:18.625 about a third of the patients  
NOTE Confidence: 0.890803468823529

00:40:18.625 --> 00:40:20.640 got into this deep responses,



NOTE Confidence: 0.890803468823529  
00:40:20.640 --> 00:40:22.230 so it's interesting to figure  
NOTE Confidence: 0.890803468823529  
00:40:22.230 --> 00:40:24.364 out who who are the patients that  
NOTE Confidence: 0.890803468823529  
00:40:24.364 --> 00:40:26.054 went into these deep responses.  
NOTE Confidence: 0.890803468823529  
00:40:26.060 --> 00:40:27.362 Perhaps? Who are those that don't  
NOTE Confidence: 0.890803468823529  
00:40:27.362 --> 00:40:28.898 respond as well to have that mind,  
NOTE Confidence: 0.890803468823529  
00:40:28.900 --> 00:40:30.979 and this was presented by Nina Shaw.  
NOTE Confidence: 0.890803468823529  
00:40:30.980 --> 00:40:33.493 This year is ash and she looked  
NOTE Confidence: 0.890803468823529  
00:40:33.493 --> 00:40:34.973 at disease characteristics at  
NOTE Confidence: 0.890803468823529  
00:40:34.973 --> 00:40:36.673 baseline and correlated it with  
NOTE Confidence: 0.890803468823529  
00:40:36.673 --> 00:40:38.719 patients who had the CR or not.  
NOTE Confidence: 0.890803468823529  
00:40:38.720 --> 00:40:40.290 What they found is that  
NOTE Confidence: 0.890803468823529  
00:40:40.290 --> 00:40:42.249 patients who did not have a CR.  
NOTE Confidence: 0.890803468823529  
00:40:42.250 --> 00:40:45.570 Tended to have a higher soluble BCMA knob.  
NOTE Confidence: 0.890803468823529  
00:40:45.570 --> 00:40:47.130 May is a receptor on the  
NOTE Confidence: 0.890803468823529  
00:40:47.130 --> 00:40:48.649 cell surface of tumor cells,  
NOTE Confidence: 0.890803468823529

00:40:48.650 --> 00:40:50.561 but it can be cleaved and then  
NOTE Confidence: 0.890803468823529

00:40:50.561 --> 00:40:52.748 circulates in the bloodstream as soluble.  
NOTE Confidence: 0.890803468823529

00:40:52.750 --> 00:40:56.376 BCMA is often seen with higher burden  
NOTE Confidence: 0.890803468823529

00:40:56.376 --> 00:41:00.229 of disease and the conservative sink,  
NOTE Confidence: 0.890803468823529

00:41:00.230 --> 00:41:02.678 so if you're giving the targeted car T  
NOTE Confidence: 0.890803468823529

00:41:02.678 --> 00:41:04.648 right instead of going to the tumor,  
NOTE Confidence: 0.890803468823529

00:41:04.650 --> 00:41:06.408 it's going to this soluble BCMA,  
NOTE Confidence: 0.890803468823529

00:41:06.410 --> 00:41:08.318 so you can imagine how this  
NOTE Confidence: 0.890803468823529

00:41:08.318 --> 00:41:09.590 would prevent its efficacy.  
NOTE Confidence: 0.890803468823529

00:41:09.590 --> 00:41:12.537 The other thing they noted is that  
NOTE Confidence: 0.890803468823529

00:41:12.537 --> 00:41:14.466 patients not achieving CR tended  
NOTE Confidence: 0.890803468823529

00:41:14.466 --> 00:41:17.069 to have a high an increase of  
NOTE Confidence: 0.890803468823529

00:41:17.069 --> 00:41:18.961 inflammatory inflammatory markers by  
NOTE Confidence: 0.890803468823529

00:41:18.961 --> 00:41:21.529 having higher fare to know D dimer.  
NOTE Confidence: 0.890803468823529

00:41:21.530 --> 00:41:23.840 Now these could be patients who are  
NOTE Confidence: 0.890803468823529

00:41:23.840 --> 00:41:26.070 sicker and more burden of disease,

NOTE Confidence: 0.890803468823529  
00:41:26.070 --> 00:41:28.478 and you might think maybe perhaps this,  
NOTE Confidence: 0.890803468823529  
00:41:28.480 --> 00:41:30.871 in you know,  
NOTE Confidence: 0.890803468823529  
00:41:30.871 --> 00:41:32.465 inflammatory microenvironment  
NOTE Confidence: 0.890803468823529  
00:41:32.465 --> 00:41:34.990 can impede T cell functionality,  
NOTE Confidence: 0.890803468823529  
00:41:34.990 --> 00:41:36.520 but again, these needs.  
NOTE Confidence: 0.890803468823529  
00:41:36.520 --> 00:41:39.250 This needs to be further dissected.  
NOTE Confidence: 0.890803468823529  
00:41:39.250 --> 00:41:40.498 These are just.  
NOTE Confidence: 0.890803468823529  
00:41:40.498 --> 00:41:42.994 The start of trying to understand  
NOTE Confidence: 0.890803468823529  
00:41:43.000 --> 00:41:44.848 biomarkers for response need  
NOTE Confidence: 0.890803468823529  
00:41:44.848 --> 00:41:47.620 to be tested in larger cohorts.  
NOTE Confidence: 0.890803468823529  
00:41:47.620 --> 00:41:49.432 They did find that having a  
NOTE Confidence: 0.890803468823529  
00:41:49.432 --> 00:41:51.349 higher vector copy number in the  
NOTE Confidence: 0.890803468823529  
00:41:51.349 --> 00:41:52.974 drug product was more associated  
NOTE Confidence: 0.890803468823529  
00:41:52.974 --> 00:41:54.520 with patients who had a CR.  
NOTE Confidence: 0.890803468823529  
00:41:54.520 --> 00:41:55.804 Now we know that number of  
NOTE Confidence: 0.890803468823529

00:41:55.804 --> 00:41:57.660 car T is not the full picture.  
NOTE Confidence: 0.890803468823529

00:41:57.660 --> 00:41:59.934 We also understand that quality of  
NOTE Confidence: 0.890803468823529

00:41:59.934 --> 00:42:02.418 T cells are important and this is  
NOTE Confidence: 0.890803468823529

00:42:02.418 --> 00:42:04.504 a diagram showing you the T cell  
NOTE Confidence: 0.890803468823529

00:42:04.575 --> 00:42:06.335 differentiation from the naive T  
NOTE Confidence: 0.890803468823529

00:42:06.335 --> 00:42:10.360 cell all the way to the T effector cell.  
NOTE Confidence: 0.890803468823529

00:42:10.360 --> 00:42:11.656 These earlier T cell,  
NOTE Confidence: 0.890803468823529

00:42:11.656 --> 00:42:13.276 the memory like phenotypes have  
NOTE Confidence: 0.890803468823529

00:42:13.276 --> 00:42:15.195 some key qualities that make it  
NOTE Confidence: 0.890803468823529

00:42:15.195 --> 00:42:16.730 quite attractive for car two  
NOTE Confidence: 0.890803468823529

00:42:16.793 --> 00:42:18.660 products example though long lived  
NOTE Confidence: 0.890803468823529

00:42:18.660 --> 00:42:20.080 so they last longer.  
NOTE Confidence: 0.890803468823529

00:42:20.080 --> 00:42:22.252 They have ability to self renew  
NOTE Confidence: 0.890803468823529

00:42:22.252 --> 00:42:25.168 and they have a T cell plasticity.  
NOTE Confidence: 0.890803468823529

00:42:25.170 --> 00:42:26.190 Furthermore, these memory,  
NOTE Confidence: 0.890803468823529

00:42:26.190 --> 00:42:27.210 like T cells,

NOTE Confidence: 0.890803468823529  
00:42:27.210 --> 00:42:29.095 were correlated with peak expansion  
NOTE Confidence: 0.890803468823529  
00:42:29.095 --> 00:42:31.510 and sustain response in kary studies.  
NOTE Confidence: 0.970727627142857  
00:42:33.910 --> 00:42:37.470 So this brings me to the next abstract,  
NOTE Confidence: 0.970727627142857  
00:42:37.470 --> 00:42:40.430 which was presented by Doctor Raj and it  
NOTE Confidence: 0.970727627142857  
00:42:40.430 --> 00:42:43.389 looked at using API 3 kinase inhibitor,  
NOTE Confidence: 0.970727627142857  
00:42:43.390 --> 00:42:46.678 maybe 007, which is known to enrich memory  
NOTE Confidence: 0.970727627142857  
00:42:46.678 --> 00:42:50.517 like T cells and combine it with Ida cell.  
NOTE Confidence: 0.970727627142857  
00:42:50.520 --> 00:42:55.398 It in vitro and this product was now termed  
NOTE Confidence: 0.970727627142857  
00:42:55.400 --> 00:42:58.704 BB 2121 seven and the hypothesis is that  
NOTE Confidence: 0.970727627142857  
00:42:58.704 --> 00:43:02.039 higher memory like T cell in the cell  
NOTE Confidence: 0.970727627142857  
00:43:02.039 --> 00:43:04.660 product will improve duration of response.  
NOTE Confidence: 0.970727627142857  
00:43:04.660 --> 00:43:06.020 The patient characteristics here  
NOTE Confidence: 0.970727627142857  
00:43:06.020 --> 00:43:08.060 were similar to other kary studies.  
NOTE Confidence: 0.970727627142857  
00:43:08.060 --> 00:43:10.034 I want to highlight a few things.  
NOTE Confidence: 0.970727627142857  
00:43:10.040 --> 00:43:11.870 This was a dose escalation study,  
NOTE Confidence: 0.970727627142857

00:43:11.870 --> 00:43:15.524 so 46 patients out of the 72  
NOTE Confidence: 0.970727627142857

00:43:15.524 --> 00:43:18.652 received the target dose. High risk.  
NOTE Confidence: 0.970727627142857

00:43:18.652 --> 00:43:20.907 Better genetics were found in  
NOTE Confidence: 0.970727627142857

00:43:20.910 --> 00:43:21.822 39% of the patients.  
NOTE Confidence: 0.970727627142857

00:43:21.822 --> 00:43:22.734 This is slightly higher.  
NOTE Confidence: 0.970727627142857

00:43:22.740 --> 00:43:24.040 That was than what was  
NOTE Confidence: 0.970727627142857

00:43:24.040 --> 00:43:25.340 reported with the back comma,  
NOTE Confidence: 0.970727627142857

00:43:25.340 --> 00:43:28.025 which was around 27% and  
NOTE Confidence: 0.970727627142857

00:43:28.025 --> 00:43:31.910 extramedullary disease was 22.  
NOTE Confidence: 0.970727627142857

00:43:31.910 --> 00:43:33.690 Safety profile with BB 2121  
NOTE Confidence: 0.970727627142857

00:43:33.690 --> 00:43:35.810 seven with similar to Avec mom.  
NOTE Confidence: 0.970727627142857

00:43:35.810 --> 00:43:38.435 Not going to go into the details  
NOTE Confidence: 0.970727627142857

00:43:38.435 --> 00:43:40.740 but briefly CR S 75% mostly grade  
NOTE Confidence: 0.970727627142857

00:43:40.740 --> 00:43:43.513 one and two I cans which is the  
NOTE Confidence: 0.970727627142857

00:43:43.513 --> 00:43:45.793 neurotoxicity that we see with car  
NOTE Confidence: 0.970727627142857

00:43:45.793 --> 00:43:48.122 T cells with 15% very comparable.

NOTE Confidence: 0.970727627142857  
00:43:48.122 --> 00:43:50.306 Said opinions are very common in  
NOTE Confidence: 0.970727627142857  
00:43:50.306 --> 00:43:52.735 general with all CAR T cells filling  
NOTE Confidence: 0.970727627142857  
00:43:52.735 --> 00:43:54.432 to the lymphodepletion that they  
NOTE Confidence: 0.970727627142857  
00:43:54.432 --> 00:43:57.170 get before and the Grade 3 and  
NOTE Confidence: 0.970727627142857  
00:43:57.170 --> 00:43:59.310 above infections which is clinically  
NOTE Confidence: 0.970727627142857  
00:43:59.392 --> 00:44:03.530 very meaningful is about 30%.  
NOTE Confidence: 0.970727627142857  
00:44:03.530 --> 00:44:06.218 In terms of efficacy.  
NOTE Confidence: 0.970727627142857  
00:44:06.220 --> 00:44:09.377 We're all response rate was 74 percent,  
NOTE Confidence: 0.970727627142857  
00:44:09.380 --> 00:44:11.172 39% with a CR and most of  
NOTE Confidence: 0.970727627142857  
00:44:11.172 --> 00:44:12.520 them being emerging negative.  
NOTE Confidence: 0.970727627142857  
00:44:12.520 --> 00:44:14.350 But this doesn't look very  
NOTE Confidence: 0.970727627142857  
00:44:14.350 --> 00:44:15.814 different than Beckman information,  
NOTE Confidence: 0.970727627142857  
00:44:15.820 --> 00:44:16.330 but really,  
NOTE Confidence: 0.970727627142857  
00:44:16.330 --> 00:44:17.860 what this study is looking at  
NOTE Confidence: 0.970727627142857  
00:44:17.860 --> 00:44:19.000 is duration of response,  
NOTE Confidence: 0.970727627142857

00:44:19.000 --> 00:44:20.659 which I'll show you in this slide.  
NOTE Confidence: 0.970727627142857

00:44:20.660 --> 00:44:23.756 So in median follow up of about two years,  
NOTE Confidence: 0.970727627142857

00:44:23.760 --> 00:44:26.540 the median progression of meaning,  
NOTE Confidence: 0.970727627142857

00:44:26.540 --> 00:44:29.054 progression of free survival for patients  
NOTE Confidence: 0.970727627142857

00:44:29.054 --> 00:44:31.614 getting the target dose with 18 months  
NOTE Confidence: 0.970727627142857

00:44:31.614 --> 00:44:33.900 and in the back MACI put in Gray.  
NOTE Confidence: 0.970727627142857

00:44:33.900 --> 00:44:35.741 Here was 12 months and this is  
NOTE Confidence: 0.970727627142857

00:44:35.741 --> 00:44:37.180 not a head-to-head comparison.  
NOTE Confidence: 0.970727627142857

00:44:37.180 --> 00:44:37.804 Any means,  
NOTE Confidence: 0.970727627142857

00:44:37.804 --> 00:44:40.300 but I want to give you this as  
NOTE Confidence: 0.970727627142857

00:44:40.377 --> 00:44:42.705 a framework to kind of digest  
NOTE Confidence: 0.970727627142857

00:44:42.705 --> 00:44:44.257 the the results here.  
NOTE Confidence: 0.970727627142857

00:44:44.260 --> 00:44:46.836 Now in patients who achieve deeper responses,  
NOTE Confidence: 0.970727627142857

00:44:46.840 --> 00:44:49.090 CR and above the median duration  
NOTE Confidence: 0.970727627142857

00:44:49.090 --> 00:44:51.532 of response was 30-4 months and in  
NOTE Confidence: 0.970727627142857

00:44:51.532 --> 00:44:55.370 the back of my disk was 21 months.



NOTE Confidence: 0.970727627142857  
00:44:55.370 --> 00:44:57.183 They did see that memory like T  
NOTE Confidence: 0.970727627142857  
00:44:57.183 --> 00:44:59.189 cells in both the car T product  
NOTE Confidence: 0.970727627142857  
00:44:59.189 --> 00:45:00.947 and peak expansion in the patient  
NOTE Confidence: 0.970727627142857  
00:45:01.010 --> 00:45:02.960 was associated with better response  
NOTE Confidence: 0.970727627142857  
00:45:02.960 --> 00:45:04.520 and duration of response.  
NOTE Confidence: 0.970727627142857  
00:45:04.520 --> 00:45:06.512 So this is a good example of how  
NOTE Confidence: 0.970727627142857  
00:45:06.512 --> 00:45:08.260 you can build on an already  
NOTE Confidence: 0.970727627142857  
00:45:08.260 --> 00:45:09.686 established party product.  
NOTE Confidence: 0.970727627142857  
00:45:09.686 --> 00:45:12.668 The next topic will be focused on  
NOTE Confidence: 0.970727627142857  
00:45:12.668 --> 00:45:14.278 information updated information on  
NOTE Confidence: 0.970727627142857  
00:45:14.278 --> 00:45:17.022 the car T cell product that will be  
NOTE Confidence: 0.970727627142857  
00:45:17.099 --> 00:45:19.409 approved next and this is self sell  
NOTE Confidence: 0.970727627142857  
00:45:19.409 --> 00:45:23.396 sell to sell is also an anti BCMA CAR T.  
NOTE Confidence: 0.970727627142857  
00:45:23.400 --> 00:45:25.020 It also has a four one.  
NOTE Confidence: 0.970727627142857  
00:45:25.020 --> 00:45:26.403 BB costimulatory domain.  
NOTE Confidence: 0.970727627142857

00:45:26.403 --> 00:45:29.630 The difference is it has two binding  
NOTE Confidence: 0.970727627142857

00:45:29.707 --> 00:45:31.900 domains here extracellularly,  
NOTE Confidence: 0.970727627142857

00:45:31.900 --> 00:45:34.406 so this was a two year follow-up  
NOTE Confidence: 0.970727627142857

00:45:34.406 --> 00:45:36.123 of the Phase 1B2.  
NOTE Confidence: 0.970727627142857

00:45:36.123 --> 00:45:39.338 Patient characteristics are represented here.  
NOTE Confidence: 0.970727627142857

00:45:39.340 --> 00:45:41.220 They had almost 100 patients,  
NOTE Confidence: 0.970727627142857

00:45:41.220 --> 00:45:42.600 heavily pretreated similar  
NOTE Confidence: 0.970727627142857

00:45:42.600 --> 00:45:44.440 to other party studies.  
NOTE Confidence: 0.970727627142857

00:45:44.440 --> 00:45:46.152 Perhaps the percentage of  
NOTE Confidence: 0.970727627142857

00:45:46.152 --> 00:45:47.436 triple refractory right.  
NOTE Confidence: 0.970727627142857

00:45:47.440 --> 00:45:49.395 This is triple class refractory  
NOTE Confidence: 0.970727627142857

00:45:49.395 --> 00:45:50.959 little bit higher 88%.  
NOTE Confidence: 0.68726596625

00:45:50.960 --> 00:45:53.570 They do comment on penta refractory  
NOTE Confidence: 0.68726596625

00:45:53.570 --> 00:45:55.896 that's refractory to two image 2  
NOTE Confidence: 0.68726596625

00:45:55.896 --> 00:45:59.172 peas and one and CD 30 antibody.  
NOTE Confidence: 0.68726596625

00:45:59.180 --> 00:46:04.298 So this is 42% they had 23% high risk

NOTE Confidence: 0.68726596625

00:46:04.298 --> 00:46:06.434 energetics, mostly deletion 17 P.

NOTE Confidence: 0.68726596625

00:46:06.434 --> 00:46:08.870 And they did have 19 patients

NOTE Confidence: 0.68726596625

00:46:08.957 --> 00:46:11.189 with extramedullary disease,

NOTE Confidence: 0.68726596625

00:46:11.190 --> 00:46:13.740 13 patients had extramedullary disease

NOTE Confidence: 0.68726596625

00:46:13.740 --> 00:46:16.290 plasmacytomas outside of the bone,

NOTE Confidence: 0.68726596625

00:46:16.290 --> 00:46:18.726 which is a higher risk feature.

NOTE Confidence: 0.68726596625

00:46:18.730 --> 00:46:19.800 So efficacy I showed you

NOTE Confidence: 0.68726596625

00:46:19.800 --> 00:46:20.870 part of this last year,

NOTE Confidence: 0.68726596625

00:46:20.870 --> 00:46:22.250 but there are some updates.

NOTE Confidence: 0.68726596625

00:46:22.250 --> 00:46:25.258 Overall response rate 89.

NOTE Confidence: 0.68726596625

00:46:25.258 --> 00:46:28.214 Sorry 98% which is great.

NOTE Confidence: 0.68726596625

00:46:28.214 --> 00:46:30.969 So literally two patients here

NOTE Confidence: 0.68726596625

00:46:30.970 --> 00:46:32.419 did not respond.

NOTE Confidence: 0.68726596625

00:46:32.419 --> 00:46:34.834 However, one of those patients

NOTE Confidence: 0.68726596625

00:46:34.834 --> 00:46:36.712 wasn't invaluable because were they?

NOTE Confidence: 0.68726596625

00:46:36.712 --> 00:46:38.452 They couldn't really assess response  
NOTE Confidence: 0.68726596625

00:46:38.452 --> 00:46:40.168 because he's not measurable disease,  
NOTE Confidence: 0.68726596625

00:46:40.170 --> 00:46:42.230 but they did clinically response.  
NOTE Confidence: 0.68726596625

00:46:42.230 --> 00:46:44.854 Really only one patient did not respond to  
NOTE Confidence: 0.68726596625

00:46:44.854 --> 00:46:47.808 this and deep responses as you see here.  
NOTE Confidence: 0.68726596625

00:46:47.810 --> 00:46:49.978 92% stringent complete response.  
NOTE Confidence: 0.68726596625

00:46:49.978 --> 00:46:51.604 Is really unprecedented.  
NOTE Confidence: 0.68726596625

00:46:51.610 --> 00:46:53.610 The median time to first  
NOTE Confidence: 0.68726596625

00:46:53.610 --> 00:46:55.210 response was one month,  
NOTE Confidence: 0.68726596625

00:46:55.210 --> 00:46:57.478 and the median time to best  
NOTE Confidence: 0.68726596625

00:46:57.478 --> 00:46:59.860 response was about 2 1/2 months  
NOTE Confidence: 0.68726596625

00:46:59.860 --> 00:47:02.540 and then at 2 year follow up the  
NOTE Confidence: 0.68726596625

00:47:02.540 --> 00:47:04.199 median progression free survival,  
NOTE Confidence: 0.68726596625

00:47:04.200 --> 00:47:06.368 overall survival and duration  
NOTE Confidence: 0.68726596625

00:47:06.368 --> 00:47:08.977 of response was not met.  
NOTE Confidence: 0.68726596625

00:47:08.977 --> 00:47:11.599 They further looked at MRD at

NOTE Confidence: 0.68726596625  
00:47:11.599 --> 00:47:14.868 10 to negative 50 based on next  
NOTE Confidence: 0.68726596625  
00:47:14.868 --> 00:47:17.198 Gen sequencing in 61 patients.  
NOTE Confidence: 0.68726596625  
00:47:17.200 --> 00:47:19.540 92 I'm really negative 30 patients  
NOTE Confidence: 0.68726596625  
00:47:19.540 --> 00:47:20.320 had sustained.  
NOTE Confidence: 0.68726596625  
00:47:20.320 --> 00:47:22.708 From our deep at six months  
NOTE Confidence: 0.68726596625  
00:47:22.708 --> 00:47:25.317 and above and 18 had sustained  
NOTE Confidence: 0.68726596625  
00:47:25.317 --> 00:47:28.095 MRD at 12 months and above.  
NOTE Confidence: 0.68726596625  
00:47:28.100 --> 00:47:29.955 Now looking at progression free  
NOTE Confidence: 0.68726596625  
00:47:29.955 --> 00:47:32.460 survival based on depth of response.  
NOTE Confidence: 0.68726596625  
00:47:32.460 --> 00:47:35.764 So patients who had a CR stringent CR  
NOTE Confidence: 0.68726596625  
00:47:35.764 --> 00:47:38.497 as exemplified by the Green Line here,  
NOTE Confidence: 0.68726596625  
00:47:38.500 --> 00:47:40.750 had a two year progression free  
NOTE Confidence: 0.68726596625  
00:47:40.750 --> 00:47:42.976 survival of 71% compared to  
NOTE Confidence: 0.68726596625  
00:47:42.976 --> 00:47:45.436 60 for the total population.  
NOTE Confidence: 0.68726596625  
00:47:45.440 --> 00:47:46.610 Now going deeper,  
NOTE Confidence: 0.68726596625

00:47:46.610 --> 00:47:48.560 sustained MRD responses at six  
NOTE Confidence: 0.68726596625

00:47:48.560 --> 00:47:50.861 months and 12 months had a  
NOTE Confidence: 0.68726596625

00:47:50.861 --> 00:47:52.736 progression free survival of 91  
NOTE Confidence: 0.68726596625

00:47:52.736 --> 00:47:55.648 and 100% at 2 year follow up.  
NOTE Confidence: 0.68726596625

00:47:55.650 --> 00:47:58.250 So this is really fantastic.  
NOTE Confidence: 0.68726596625

00:47:58.250 --> 00:48:00.062 You might be wondering what is  
NOTE Confidence: 0.68726596625

00:48:00.062 --> 00:48:01.969 driving that the blue curve down.  
NOTE Confidence: 0.68726596625

00:48:01.970 --> 00:48:03.146 You know a lot of these patients  
NOTE Confidence: 0.68726596625

00:48:03.146 --> 00:48:03.650 did the cheap,  
NOTE Confidence: 0.68726596625

00:48:03.650 --> 00:48:06.562 really great responses and they did do a  
NOTE Confidence: 0.68726596625

00:48:06.562 --> 00:48:08.989 subgroup analysis trying to understand this,  
NOTE Confidence: 0.68726596625

00:48:08.990 --> 00:48:11.244 and they found that the two year  
NOTE Confidence: 0.68726596625

00:48:11.244 --> 00:48:13.443 progression first level was lower for  
NOTE Confidence: 0.68726596625

00:48:13.443 --> 00:48:15.388 patients who had baseline plasmacytomas,  
NOTE Confidence: 0.68726596625

00:48:15.390 --> 00:48:17.230 high risk cytogenetics and  
NOTE Confidence: 0.68726596625

00:48:17.230 --> 00:48:18.610 high tumor boarding.

NOTE Confidence: 0.68726596625

00:48:18.610 --> 00:48:20.010 So this is important to keep in mind.

NOTE Confidence: 0.68726596625

00:48:20.010 --> 00:48:21.434 Certainly these patients benefit,

NOTE Confidence: 0.68726596625

00:48:21.434 --> 00:48:24.480 but they might not benefit as well as others.

NOTE Confidence: 0.77864265

00:48:26.710 --> 00:48:30.904 Safety. CRS was extremely common

NOTE Confidence: 0.77864265

00:48:30.904 --> 00:48:33.100 and most everyone had it mostly

NOTE Confidence: 0.77864265

00:48:33.167 --> 00:48:35.255 grade one followed by grade two.

NOTE Confidence: 0.77864265

00:48:35.260 --> 00:48:37.420 They did have a good amount

NOTE Confidence: 0.77864265

00:48:37.420 --> 00:48:39.500 of use totals map at 70%,

NOTE Confidence: 0.77864265

00:48:39.500 --> 00:48:40.730 which is higher than what's

NOTE Confidence: 0.77864265

00:48:40.730 --> 00:48:41.714 reported with the beckmeyer.

NOTE Confidence: 0.77864265

00:48:41.720 --> 00:48:44.855 Around 50% that I cams

NOTE Confidence: 0.77864265

00:48:44.855 --> 00:48:46.736 neurotoxicity was comparable.

NOTE Confidence: 0.77864265

00:48:46.740 --> 00:48:49.766 17% infections grade 3 or above 20%.

NOTE Confidence: 0.77864265

00:48:49.766 --> 00:48:54.140 There was six deaths related to cell to cell.

NOTE Confidence: 0.77864265

00:48:54.140 --> 00:48:56.405 Predominantly driven by infections and

NOTE Confidence: 0.77864265

00:48:56.405 --> 00:48:59.719 it followed by CRS and art existing,  
NOTE Confidence: 0.77864265

00:48:59.720 --> 00:49:01.764 they saw 15 events,  
NOTE Confidence: 0.77864265

00:49:01.764 --> 00:49:04.319 secondary primary malignancy and 11  
NOTE Confidence: 0.77864265

00:49:04.319 --> 00:49:06.561 patients which were felt unrelated  
NOTE Confidence: 0.77864265

00:49:06.561 --> 00:49:09.100 to me from from cell to cell.  
NOTE Confidence: 0.77864265

00:49:09.100 --> 00:49:11.319 And the thought is that this is  
NOTE Confidence: 0.77864265

00:49:11.320 --> 00:49:15.009 not out of the usual for this.  
NOTE Confidence: 0.77864265

00:49:15.010 --> 00:49:17.906 Multiply relapsed heavily pretreated  
NOTE Confidence: 0.77864265

00:49:17.906 --> 00:49:20.078 myeloma patient population.  
NOTE Confidence: 0.77864265

00:49:20.080 --> 00:49:21.814 One thing to note that it's  
NOTE Confidence: 0.77864265

00:49:21.814 --> 00:49:23.318 different with silty cells opposed  
NOTE Confidence: 0.77864265

00:49:23.318 --> 00:49:25.580 to either sell or Beckman is that  
NOTE Confidence: 0.77864265

00:49:25.580 --> 00:49:28.345 the CRS it has a later onset.  
NOTE Confidence: 0.77864265

00:49:28.350 --> 00:49:30.520 The median of seven days after infusion  
NOTE Confidence: 0.77864265

00:49:30.520 --> 00:49:32.869 compared to two days after a back comma.  
NOTE Confidence: 0.77864265

00:49:32.870 --> 00:49:35.381 So it is a great possibility to give it



NOTE Confidence: 0.77864265

00:49:35.381 --> 00:49:38.123 in alkylation setting and it is being

NOTE Confidence: 0.77864265

00:49:38.123 --> 00:49:40.449 tested in clinical trials like that.

NOTE Confidence: 0.77864265

00:49:40.450 --> 00:49:42.080 Last thing to comment about

NOTE Confidence: 0.77864265

00:49:42.080 --> 00:49:44.287 Silver cell is this movement and

NOTE Confidence: 0.77864265

00:49:44.287 --> 00:49:45.817 neurocognitive adverse effects.

NOTE Confidence: 0.77864265

00:49:45.820 --> 00:49:47.948 When the cell to cell was first given

NOTE Confidence: 0.77864265

00:49:47.948 --> 00:49:49.730 to patients, they saw the incidence of.

NOTE Confidence: 0.77864265

00:49:49.730 --> 00:49:53.943 He's at 12% and actually was concerning the

NOTE Confidence: 0.77864265

00:49:53.943 --> 00:49:57.170 risk factors that they found to develop.

NOTE Confidence: 0.77864265

00:49:57.170 --> 00:49:58.510 This was high tumor burden.

NOTE Confidence: 0.77864265

00:49:58.510 --> 00:49:59.304 High car,

NOTE Confidence: 0.77864265

00:49:59.304 --> 00:50:01.289 T cell expansion and persistence,

NOTE Confidence: 0.77864265

00:50:01.290 --> 00:50:03.495 development of AI camps and

NOTE Confidence: 0.77864265

00:50:03.495 --> 00:50:05.700 CRS grade two or above.

NOTE Confidence: 0.77864265

00:50:05.700 --> 00:50:07.702 So Jameson and Team decided that they

NOTE Confidence: 0.77864265

00:50:07.702 --> 00:50:10.499 need to do something about this and  
NOTE Confidence: 0.77864265

00:50:10.499 --> 00:50:12.375 develop patient management strategies,  
NOTE Confidence: 0.77864265

00:50:12.380 --> 00:50:14.725 including enhancing bridging therapy to  
NOTE Confidence: 0.77864265

00:50:14.725 --> 00:50:17.760 reduce tumor burden before they get the  
NOTE Confidence: 0.77864265

00:50:17.760 --> 00:50:20.020 Kartik and early and aggressive treatment.  
NOTE Confidence: 0.77864265

00:50:20.020 --> 00:50:21.772 For CRS and I cans and  
NOTE Confidence: 0.77864265

00:50:21.772 --> 00:50:22.940 probably is with driving,  
NOTE Confidence: 0.77864265

00:50:22.940 --> 00:50:25.740 the higher use of toasting in this agent.  
NOTE Confidence: 0.77864265

00:50:25.740 --> 00:50:28.484 With this there have been no further  
NOTE Confidence: 0.77864265

00:50:28.484 --> 00:50:30.658 toxicities in the current incidents  
NOTE Confidence: 0.77864265

00:50:30.658 --> 00:50:33.424 in over 200 patients treated on  
NOTE Confidence: 0.77864265

00:50:33.424 --> 00:50:35.986 several clinical trials at 0.05,  
NOTE Confidence: 0.77864265

00:50:35.986 --> 00:50:38.128 and this is important because this is  
NOTE Confidence: 0.77864265

00:50:38.128 --> 00:50:40.222 what held up after your approval of  
NOTE Confidence: 0.77864265

00:50:40.222 --> 00:50:42.353 this drug last year and now seems to  
NOTE Confidence: 0.77864265

00:50:42.353 --> 00:50:44.640 be much better in much better shape

NOTE Confidence: 0.77864265

00:50:44.640 --> 00:50:47.380 and will likely be approved next week.

NOTE Confidence: 0.77864265

00:50:47.380 --> 00:50:49.168 I do want to highlight that

NOTE Confidence: 0.77864265

00:50:49.168 --> 00:50:50.360 solar cells being used.

NOTE Confidence: 0.77864265

00:50:50.360 --> 00:50:52.310 Earlier in in the treatment course

NOTE Confidence: 0.77864265

00:50:52.310 --> 00:50:54.802 for myeloma and we will have a study

NOTE Confidence: 0.77864265

00:50:54.802 --> 00:50:56.937 open here using cell to cell as

NOTE Confidence: 0.77864265

00:50:56.937 --> 00:50:58.827 part of upfront treatment myeloma.

NOTE Confidence: 0.77864265

00:50:58.830 --> 00:51:01.217 The last topic I will talk about

NOTE Confidence: 0.77864265

00:51:01.217 --> 00:51:03.818 is another car T product that is

NOTE Confidence: 0.77864265

00:51:03.818 --> 00:51:06.166 targeting the GPRC 5D protein.

NOTE Confidence: 0.77864265

00:51:06.166 --> 00:51:08.750 This is called mcar H 109.

NOTE Confidence: 0.717015916428571

00:51:10.920 --> 00:51:12.677 GPRC 5D is expressing my luma cells

NOTE Confidence: 0.717015916428571

00:51:12.677 --> 00:51:14.800 as well as skin and hair follicles.

NOTE Confidence: 0.717015916428571

00:51:14.800 --> 00:51:17.170 It's a. It's a receptor that actually

NOTE Confidence: 0.717015916428571

00:51:17.170 --> 00:51:19.900 no one really understands what it does.

NOTE Confidence: 0.717015916428571

00:51:19.900 --> 00:51:22.160 This is a small study.  
NOTE Confidence: 0.717015916428571

00:51:22.160 --> 00:51:24.800 At Memorial Sloan Kettering 16 patients.  
NOTE Confidence: 0.717015916428571

00:51:24.800 --> 00:51:27.384 But what is unique is that these are  
NOTE Confidence: 0.717015916428571

00:51:27.384 --> 00:51:29.369 really heavily pretreated patients.  
NOTE Confidence: 0.717015916428571

00:51:29.370 --> 00:51:31.570 Very high risk population,  
NOTE Confidence: 0.717015916428571

00:51:31.570 --> 00:51:34.320 so everyone was panda exposed.  
NOTE Confidence: 0.717015916428571

00:51:34.320 --> 00:51:37.278 Almost everyone was triple class refractory.  
NOTE Confidence: 0.717015916428571

00:51:37.280 --> 00:51:38.856 60% had higher risk,  
NOTE Confidence: 0.717015916428571

00:51:38.856 --> 00:51:40.038 may targeted therapy.  
NOTE Confidence: 0.717015916428571

00:51:40.040 --> 00:51:43.856 Most of that car T 77 had high risk.  
NOTE Confidence: 0.717015916428571

00:51:43.860 --> 00:51:44.642 Better genetics,  
NOTE Confidence: 0.717015916428571

00:51:44.642 --> 00:51:46.597 including one Q amplification which  
NOTE Confidence: 0.717015916428571

00:51:46.597 --> 00:51:48.719 you know it's very high risk.  
NOTE Confidence: 0.717015916428571

00:51:48.720 --> 00:51:52.416 About half had plasmacytoma months and.  
NOTE Confidence: 0.717015916428571

00:51:52.420 --> 00:51:54.670 About 20% had non secretory Malama,  
NOTE Confidence: 0.717015916428571

00:51:54.670 --> 00:51:57.309 which is really a patient population not

NOTE Confidence: 0.717015916428571

00:51:57.309 --> 00:51:59.600 represented in the clinical studies.

NOTE Confidence: 0.717015916428571

00:51:59.600 --> 00:52:02.296 So this is a swim plot of swimmers

NOTE Confidence: 0.717015916428571

00:52:02.296 --> 00:52:04.200 plot of responsive follow-up

NOTE Confidence: 0.717015916428571

00:52:04.200 --> 00:52:07.065 of 18 months dose escalation.

NOTE Confidence: 0.717015916428571

00:52:07.070 --> 00:52:08.904 You see here the doses go up

NOTE Confidence: 0.717015916428571

00:52:08.904 --> 00:52:09.690 with higher doses.

NOTE Confidence: 0.717015916428571

00:52:09.690 --> 00:52:11.650 It does seem that there are deeper

NOTE Confidence: 0.717015916428571

00:52:11.650 --> 00:52:13.730 responses you can see by the green bars.

NOTE Confidence: 0.717015916428571

00:52:13.730 --> 00:52:15.505 The follow up is relatively

NOTE Confidence: 0.717015916428571

00:52:15.505 --> 00:52:16.925 short for these patients.

NOTE Confidence: 0.717015916428571

00:52:16.930 --> 00:52:19.980 Overall response rate about 70%.

NOTE Confidence: 0.717015916428571

00:52:19.980 --> 00:52:22.308 About 1/4 achieved a complete response.

NOTE Confidence: 0.717015916428571

00:52:22.310 --> 00:52:23.196 All populations,

NOTE Confidence: 0.717015916428571

00:52:23.196 --> 00:52:25.854 so more to follow on that

NOTE Confidence: 0.717015916428571

00:52:25.854 --> 00:52:27.750 safety was manageable.

NOTE Confidence: 0.717015916428571

00:52:27.750 --> 00:52:31.306 Sierras 93% similar to cell to cell.  
NOTE Confidence: 0.717015916428571

00:52:31.310 --> 00:52:34.586 There was one patient that had a  
NOTE Confidence: 0.717015916428571

00:52:34.586 --> 00:52:37.982 grade 3IN neurotoxicity in terms of  
NOTE Confidence: 0.717015916428571

00:52:37.982 --> 00:52:40.770 off off tumor on target side effects,  
NOTE Confidence: 0.717015916428571

00:52:40.770 --> 00:52:43.440 nail changes, rash taste changes.  
NOTE Confidence: 0.717015916428571

00:52:43.440 --> 00:52:47.677 We're seeing all grade one all transient.  
NOTE Confidence: 0.717015916428571

00:52:47.677 --> 00:52:51.446 So this is a great product is furthering it.  
NOTE Confidence: 0.717015916428571

00:52:51.446 --> 00:52:52.400 It goes into.  
NOTE Confidence: 0.717015916428571

00:52:52.400 --> 00:52:54.532 Further development with the  
NOTE Confidence: 0.717015916428571

00:52:54.532 --> 00:52:55.598 multicenter study.  
NOTE Confidence: 0.717015916428571

00:52:55.600 --> 00:52:59.450 So with that I will end my part of the talk.  
NOTE Confidence: 0.28848618

00:53:04.940 --> 00:53:06.630 And move on to doctor Browning.  
NOTE Confidence: 0.90937686

00:53:14.080 --> 00:53:16.100 OK great so thank you again  
NOTE Confidence: 0.90937686

00:53:16.100 --> 00:53:17.400 to all for for joining  
NOTE Confidence: 0.939349571481482

00:53:17.465 --> 00:53:19.575 and those who may be able to stay on a  
NOTE Confidence: 0.939349571481482

00:53:19.630 --> 00:53:21.737 little bit past the 1:00 o'clock hour.

NOTE Confidence: 0.939349571481482

00:53:21.740 --> 00:53:23.518 So with the remaining time I will

NOTE Confidence: 0.939349571481482

00:53:23.518 --> 00:53:25.151 review a few abstracts highlighting

NOTE Confidence: 0.939349571481482

00:53:25.151 --> 00:53:27.575 basic and preclinical work in multiple

NOTE Confidence: 0.939349571481482

00:53:27.575 --> 00:53:29.703 myeloma and then provide an update

NOTE Confidence: 0.939349571481482

00:53:29.703 --> 00:53:31.593 on the management of patients with

NOTE Confidence: 0.939349571481482

00:53:31.600 --> 00:53:34.590 light chain or AL amyloidosis.

NOTE Confidence: 0.939349571481482

00:53:34.590 --> 00:53:36.865 And I have no disclosures to report,

NOTE Confidence: 0.939349571481482

00:53:36.870 --> 00:53:38.538 so this slide outlines the abstracts

NOTE Confidence: 0.939349571481482

00:53:38.538 --> 00:53:40.210 I will review with you today.

NOTE Confidence: 0.939349571481482

00:53:40.210 --> 00:53:42.555 I'd note that there were many exciting

NOTE Confidence: 0.939349571481482

00:53:42.555 --> 00:53:44.232 preclinical updates in myeloma with

NOTE Confidence: 0.939349571481482

00:53:44.232 --> 00:53:46.381 a focus really on immunology in the

NOTE Confidence: 0.939349571481482

00:53:46.381 --> 00:53:48.069 myeloma immune microenvironment,

NOTE Confidence: 0.939349571481482

00:53:48.070 --> 00:53:50.428 as well as advances in genomics

NOTE Confidence: 0.939349571481482

00:53:50.428 --> 00:53:51.607 and myeloma pathogenesis.

NOTE Confidence: 0.939349571481482

00:53:51.610 --> 00:53:53.964 And I will highlight abstract 159,  
NOTE Confidence: 0.939349571481482

00:53:53.964 --> 00:53:56.208 which provides us with an updated  
NOTE Confidence: 0.939349571481482

00:53:56.208 --> 00:53:58.376 analysis from a practice changing  
NOTE Confidence: 0.939349571481482

00:53:58.376 --> 00:54:00.316 study in AL Amyloidosis.  
NOTE Confidence: 0.939349571481482

00:54:00.320 --> 00:54:01.259 So to begin,  
NOTE Confidence: 0.939349571481482

00:54:01.259 --> 00:54:03.137 obesity is is closely linked to  
NOTE Confidence: 0.939349571481482

00:54:03.137 --> 00:54:05.887 my Loma pathogenesis and has also  
NOTE Confidence: 0.939349571481482

00:54:05.887 --> 00:54:07.779 been associated with increased  
NOTE Confidence: 0.939349571481482

00:54:07.779 --> 00:54:09.658 mortality in multiple myeloma.  
NOTE Confidence: 0.939349571481482

00:54:09.660 --> 00:54:12.120 It is thought that obesity increases  
NOTE Confidence: 0.939349571481482

00:54:12.120 --> 00:54:13.760 the production of proinflammatory  
NOTE Confidence: 0.939349571481482

00:54:13.827 --> 00:54:15.515 cytokines and adipokines adipokines  
NOTE Confidence: 0.939349571481482

00:54:15.515 --> 00:54:18.047 and leads to ectopic accumulation of  
NOTE Confidence: 0.939349571481482

00:54:18.112 --> 00:54:20.366 adipocytes in the bone marrow which can  
NOTE Confidence: 0.939349571481482

00:54:20.366 --> 00:54:22.208 change the bone marrow microenvironment.  
NOTE Confidence: 0.939349571481482

00:54:22.208 --> 00:54:24.378 And in this abstract presented



NOTE Confidence: 0.939349571481482  
00:54:24.378 --> 00:54:26.977 by Doctor Hsu from the Sun Yat  
NOTE Confidence: 0.939349571481482  
00:54:26.977 --> 00:54:28.512 Sen Cancer Center in China,  
NOTE Confidence: 0.939349571481482  
00:54:28.520 --> 00:54:29.675 the authors aim to investigate  
NOTE Confidence: 0.939349571481482  
00:54:29.675 --> 00:54:30.830 the role of bone marrow.  
NOTE Confidence: 0.939349571481482  
00:54:30.830 --> 00:54:33.932 Adipocytes in myeloma Genesis and explore  
NOTE Confidence: 0.939349571481482  
00:54:33.932 --> 00:54:36.053 potential novel therapeutic agents  
NOTE Confidence: 0.939349571481482  
00:54:36.053 --> 00:54:38.868 targeting the bone marrow microenvironment.  
NOTE Confidence: 0.939349571481482  
00:54:38.870 --> 00:54:41.582 They evaluated patients with newly diagnosed  
NOTE Confidence: 0.939349571481482  
00:54:41.582 --> 00:54:44.010 multiple myeloma and healthy controls.  
NOTE Confidence: 0.939349571481482  
00:54:44.010 --> 00:54:45.775 The myeloma patients were separated  
NOTE Confidence: 0.939349571481482  
00:54:45.775 --> 00:54:48.312 into two groups based on BMI and  
NOTE Confidence: 0.939349571481482  
00:54:48.312 --> 00:54:50.077 underwent testing from bone marrow  
NOTE Confidence: 0.939349571481482  
00:54:50.077 --> 00:54:51.850 that included RNA sequencing,  
NOTE Confidence: 0.939349571481482  
00:54:51.850 --> 00:54:54.740 metabolomics and flow cytometry analysis.  
NOTE Confidence: 0.915951835  
00:54:57.130 --> 00:54:59.314 And there was an increase in bone marrow  
NOTE Confidence: 0.915951835

00:54:59.314 --> 00:55:01.371 adipocytes in patients with myeloma and  
NOTE Confidence: 0.915951835

00:55:01.371 --> 00:55:03.191 and metabolomic analysis revealed that  
NOTE Confidence: 0.915951835

00:55:03.191 --> 00:55:05.127 several metabolites work very closely,  
NOTE Confidence: 0.915951835

00:55:05.130 --> 00:55:07.875 associated with BMI with glycerolipid  
NOTE Confidence: 0.915951835

00:55:07.875 --> 00:55:10.071 metabolism enriched in myeloma  
NOTE Confidence: 0.915951835

00:55:10.071 --> 00:55:12.160 patients with obesity RNA sequencing  
NOTE Confidence: 0.915951835

00:55:12.160 --> 00:55:13.685 data from the bone marrow.  
NOTE Confidence: 0.915951835

00:55:13.690 --> 00:55:16.010 Adipocytes showed that patients with  
NOTE Confidence: 0.915951835

00:55:16.010 --> 00:55:18.738 myeloma had an increased expression of  
NOTE Confidence: 0.915951835

00:55:18.738 --> 00:55:21.104 fatty acid binding protein or FAP four,  
NOTE Confidence: 0.915951835

00:55:21.110 --> 00:55:23.860 and this is seen in figures A&B with FA PB  
NOTE Confidence: 0.915951835

00:55:23.927 --> 00:55:26.807 4 having an important role in linking lipid.  
NOTE Confidence: 0.915951835

00:55:26.810 --> 00:55:30.080 Metabolism with immunity and inflammation  
NOTE Confidence: 0.915951835

00:55:30.080 --> 00:55:32.220 and obesity further enhanced the  
NOTE Confidence: 0.915951835

00:55:32.220 --> 00:55:35.432 expression of FA FA BP4 in these studies  
NOTE Confidence: 0.915951835

00:55:35.432 --> 00:55:37.670 to further evaluate the potential role

NOTE Confidence: 0.915951835

00:55:37.740 --> 00:55:40.020 of fabp 4IN pathogenesis in myeloma,

NOTE Confidence: 0.915951835

00:55:40.020 --> 00:55:42.610 the authors studied of fabp 4 knockout

NOTE Confidence: 0.915951835

00:55:42.610 --> 00:55:45.499 and wild type mice who were fed a high

NOTE Confidence: 0.915951835

00:55:45.499 --> 00:55:48.315 fat diet for 12 weeks and you can see

NOTE Confidence: 0.915951835

00:55:48.315 --> 00:55:50.550 here in figure see that the knockout

NOTE Confidence: 0.915951835

00:55:50.550 --> 00:55:52.755 mountain mice had less tumor burden by

NOTE Confidence: 0.915951835

00:55:52.755 --> 00:55:55.134 PET scan and as displayed in figured D,

NOTE Confidence: 0.915951835

00:55:55.140 --> 00:55:57.666 they also had improved overall survival.

NOTE Confidence: 0.7780690435

00:55:59.840 --> 00:56:02.498 The authors then applied and FAP

NOTE Confidence: 0.7780690435

00:56:02.498 --> 00:56:05.044 4 inhibitor known as BMS 309403,

NOTE Confidence: 0.7780690435

00:56:05.044 --> 00:56:06.592 which resulted in significant

NOTE Confidence: 0.7780690435

00:56:06.592 --> 00:56:08.580 attenuation of the tumor burden

NOTE Confidence: 0.7780690435

00:56:08.580 --> 00:56:10.455 and improved survival and obesity

NOTE Confidence: 0.7780690435

00:56:10.455 --> 00:56:12.331 induced myeloma mice as outlined

NOTE Confidence: 0.7780690435

00:56:12.331 --> 00:56:14.487 in the two figures on this slide.

NOTE Confidence: 0.7780690435

00:56:14.490 --> 00:56:16.482 So, in summary, these data suggest  
NOTE Confidence: 0.7780690435

00:56:16.482 --> 00:56:17.810 that bone marrow adipocytes,  
NOTE Confidence: 0.7780690435

00:56:17.810 --> 00:56:19.470 which are increased in obesity,  
NOTE Confidence: 0.7780690435

00:56:19.470 --> 00:56:21.550 may shape metabolism and immunity  
NOTE Confidence: 0.7780690435

00:56:21.550 --> 00:56:23.630 in the bone marrow microenvironment  
NOTE Confidence: 0.7780690435

00:56:23.691 --> 00:56:26.181 environment and play a role in  
NOTE Confidence: 0.7780690435

00:56:26.181 --> 00:56:27.426 promoting myeloma pathogenesis.  
NOTE Confidence: 0.7780690435

00:56:27.430 --> 00:56:29.094 This certainly requires further  
NOTE Confidence: 0.7780690435

00:56:29.094 --> 00:56:31.110 investigation, though it does raise.  
NOTE Confidence: 0.7780690435

00:56:31.110 --> 00:56:32.710 An important question regarding  
NOTE Confidence: 0.7780690435

00:56:32.710 --> 00:56:34.108 whether modification of obesity  
NOTE Confidence: 0.7780690435

00:56:34.108 --> 00:56:35.754 and other such associated risk  
NOTE Confidence: 0.7780690435

00:56:35.754 --> 00:56:37.962 factors can serve as a preventative  
NOTE Confidence: 0.7780690435

00:56:37.962 --> 00:56:39.518 strategy in multiple myeloma.  
NOTE Confidence: 0.82772043525

00:56:42.390 --> 00:56:44.328 In this next abstract that was  
NOTE Confidence: 0.82772043525

00:56:44.328 --> 00:56:46.035 presented by Doctor Simone Mini

NOTE Confidence: 0.82772043525

00:56:46.035 --> 00:56:47.825 at Fred Hutchinson Cancer Center,

NOTE Confidence: 0.82772043525

00:56:47.830 --> 00:56:49.678 the combination of immunomodulatory,

NOTE Confidence: 0.82772043525

00:56:49.678 --> 00:56:51.064 the immunomodulatory drug,

NOTE Confidence: 0.82772043525

00:56:51.070 --> 00:56:52.750 Lenalidomide, and an antigen

NOTE Confidence: 0.82772043525

00:56:52.750 --> 00:56:54.850 antibody was studied in mice.

NOTE Confidence: 0.82772043525

00:56:54.850 --> 00:56:56.539 After undergoing autologous

NOTE Confidence: 0.82772043525

00:56:56.539 --> 00:56:58.228 stem cell transplantation.

NOTE Confidence: 0.82772043525

00:56:58.230 --> 00:56:59.210 As many of you know,

NOTE Confidence: 0.82772043525

00:56:59.210 --> 00:57:00.955 high dose chemotherapy and autologous

NOTE Confidence: 0.82772043525

00:57:00.955 --> 00:57:03.542 stem cell rescue has been shown to

NOTE Confidence: 0.82772043525

00:57:03.542 --> 00:57:05.114 provide progression free survival

NOTE Confidence: 0.82772043525

00:57:05.114 --> 00:57:06.686 benefit in multiple myeloma.

NOTE Confidence: 0.82772043525

00:57:06.690 --> 00:57:08.026 Though in myeloma disease,

NOTE Confidence: 0.82772043525

00:57:08.026 --> 00:57:09.028 relapses are expected,

NOTE Confidence: 0.82772043525

00:57:09.030 --> 00:57:10.670 and there is definitely a

NOTE Confidence: 0.82772043525

00:57:10.670 --> 00:57:12.310 need to enhance the antitumor  
NOTE Confidence: 0.82772043525

00:57:12.377 --> 00:57:14.347 efficacy of stem cell transplant.  
NOTE Confidence: 0.82772043525

00:57:14.350 --> 00:57:16.070 As you can see in the figure here,  
NOTE Confidence: 0.82772043525

00:57:16.070 --> 00:57:18.482 autologous stem cell transplant  
NOTE Confidence: 0.82772043525

00:57:18.482 --> 00:57:20.894 via lymphodepletion and immune  
NOTE Confidence: 0.82772043525

00:57:20.894 --> 00:57:22.564 reconstitution reconstitution is  
NOTE Confidence: 0.82772043525

00:57:22.564 --> 00:57:24.529 thought to establish a myeloma  
NOTE Confidence: 0.82772043525

00:57:24.529 --> 00:57:26.101 immune equilibrium with an  
NOTE Confidence: 0.82772043525

00:57:26.172 --> 00:57:28.140 inflammatory microenvironment.  
NOTE Confidence: 0.82772043525

00:57:28.140 --> 00:57:30.020 However, tumor escape is inevitable,  
NOTE Confidence: 0.82772043525

00:57:30.020 --> 00:57:32.096 and exhaustion of CD 8 positive  
NOTE Confidence: 0.82772043525

00:57:32.096 --> 00:57:34.594 T cells is thought to play a  
NOTE Confidence: 0.82772043525

00:57:34.594 --> 00:57:36.324 major role in disease relapse.  
NOTE Confidence: 0.82772043525

00:57:36.330 --> 00:57:38.430 TIGIT, which is an inhibitory receptor,  
NOTE Confidence: 0.82772043525

00:57:38.430 --> 00:57:40.960 is upregulated on exhausted T  
NOTE Confidence: 0.82772043525

00:57:40.960 --> 00:57:43.246 cells and is thought to play a

NOTE Confidence: 0.82772043525

00:57:43.246 --> 00:57:45.209 major role in disease of relapse,

NOTE Confidence: 0.82772043525

00:57:45.210 --> 00:57:47.295 with studies showing a strong

NOTE Confidence: 0.82772043525

00:57:47.295 --> 00:57:49.380 association between myeloma burden and

NOTE Confidence: 0.82772043525

00:57:49.448 --> 00:57:51.506 expression of TIGIT on CD 8 positive

NOTE Confidence: 0.82772043525

00:57:51.506 --> 00:57:53.969 T cells and mice status post stem

NOTE Confidence: 0.82772043525

00:57:53.969 --> 00:57:55.510 cell transplant there for you guys.

NOTE Confidence: 0.82772043525

00:57:55.510 --> 00:57:56.290 As you can imagine,

NOTE Confidence: 0.82772043525

00:57:56.290 --> 00:57:59.188 TIGIT has emerged as an attractive target

NOTE Confidence: 0.82772043525

00:57:59.188 --> 00:58:01.639 for immunotherapy in multiple myeloma.

NOTE Confidence: 0.82772043525

00:58:01.640 --> 00:58:02.808 So in this study,

NOTE Confidence: 0.82772043525

00:58:02.808 --> 00:58:04.268 myeloma mice underwent high dose

NOTE Confidence: 0.82772043525

00:58:04.268 --> 00:58:06.108 Milo ablative radiation and then

NOTE Confidence: 0.82772043525

00:58:06.108 --> 00:58:07.596 received bone marrow grafts,

NOTE Confidence: 0.82772043525

00:58:07.600 --> 00:58:09.652 followed by the administration

NOTE Confidence: 0.82772043525

00:58:09.652 --> 00:58:12.217 of a antigen monoclonal antibody,

NOTE Confidence: 0.82772043525

00:58:12.220 --> 00:58:13.650 twice weekly for five weeks,  
NOTE Confidence: 0.82772043525

00:58:13.650 --> 00:58:15.682 starting on the day of transplant or day  
NOTE Confidence: 0.82772043525

00:58:15.682 --> 00:58:17.328 zero and then Lenalidomide administered  
NOTE Confidence: 0.82772043525

00:58:17.328 --> 00:58:19.862 daily for three weeks beginning on day,  
NOTE Confidence: 0.82772043525

00:58:19.870 --> 00:58:22.234 plus 14 and synergistic anti myeloma  
NOTE Confidence: 0.82772043525

00:58:22.234 --> 00:58:24.940 activity was observed with this combination.  
NOTE Confidence: 0.82772043525

00:58:24.940 --> 00:58:27.320 As you can see in figure B,  
NOTE Confidence: 0.82772043525

00:58:27.320 --> 00:58:28.650 there was a significant reduction  
NOTE Confidence: 0.82772043525

00:58:28.650 --> 00:58:30.347 in the rate of tumor growth  
NOTE Confidence: 0.82772043525

00:58:30.347 --> 00:58:31.607 and also improved median.  
NOTE Confidence: 0.82772043525

00:58:31.610 --> 00:58:34.274 Overall survival in the mice who  
NOTE Confidence: 0.82772043525

00:58:34.274 --> 00:58:36.050 received this combination post  
NOTE Confidence: 0.82772043525

00:58:36.125 --> 00:58:39.130 transplant and the authors also found,  
NOTE Confidence: 0.82772043525

00:58:39.130 --> 00:58:41.230 through flow cytometry and flow,  
NOTE Confidence: 0.82772043525

00:58:41.230 --> 00:58:42.082 some clustering,  
NOTE Confidence: 0.82772043525

00:58:42.082 --> 00:58:44.212 that this combination increased T



NOTE Confidence: 0.82772043525  
00:58:44.212 --> 00:58:46.396 cell memory and reduced exhaustion  
NOTE Confidence: 0.82772043525  
00:58:46.396 --> 00:58:48.491 as displayed in the representative  
NOTE Confidence: 0.82772043525  
00:58:48.491 --> 00:58:50.724 heat map on the bottom right  
NOTE Confidence: 0.82772043525  
00:58:50.724 --> 00:58:52.372 in Figure C and lastly,  
NOTE Confidence: 0.82772043525  
00:58:52.372 --> 00:58:54.598 the combination of of an anti  
NOTE Confidence: 0.82772043525  
00:58:54.598 --> 00:58:56.385 TIGIT monoclonal antibody and the  
NOTE Confidence: 0.82772043525  
00:58:56.385 --> 00:58:58.341 4th generation image or cell mod  
NOTE Confidence: 0.82772043525  
00:58:58.341 --> 00:59:00.725 I iberty mid which was discussed  
NOTE Confidence: 0.82772043525  
00:59:00.725 --> 00:59:02.317 by Doctor Parker earlier.  
NOTE Confidence: 0.82772043525  
00:59:02.320 --> 00:59:05.290 In our discussion is now entering  
NOTE Confidence: 0.82772043525  
00:59:05.290 --> 00:59:06.870 human trials shortly.  
NOTE Confidence: 0.82114971  
00:59:09.580 --> 00:59:12.100 So to move, move along light chain or  
NOTE Confidence: 0.82114971  
00:59:12.100 --> 00:59:14.632 a lymphoid ossis is a rare systemic  
NOTE Confidence: 0.82114971  
00:59:14.632 --> 00:59:16.467 disorder of clonal plasma cells  
NOTE Confidence: 0.82114971  
00:59:16.539 --> 00:59:19.099 that generate aberrant or abnormal  
NOTE Confidence: 0.82114971

00:59:19.099 --> 00:59:21.147 immunoglobulin light chains which  
NOTE Confidence: 0.82114971

00:59:21.147 --> 00:59:23.752 misfolded form insoluble amyloid fibrils.  
NOTE Confidence: 0.82114971

00:59:23.752 --> 00:59:26.367 These fibrils then deposit into  
NOTE Confidence: 0.82114971

00:59:26.367 --> 00:59:28.763 extracellular tissues and organs resulting  
NOTE Confidence: 0.82114971

00:59:28.763 --> 00:59:31.457 in impairment of vital organ function  
NOTE Confidence: 0.82114971

00:59:31.525 --> 00:59:33.705 and sometimes or often death with  
NOTE Confidence: 0.82114971

00:59:33.705 --> 00:59:35.080 the introduction of novel therapies,  
NOTE Confidence: 0.82114971

00:59:35.080 --> 00:59:36.815 there has been improvement in  
NOTE Confidence: 0.82114971

00:59:36.815 --> 00:59:38.203 overall outcomes and prognosis  
NOTE Confidence: 0.82114971

00:59:38.203 --> 00:59:40.070 for AL amyloidosis which were.  
NOTE Confidence: 0.82114971

00:59:40.070 --> 00:59:42.178 Historically, very, very grim.  
NOTE Confidence: 0.82114971

00:59:42.178 --> 00:59:44.080 In an abstract 155,  
NOTE Confidence: 0.82114971

00:59:44.080 --> 00:59:46.320 which was presented by Doctor Starin from  
NOTE Confidence: 0.82114971

00:59:46.320 --> 00:59:48.699 the Boston University Amyloidosis Center,  
NOTE Confidence: 0.82114971

00:59:48.700 --> 00:59:50.506 there was a 40 year Natural History  
NOTE Confidence: 0.82114971

00:59:50.506 --> 00:59:52.224 study that was reviewed on outcomes

NOTE Confidence: 0.82114971

00:59:52.224 --> 00:59:53.994 for patients with a lambdoid seen

NOTE Confidence: 0.82114971

00:59:53.994 --> 00:59:55.919 at their center and what they found

NOTE Confidence: 0.82114971

00:59:55.919 --> 00:59:57.596 is displayed on on the slide.

NOTE Confidence: 0.82114971

00:59:57.596 --> 00:59:59.752 Here was that in a cohort of

NOTE Confidence: 0.82114971

00:59:59.752 --> 01:00:01.924 a slightly over 2300 patients,

NOTE Confidence: 0.82114971

01:00:01.924 --> 01:00:04.336 the five year overall survival improved

NOTE Confidence: 0.82114971

01:00:04.336 --> 01:00:07.982 from 15% between 1980 and 1989 to 48%

NOTE Confidence: 0.82114971

01:00:07.982 --> 01:00:10.238 in the most recent decade that was studied,

NOTE Confidence: 0.82114971

01:00:10.240 --> 01:00:13.170 which was 2010 to 2019.

NOTE Confidence: 0.82114971

01:00:13.170 --> 01:00:15.470 Median overall survival improved from

NOTE Confidence: 0.82114971

01:00:15.470 --> 01:00:18.174 1.4 to 4.6 years and the six month

NOTE Confidence: 0.82114971

01:00:18.174 --> 01:00:21.085 mortality rate dropped from 23% to 13%.

NOTE Confidence: 0.82114971

01:00:21.085 --> 01:00:22.865 When comparing between these

NOTE Confidence: 0.82114971

01:00:22.865 --> 01:00:24.575 two time periods, however,

NOTE Confidence: 0.82114971

01:00:24.575 --> 01:00:26.450 amyloid remains a challenging disease,

NOTE Confidence: 0.82114971

01:00:26.450 --> 01:00:28.226 both due to delays in diagnosis  
NOTE Confidence: 0.82114971

01:00:28.226 --> 01:00:30.010 and and challenges with treatment,  
NOTE Confidence: 0.82114971

01:00:30.010 --> 01:00:30.470 notably,  
NOTE Confidence: 0.82114971

01:00:30.470 --> 01:00:32.770 in patients with cardiac involvement  
NOTE Confidence: 0.82114971

01:00:32.770 --> 01:00:35.137 and further advances in therapy  
NOTE Confidence: 0.82114971

01:00:35.137 --> 01:00:36.490 are really crucial.  
NOTE Confidence: 0.82114971

01:00:36.490 --> 01:00:39.562 So the Andromeda study is a phase three  
NOTE Confidence: 0.82114971

01:00:39.562 --> 01:00:41.726 randomized open label controlled trial  
NOTE Confidence: 0.82114971

01:00:41.726 --> 01:00:44.366 that compares our prior standard of  
NOTE Confidence: 0.82114971

01:00:44.366 --> 01:00:47.187 care for amyloid which was Bortezomib,  
NOTE Confidence: 0.82114971

01:00:47.190 --> 01:00:49.563 cyclophosphamide and dexamethasone.  
NOTE Confidence: 0.82114971

01:00:49.563 --> 01:00:51.936 Orved versus VCT,  
NOTE Confidence: 0.82114971

01:00:51.940 --> 01:00:52.402 VCD,  
NOTE Confidence: 0.82114971

01:00:52.402 --> 01:00:55.174 plus the anti CD 38 monoclonal  
NOTE Confidence: 0.82114971

01:00:55.174 --> 01:00:57.408 antibody daratumumab which was  
NOTE Confidence: 0.82114971

01:00:57.408 --> 01:00:59.256 administered subcutaneously in

NOTE Confidence: 0.82114971

01:00:59.256 --> 01:01:00.786 patients with newly diagnosed tail.

NOTE Confidence: 0.82114971

01:01:00.790 --> 01:01:03.989 Amyloid and cardiac stage one through 3/8

NOTE Confidence: 0.82114971

01:01:03.989 --> 01:01:06.438 disease were recruited for the study.

NOTE Confidence: 0.82114971

01:01:06.440 --> 01:01:08.575 And both arms received for

NOTE Confidence: 0.82114971

01:01:08.575 --> 01:01:10.710 six cycles with the study,

NOTE Confidence: 0.82114971

01:01:10.710 --> 01:01:12.675 the protocol or daratumumab arm

NOTE Confidence: 0.82114971

01:01:12.675 --> 01:01:15.065 getting VCD Times 6 studies 6

NOTE Confidence: 0.82114971

01:01:15.065 --> 01:01:16.860 cycles and then monotherapy with

NOTE Confidence: 0.82114971

01:01:16.860 --> 01:01:19.019 their two mab every four weeks

NOTE Confidence: 0.82114971

01:01:19.019 --> 01:01:21.294 for a maximum of 24 total cycles.

NOTE Confidence: 0.82114971

01:01:21.300 --> 01:01:23.442 Prior analysis at 6 and 12 months

NOTE Confidence: 0.82114971

01:01:23.442 --> 01:01:25.050 revealed that the addition of

NOTE Confidence: 0.82114971

01:01:25.050 --> 01:01:26.610 subcutaneous there are two in

NOTE Confidence: 0.82114971

01:01:26.610 --> 01:01:29.101 map to VCD resulted in deeper and

NOTE Confidence: 0.82114971

01:01:29.101 --> 01:01:30.589 more rapid hematologic response

NOTE Confidence: 0.82114971

01:01:30.589 --> 01:01:32.344 is also improved organ,  
NOTE Confidence: 0.82114971

01:01:32.344 --> 01:01:34.854 responses and prolongation of major  
NOTE Confidence: 0.82114971

01:01:34.854 --> 01:01:37.210 major organ deterioration progression.  
NOTE Confidence: 0.82114971

01:01:37.210 --> 01:01:40.290 Free survival and this data led to  
NOTE Confidence: 0.82114971

01:01:40.290 --> 01:01:42.650 Derived being the first approved  
NOTE Confidence: 0.82114971

01:01:42.650 --> 01:01:45.968 therapy for a limoy dose in nine  
NOTE Confidence: 0.82114971

01:01:45.968 --> 01:01:48.117 countries with FDA accelerated  
NOTE Confidence: 0.82114971

01:01:48.117 --> 01:01:51.191 approval granted in January of 2021,  
NOTE Confidence: 0.82114971

01:01:51.191 --> 01:01:53.717 and so the current abstract presented  
NOTE Confidence: 0.82114971

01:01:53.717 --> 01:01:56.361 by Doctor Raymond Comenzo from Tufts  
NOTE Confidence: 0.82114971

01:01:56.361 --> 01:01:58.536 University provided an update after  
NOTE Confidence: 0.82114971

01:01:58.536 --> 01:02:01.030 a median follow-up of 25.8 months.  
NOTE Confidence: 0.945517786470588

01:02:03.120 --> 01:02:05.412 So these tables outline the demographics  
NOTE Confidence: 0.945517786470588

01:02:05.412 --> 01:02:07.346 and baseline characteristics of patients  
NOTE Confidence: 0.945517786470588

01:02:07.346 --> 01:02:09.440 that have been enrolled in Andromeda,  
NOTE Confidence: 0.945517786470588

01:02:09.440 --> 01:02:10.990 and they were well balanced

NOTE Confidence: 0.945517786470588

01:02:10.990 --> 01:02:12.540 between the two treatment arms.

NOTE Confidence: 0.945517786470588

01:02:12.540 --> 01:02:14.794 The median age of in the dairy

NOTE Confidence: 0.945517786470588

01:02:14.794 --> 01:02:17.867 VCD arm was 62 years and both arms

NOTE Confidence: 0.945517786470588

01:02:17.867 --> 01:02:19.897 had a slate mail predominance.

NOTE Confidence: 0.945517786470588

01:02:19.900 --> 01:02:21.678 I would like to point out that

NOTE Confidence: 0.945517786470588

01:02:21.678 --> 01:02:23.556 only three to 4% of patients on

NOTE Confidence: 0.945517786470588

01:02:23.556 --> 01:02:25.428 both arms in this study identified

NOTE Confidence: 0.945517786470588

01:02:25.428 --> 01:02:27.360 as black or African American,

NOTE Confidence: 0.945517786470588

01:02:27.360 --> 01:02:29.322 which is important in considering the

NOTE Confidence: 0.945517786470588

01:02:29.322 --> 01:02:31.080 the generalizability of these results,

NOTE Confidence: 0.945517786470588

01:02:31.080 --> 01:02:32.970 and was a a discussion when

NOTE Confidence: 0.945517786470588

01:02:32.970 --> 01:02:34.460 this abstract was presented at.

NOTE Confidence: 0.945517786470588

01:02:34.460 --> 01:02:36.626 Gosh, I think really highlighting the

NOTE Confidence: 0.945517786470588

01:02:36.626 --> 01:02:38.070 importance of improving improving

NOTE Confidence: 0.945517786470588

01:02:38.122 --> 01:02:39.797 diversity in our clinical trials,

NOTE Confidence: 0.945517786470588

01:02:39.800 --> 01:02:42.375 and that includes in trials  
NOTE Confidence: 0.945517786470588

01:02:42.375 --> 01:02:44.435 of plasma cell disorders.  
NOTE Confidence: 0.945517786470588

01:02:44.440 --> 01:02:46.274 66% of patients had involvement of two  
NOTE Confidence: 0.945517786470588

01:02:46.274 --> 01:02:48.368 or more organs with cardiac and renal  
NOTE Confidence: 0.945517786470588

01:02:48.368 --> 01:02:49.933 involvement being the most common,  
NOTE Confidence: 0.945517786470588

01:02:49.940 --> 01:02:50.752 and importantly,  
NOTE Confidence: 0.945517786470588

01:02:50.752 --> 01:02:54.000 36% of the patients in the dairy VCD  
NOTE Confidence: 0.945517786470588

01:02:54.083 --> 01:02:56.992 arm had stage 3A cardiac disease at  
NOTE Confidence: 0.945517786470588

01:02:56.992 --> 01:03:00.930 the median follow-up of 25.8 months.  
NOTE Confidence: 0.945517786470588

01:03:00.930 --> 01:03:03.442 77.2% of patients in the dairy VCD arm  
NOTE Confidence: 0.945517786470588

01:03:03.442 --> 01:03:05.619 had received daratumumab monotherapy.  
NOTE Confidence: 0.945517786470588

01:03:05.620 --> 01:03:09.040 After six cycles of Derrived and 36%  
NOTE Confidence: 0.945517786470588

01:03:09.040 --> 01:03:12.120 of patients and either in both groups  
NOTE Confidence: 0.945517786470588

01:03:12.120 --> 01:03:14.290 had discontinued study treatment.  
NOTE Confidence: 0.945517786470588

01:03:14.290 --> 01:03:16.439 So over two years of follow up,  
NOTE Confidence: 0.945517786470588

01:03:16.440 --> 01:03:18.595 more patients achieved a hematologic



NOTE Confidence: 0.945517786470588

01:03:18.595 --> 01:03:21.190 complete response in the Derived arm at

NOTE Confidence: 0.945517786470588

01:03:21.190 --> 01:03:24.850 60% compared to only 19% on the VCD arm.

NOTE Confidence: 0.945517786470588

01:03:24.850 --> 01:03:26.770 And you can see this hematologic

NOTE Confidence: 0.945517786470588

01:03:26.839 --> 01:03:28.627 complete response response is

NOTE Confidence: 0.945517786470588

01:03:28.627 --> 01:03:31.309 deepened overtime in the dairy group.

NOTE Confidence: 0.945517786470588

01:03:31.310 --> 01:03:33.626 Patients achieving a very good partial

NOTE Confidence: 0.945517786470588

01:03:33.626 --> 01:03:35.820 response or better improved from 77%

NOTE Confidence: 0.945517786470588

01:03:35.820 --> 01:03:38.270 of the time of primary analysis to

NOTE Confidence: 0.945517786470588

01:03:38.270 --> 01:03:41.630 79% in this updated analysis analysis.

NOTE Confidence: 0.945517786470588

01:03:41.630 --> 01:03:42.087 Importantly,

NOTE Confidence: 0.945517786470588

01:03:42.087 --> 01:03:44.372 hematologic complete response was higher

NOTE Confidence: 0.945517786470588

01:03:44.372 --> 01:03:47.346 with therapy CD and all prespecified

NOTE Confidence: 0.945517786470588

01:03:47.346 --> 01:03:49.694 subgroups and those included groups

NOTE Confidence: 0.945517786470588

01:03:49.694 --> 01:03:51.949 with cardiac involvement at baseline.

NOTE Confidence: 0.945517786470588

01:03:51.950 --> 01:03:54.232 Those who had cardiac stage three disease

NOTE Confidence: 0.945517786470588

01:03:54.232 --> 01:03:56.432 and those with translocation 1114,  
NOTE Confidence: 0.945517786470588

01:03:56.432 --> 01:03:59.246 which makes up about 50 to 60%  
NOTE Confidence: 0.945517786470588

01:03:59.250 --> 01:04:01.680 of our ale amyloid population.  
NOTE Confidence: 0.9563511975

01:04:03.820 --> 01:04:05.356 And as you can see in these graphs,  
NOTE Confidence: 0.9563511975

01:04:05.360 --> 01:04:07.982 the cardiac and renal response rates  
NOTE Confidence: 0.9563511975

01:04:07.982 --> 01:04:10.163 in patients receiving derived were  
NOTE Confidence: 0.9563511975

01:04:10.163 --> 01:04:12.669 significantly higher at both 6 and 18  
NOTE Confidence: 0.9563511975

01:04:12.669 --> 01:04:15.282 months when compared to the VCD arm at  
NOTE Confidence: 0.9563511975

01:04:15.282 --> 01:04:17.698 the 18 month mark presented at this ash,  
NOTE Confidence: 0.9563511975

01:04:17.700 --> 01:04:19.365 both cardiac and renal response  
NOTE Confidence: 0.9563511975

01:04:19.365 --> 01:04:21.404 rates were more than twice as  
NOTE Confidence: 0.9563511975

01:04:21.404 --> 01:04:23.264 high as the organ responses that  
NOTE Confidence: 0.9563511975

01:04:23.264 --> 01:04:25.118 were achieved with just VCD alone,  
NOTE Confidence: 0.9563511975

01:04:25.120 --> 01:04:27.353 and it's important to to remember that  
NOTE Confidence: 0.9563511975

01:04:27.353 --> 01:04:29.058 organ response and Dale amyloidosis  
NOTE Confidence: 0.9563511975

01:04:29.058 --> 01:04:31.116 can be delayed or lagged behind.

NOTE Confidence: 0.9563511975

01:04:31.120 --> 01:04:34.768 Hematologic response in that organ responses.

NOTE Confidence: 0.9563511975

01:04:34.770 --> 01:04:37.920 Are thought to really improve quality of

NOTE Confidence: 0.9563511975

01:04:37.920 --> 01:04:41.649 life in this complex patient population.

NOTE Confidence: 0.9563511975

01:04:41.650 --> 01:04:43.834 There were a greater number of deaths

NOTE Confidence: 0.9563511975

01:04:43.834 --> 01:04:45.126 related to disease progression

NOTE Confidence: 0.9563511975

01:04:45.126 --> 01:04:46.326 in the VCD arm,

NOTE Confidence: 0.9563511975

01:04:46.330 --> 01:04:48.178 though with a longer time on therapy,

NOTE Confidence: 0.9563511975

01:04:48.180 --> 01:04:50.511 the absolute number of deaths while on

NOTE Confidence: 0.9563511975

01:04:50.511 --> 01:04:52.698 treatment was higher in the Derived arm?

NOTE Confidence: 0.9563511975

01:04:52.700 --> 01:04:53.704 Serious treatment,

NOTE Confidence: 0.9563511975

01:04:53.704 --> 01:04:56.214 emergent adverse events occurred in

NOTE Confidence: 0.9563511975

01:04:56.220 --> 01:04:58.635 47% of patients on the Derived arm.

NOTE Confidence: 0.9563511975

01:04:58.640 --> 01:05:02.108 And 36% of patients receiving VCD

NOTE Confidence: 0.9563511975

01:05:02.108 --> 01:05:04.058 alone with pneumonia being the

NOTE Confidence: 0.9563511975

01:05:04.058 --> 01:05:05.768 most common serious adverse event

NOTE Confidence: 0.9563511975

01:05:05.768 --> 01:05:07.688 that was observed in both groups.  
NOTE Confidence: 0.9563511975

01:05:07.690 --> 01:05:09.634 The rate of discontinuation due to  
NOTE Confidence: 0.9563511975

01:05:09.634 --> 01:05:11.557 treatment emergent events was similar in  
NOTE Confidence: 0.9563511975

01:05:11.557 --> 01:05:13.573 both groups and the most common adverse  
NOTE Confidence: 0.9563511975

01:05:13.573 --> 01:05:15.688 events observed in the study are outlined,  
NOTE Confidence: 0.9563511975

01:05:15.690 --> 01:05:20.667 and the tables at the bottom of this slide.  
NOTE Confidence: 0.9563511975

01:05:20.670 --> 01:05:21.588 So in summary,  
NOTE Confidence: 0.9563511975

01:05:21.588 --> 01:05:23.730 after more than two years of follow-up  
NOTE Confidence: 0.9563511975

01:05:23.791 --> 01:05:25.756 hematologic and Oregon response has  
NOTE Confidence: 0.9563511975

01:05:25.756 --> 01:05:28.108 continued to increase with their trauma  
NOTE Confidence: 0.9563511975

01:05:28.108 --> 01:05:30.088 BCD when compared with VCD alone.  
NOTE Confidence: 0.9563511975

01:05:30.090 --> 01:05:30.421 Fortunately,  
NOTE Confidence: 0.9563511975

01:05:30.421 --> 01:05:33.069 there were no new safety concerns that were  
NOTE Confidence: 0.9563511975

01:05:33.069 --> 01:05:34.790 identified with this longer follow-up,  
NOTE Confidence: 0.9563511975

01:05:34.790 --> 01:05:37.625 and overall survival will be analyzed and  
NOTE Confidence: 0.9563511975

01:05:37.625 --> 01:05:39.630 major organ deterioration progression.

NOTE Confidence: 0.9563511975

01:05:39.630 --> 01:05:42.015 Free survival will be updated

NOTE Confidence: 0.9563511975

01:05:42.015 --> 01:05:43.923 after approximately 200 events,

NOTE Confidence: 0.9563511975

01:05:43.930 --> 01:05:46.160 though at the median follow-up

NOTE Confidence: 0.9563511975

01:05:46.160 --> 01:05:48.130 presented here of 25.8 months,

NOTE Confidence: 0.9563511975

01:05:48.130 --> 01:05:49.475 there were fewer deaths that

NOTE Confidence: 0.9563511975

01:05:49.475 --> 01:05:50.820 were observed in the derived.

NOTE Confidence: 0.9563511975

01:05:50.820 --> 01:05:52.432 Farm as outlined here.

NOTE Confidence: 0.9563511975

01:05:52.432 --> 01:05:54.850 And so this updated analysis really

NOTE Confidence: 0.9563511975

01:05:54.922 --> 01:05:56.746 confirms the treatment benefit

NOTE Confidence: 0.9563511975

01:05:56.746 --> 01:05:59.320 of this regimen out to 18 months,

NOTE Confidence: 0.9563511975

01:05:59.320 --> 01:06:01.120 and supports derived as a new

NOTE Confidence: 0.9563511975

01:06:01.187 --> 01:06:03.359 standard of care for our patients

NOTE Confidence: 0.9563511975

01:06:03.359 --> 01:06:05.630 with newly diagnosed AL amyloidosis?

NOTE Confidence: 0.902004587368421

01:06:08.070 --> 01:06:10.030 So the final abstract that I will

NOTE Confidence: 0.902004587368421

01:06:10.030 --> 01:06:12.074 touch upon was presented by Doctor

NOTE Confidence: 0.902004587368421

01:06:12.074 --> 01:06:14.366 Jason Valent from the Cleveland Clinic,  
NOTE Confidence: 0.902004587368421

01:06:14.370 --> 01:06:16.694 and it reviewed the safety and tolerability  
NOTE Confidence: 0.902004587368421

01:06:16.694 --> 01:06:19.663 of Cal 101 in combination with anti plasma  
NOTE Confidence: 0.902004587368421

01:06:19.663 --> 01:06:22.069 cell therapy for patients with a lamb.  
NOTE Confidence: 0.902004587368421

01:06:22.070 --> 01:06:24.968 Lloyd Ossis and this was from a one year  
NOTE Confidence: 0.902004587368421

01:06:24.968 --> 01:06:27.705 results from an open label phase two trial.  
NOTE Confidence: 0.902004587368421

01:06:27.710 --> 01:06:29.830 So, as we previously discussed,  
NOTE Confidence: 0.902004587368421

01:06:29.830 --> 01:06:31.286 amyloid fibril deposition and  
NOTE Confidence: 0.902004587368421

01:06:31.286 --> 01:06:33.106 organs results in organ dysfunction  
NOTE Confidence: 0.902004587368421

01:06:33.106 --> 01:06:34.590 with significant morbidity and  
NOTE Confidence: 0.902004587368421

01:06:34.590 --> 01:06:36.708 mortality for patients with a lamb.  
NOTE Confidence: 0.902004587368421

01:06:36.710 --> 01:06:39.342 Lloyd and our standard of care anti  
NOTE Confidence: 0.902004587368421

01:06:39.342 --> 01:06:41.769 plasma cell therapy is just discussed.  
NOTE Confidence: 0.902004587368421

01:06:41.770 --> 01:06:43.790 Really decreases the production of  
NOTE Confidence: 0.902004587368421

01:06:43.790 --> 01:06:46.305 amyloid oh genic like chains by  
NOTE Confidence: 0.902004587368421

01:06:46.305 --> 01:06:48.415 targeting abnormal bone marrow plasma

NOTE Confidence: 0.902004587368421

01:06:48.415 --> 01:06:50.465 cells but doesn't address the amyloid

NOTE Confidence: 0.902004587368421

01:06:50.465 --> 01:06:52.520 fibrils already present in and organs.

NOTE Confidence: 0.902004587368421

01:06:52.520 --> 01:06:55.215 So Cal 101 is a chimeric monoclonal

NOTE Confidence: 0.902004587368421

01:06:55.215 --> 01:06:58.039 antibody and it binds annio appetite.

NOTE Confidence: 0.902004587368421

01:06:58.040 --> 01:06:59.790 That's present on both Kappa

NOTE Confidence: 0.902004587368421

01:06:59.790 --> 01:07:01.540 and Lambda light chain fibrils,

NOTE Confidence: 0.902004587368421

01:07:01.540 --> 01:07:03.595 resulting in proteolysis and removal

NOTE Confidence: 0.902004587368421

01:07:03.595 --> 01:07:06.108 of the amyloid fibrils from tissues

NOTE Confidence: 0.902004587368421

01:07:06.108 --> 01:07:07.612 and organs in a phase.

NOTE Confidence: 0.902004587368421

01:07:07.612 --> 01:07:09.708 One study of this agent Cal 101 was

NOTE Confidence: 0.902004587368421

01:07:09.708 --> 01:07:11.652 well tolerated up to 500 milligrams

NOTE Confidence: 0.902004587368421

01:07:11.652 --> 01:07:13.687 per meter squared in patients who

NOTE Confidence: 0.902004587368421

01:07:13.687 --> 01:07:15.357 had relapsed or refractory ale,

NOTE Confidence: 0.902004587368421

01:07:15.360 --> 01:07:17.565 amyloid and in the phase two component.

NOTE Confidence: 0.902004587368421

01:07:17.570 --> 01:07:19.768 It was tolerated up to 1000 milligrams

NOTE Confidence: 0.902004587368421

01:07:19.768 --> 01:07:21.445 per meter squared when administered  
NOTE Confidence: 0.902004587368421

01:07:21.445 --> 01:07:23.130 in combination with standard of  
NOTE Confidence: 0.902004587368421

01:07:23.130 --> 01:07:25.319 care and I plasma cell therapy,  
NOTE Confidence: 0.902004587368421

01:07:25.320 --> 01:07:27.546 and this was the patients recruited had  
NOTE Confidence: 0.902004587368421

01:07:27.546 --> 01:07:29.900 cardiac stage one through three a disease.  
NOTE Confidence: 0.909779082380952

01:07:32.020 --> 01:07:34.012 So 25 patients are included in  
NOTE Confidence: 0.909779082380952

01:07:34.012 --> 01:07:35.761 the analysis that was presented  
NOTE Confidence: 0.909779082380952

01:07:35.761 --> 01:07:38.260 at ASH and all had a confirmed  
NOTE Confidence: 0.909779082380952

01:07:38.260 --> 01:07:40.681 diagnosis avail amyloid at least a  
NOTE Confidence: 0.909779082380952

01:07:40.681 --> 01:07:42.666 six month minimum life expectancy.  
NOTE Confidence: 0.909779082380952

01:07:42.670 --> 01:07:44.270 And there were the patients  
NOTE Confidence: 0.909779082380952

01:07:44.270 --> 01:07:45.870 recruited were not planned for  
NOTE Confidence: 0.909779082380952

01:07:45.933 --> 01:07:47.533 autologous stem cell transplant in  
NOTE Confidence: 0.909779082380952

01:07:47.533 --> 01:07:49.749 the first six months of the study.  
NOTE Confidence: 0.909779082380952

01:07:49.750 --> 01:07:51.892 Patients were excluded if they had  
NOTE Confidence: 0.909779082380952

01:07:51.892 --> 01:07:53.320 concomitant multiple myeloma or



NOTE Confidence: 0.909779082380952  
01:07:53.380 --> 01:07:55.330 symptomatic orthostatic hypotension.  
NOTE Confidence: 0.909779082380952  
01:07:55.330 --> 01:07:56.850 And subjects received four  
NOTE Confidence: 0.909779082380952  
01:07:56.850 --> 01:07:58.370 weekly doses of Cal.  
NOTE Confidence: 0.909779082380952  
01:07:58.370 --> 01:08:00.605 101 and then biweekly dosing  
NOTE Confidence: 0.909779082380952  
01:08:00.605 --> 01:08:01.946 until clinical deterioration,  
NOTE Confidence: 0.909779082380952  
01:08:01.950 --> 01:08:02.793 toxicity or death,  
NOTE Confidence: 0.909779082380952  
01:08:02.793 --> 01:08:05.121 and as you can see in the schema  
NOTE Confidence: 0.909779082380952  
01:08:05.121 --> 01:08:07.186 in the top left of this slide,  
NOTE Confidence: 0.909779082380952  
01:08:07.190 --> 01:08:09.353 Part B of the study added daratumumab  
NOTE Confidence: 0.909779082380952  
01:08:09.353 --> 01:08:11.327 to the standard of care therapy  
NOTE Confidence: 0.909779082380952  
01:08:11.327 --> 01:08:12.967 based on the Andromeda trial.  
NOTE Confidence: 0.909779082380952  
01:08:12.970 --> 01:08:14.692 The mean age of the study  
NOTE Confidence: 0.909779082380952  
01:08:14.692 --> 01:08:16.086 group was 65.2 years,  
NOTE Confidence: 0.909779082380952  
01:08:16.086 --> 01:08:18.126 with the majority being male.  
NOTE Confidence: 0.909779082380952  
01:08:18.130 --> 01:08:20.140 80% of the patients had cardiac  
NOTE Confidence: 0.909779082380952

01:08:20.140 --> 01:08:21.990 amyloid involvement in 92% of  
NOTE Confidence: 0.909779082380952

01:08:21.990 --> 01:08:23.670 these individuals had cardiac  
NOTE Confidence: 0.909779082380952

01:08:23.670 --> 01:08:26.199 stage two or three a disease.  
NOTE Confidence: 0.909779082380952

01:08:26.200 --> 01:08:27.870 96% of patients had treatment  
NOTE Confidence: 0.909779082380952

01:08:27.870 --> 01:08:29.540 emergent adverse events with the  
NOTE Confidence: 0.909779082380952

01:08:29.600 --> 01:08:31.184 most common ones being listed in  
NOTE Confidence: 0.909779082380952

01:08:31.184 --> 01:08:33.000 the table at the bottom right.  
NOTE Confidence: 0.909779082380952

01:08:33.000 --> 01:08:33.328 Here,  
NOTE Confidence: 0.909779082380952

01:08:33.328 --> 01:08:35.624 the only 24% of those were felt  
NOTE Confidence: 0.909779082380952

01:08:35.624 --> 01:08:38.125 to be related to treatment and  
NOTE Confidence: 0.909779082380952

01:08:38.125 --> 01:08:40.335 most adverse events were were  
NOTE Confidence: 0.909779082380952

01:08:40.335 --> 01:08:43.160 low grade with the the thought  
NOTE Confidence: 0.909779082380952

01:08:43.160 --> 01:08:46.040 that the cardiac safety of this  
NOTE Confidence: 0.909779082380952

01:08:46.134 --> 01:08:49.879 agent was really more warm or well  
NOTE Confidence: 0.909779082380952

01:08:49.879 --> 01:08:52.320 tolerated than expected overall.  
NOTE Confidence: 0.909779082380952

01:08:52.320 --> 01:08:54.198 So though there was a limited

NOTE Confidence: 0.909779082380952

01:08:54.198 --> 01:08:55.137 number of patients,

NOTE Confidence: 0.909779082380952

01:08:55.140 --> 01:08:57.996 18 of the 20 patients with cardiac

NOTE Confidence: 0.909779082380952

01:08:57.996 --> 01:08:59.625 involvement showed stability or

NOTE Confidence: 0.909779082380952

01:08:59.625 --> 01:09:02.273 improvement based on the NT Pro BNP values,

NOTE Confidence: 0.909779082380952

01:09:02.280 --> 01:09:05.944 with some of the 35% of those who responded,

NOTE Confidence: 0.909779082380952

01:09:05.944 --> 01:09:07.297 reportedly showing dramatic

NOTE Confidence: 0.909779082380952

01:09:07.297 --> 01:09:09.489 improvement and similarly eight of

NOTE Confidence: 0.909779082380952

01:09:09.489 --> 01:09:11.424 nine patients with renal involvement

NOTE Confidence: 0.909779082380952

01:09:11.424 --> 01:09:13.310 at baseline achieved renal responses

NOTE Confidence: 0.909779082380952

01:09:13.310 --> 01:09:15.556 with more than 30% reduction in

NOTE Confidence: 0.909779082380952

01:09:15.556 --> 01:09:17.846 their proteinuria and some patients

NOTE Confidence: 0.909779082380952

01:09:17.846 --> 01:09:20.619 having very rapid and deep responses.

NOTE Confidence: 0.909779082380952

01:09:20.620 --> 01:09:21.457 So to summarize,

NOTE Confidence: 0.909779082380952

01:09:21.457 --> 01:09:24.050 Cal 101 appears to be very well tolerated.

NOTE Confidence: 0.909779082380952

01:09:24.050 --> 01:09:25.615 And safe in combination with

NOTE Confidence: 0.909779082380952

01:09:25.615 --> 01:09:27.556 our standard of care anti plasma  
NOTE Confidence: 0.909779082380952

01:09:27.556 --> 01:09:29.146 cell therapy which is now.  
NOTE Confidence: 0.909779082380952

01:09:29.150 --> 01:09:31.145 There are two memorable plus V CD  
NOTE Confidence: 0.909779082380952

01:09:31.145 --> 01:09:33.677 and it has yielded cardiac and renal  
NOTE Confidence: 0.909779082380952

01:09:33.677 --> 01:09:36.089 responses in a majority of patients.  
NOTE Confidence: 0.909779082380952

01:09:36.090 --> 01:09:37.752 Cal 101 is now being studied  
NOTE Confidence: 0.909779082380952

01:09:37.752 --> 01:09:38.860 in phase three trials.  
NOTE Confidence: 0.909779082380952

01:09:38.860 --> 01:09:41.030 For patients with Mayo stage  
NOTE Confidence: 0.909779082380952

01:09:41.030 --> 01:09:43.990 3/8 and also stage 3B disease.  
NOTE Confidence: 0.909779082380952

01:09:43.990 --> 01:09:46.085 Cardiac disease which was previously  
NOTE Confidence: 0.909779082380952

01:09:46.085 --> 01:09:49.027 excluded from this and from a patients  
NOTE Confidence: 0.909779082380952

01:09:49.027 --> 01:09:50.962 that were previously excluded from  
NOTE Confidence: 0.909779082380952

01:09:50.962 --> 01:09:53.499 this and from the Andromeda trial.  
NOTE Confidence: 0.909779082380952

01:09:53.500 --> 01:09:56.176 So I will stop there and.  
NOTE Confidence: 0.909779082380952

01:09:56.180 --> 01:09:58.770 We will move to questions and answers.  
NOTE Confidence: 0.825972825714286

01:10:01.270 --> 01:10:03.714 OK, thank you everyone

NOTE Confidence: 0.825972825714286  
01:10:03.714 --> 01:10:05.547 for great presentations.  
NOTE Confidence: 0.825972825714286  
01:10:05.550 --> 01:10:06.982 I will start by asking know  
NOTE Confidence: 0.825972825714286  
01:10:06.982 --> 01:10:08.620 far could you tell us your  
NOTE Confidence: 0.825972825714286  
01:10:08.682 --> 01:10:10.367 perspective on how would you  
NOTE Confidence: 0.825972825714286  
01:10:10.367 --> 01:10:12.445 envision CAR T cell therapies in  
NOTE Confidence: 0.825972825714286  
01:10:12.445 --> 01:10:14.431 the coming years in the future  
NOTE Confidence: 0.825972825714286  
01:10:14.431 --> 01:10:15.880 for transplant eligible patients?  
NOTE Confidence: 0.828394885714286  
01:10:16.850 --> 01:10:18.327 I think it's a very good question.  
NOTE Confidence: 0.828394885714286  
01:10:18.330 --> 01:10:20.074 I mean, many studies are looking at that.  
NOTE Confidence: 0.828394885714286  
01:10:20.080 --> 01:10:22.378 I think moving clearly you see  
NOTE Confidence: 0.828394885714286  
01:10:22.378 --> 01:10:24.354 unbelievable responses in patients who  
NOTE Confidence: 0.828394885714286  
01:10:24.354 --> 01:10:26.269 typically didn't respond like this.  
NOTE Confidence: 0.828394885714286  
01:10:26.270 --> 01:10:28.406 So one could imagine even better  
NOTE Confidence: 0.828394885714286  
01:10:28.406 --> 01:10:30.210 responses and longer duration of  
NOTE Confidence: 0.828394885714286  
01:10:30.210 --> 01:10:32.422 responses and more fit patients with a  
NOTE Confidence: 0.828394885714286

01:10:32.422 --> 01:10:34.610 better immune system and given up front.

NOTE Confidence: 0.828394885714286

01:10:34.610 --> 01:10:36.815 So then I think this is what?

NOTE Confidence: 0.828394885714286

01:10:36.820 --> 01:10:37.960 The future is going to be.

NOTE Confidence: 0.828394885714286

01:10:37.960 --> 01:10:40.739 It's going to be evaluated upfront in

NOTE Confidence: 0.828394885714286

01:10:40.739 --> 01:10:43.300 transplant eligible and ineligible patients.

NOTE Confidence: 0.76973582

01:10:44.560 --> 01:10:46.336 Right, and can you comment either?

NOTE Confidence: 0.76973582

01:10:46.340 --> 01:10:49.876 Either the M car or the cell to cell.

NOTE Confidence: 0.76973582

01:10:49.880 --> 01:10:52.778 Were there any any subjects included

NOTE Confidence: 0.76973582

01:10:52.778 --> 01:10:54.920 with them? CNS involvement.

NOTE Confidence: 0.80907222

01:10:56.940 --> 01:11:01.129 No CNS involvement. These are excluded.

NOTE Confidence: 0.881572445

01:11:03.290 --> 01:11:04.838 I think within our practice we

NOTE Confidence: 0.881572445

01:11:04.838 --> 01:11:06.779 have had patients who had a CNS

NOTE Confidence: 0.881572445

01:11:06.779 --> 01:11:08.204 enrollment and they've been treated.

NOTE Confidence: 0.881572445

01:11:08.210 --> 01:11:09.410 These are anecdotal,

NOTE Confidence: 0.881572445

01:11:09.410 --> 01:11:11.130 but I'm sure it's evolving.

NOTE Confidence: 0.870017306842105

01:11:14.760 --> 01:11:17.320 I also wanted to ask a question of

NOTE Confidence: 0.870017306842105  
01:11:17.320 --> 01:11:19.617 doctor Browning Sobrino how how do  
NOTE Confidence: 0.870017306842105  
01:11:19.617 --> 01:11:21.607 you approach treating your frontline.  
NOTE Confidence: 0.870017306842105  
01:11:21.610 --> 01:11:23.210 A Lloyd doses patients.  
NOTE Confidence: 0.771040846  
01:11:24.600 --> 01:11:25.280 Yeah, I think you know.  
NOTE Confidence: 0.771040846  
01:11:25.280 --> 01:11:27.224 I think that's that's an important  
NOTE Confidence: 0.771040846  
01:11:27.224 --> 01:11:28.915 question because of the role  
NOTE Confidence: 0.771040846  
01:11:28.915 --> 01:11:30.590 that that autologous stem cell  
NOTE Confidence: 0.771040846  
01:11:30.590 --> 01:11:32.440 transplant has played in amyloid.  
NOTE Confidence: 0.771040846  
01:11:32.440 --> 01:11:33.700 In terms of, you know,  
NOTE Confidence: 0.771040846  
01:11:33.700 --> 01:11:35.188 improve improvement in progression,  
NOTE Confidence: 0.771040846  
01:11:35.188 --> 01:11:36.676 free and overall survival,  
NOTE Confidence: 0.771040846  
01:11:36.680 --> 01:11:39.192 but I think now you know the the  
NOTE Confidence: 0.771040846  
01:11:39.192 --> 01:11:40.661 hematologic and organ response  
NOTE Confidence: 0.771040846  
01:11:40.661 --> 01:11:42.591 rates in Andromeda with their  
NOTE Confidence: 0.771040846  
01:11:42.591 --> 01:11:44.540 VCD are really impressive,  
NOTE Confidence: 0.771040846

01:11:44.540 --> 01:11:46.180 and I think importantly,  
NOTE Confidence: 0.771040846

01:11:46.180 --> 01:11:47.820 the responses occur rapidly,  
NOTE Confidence: 0.771040846

01:11:47.820 --> 01:11:49.860 which is an important in terms  
NOTE Confidence: 0.771040846

01:11:49.860 --> 01:11:51.220 of subsequent organ responses.  
NOTE Confidence: 0.771040846

01:11:51.220 --> 01:11:53.642 So I would say that you know,  
NOTE Confidence: 0.771040846

01:11:53.642 --> 01:11:54.666 I think in in.  
NOTE Confidence: 0.771040846

01:11:54.670 --> 01:11:56.542 Most of our patients we should  
NOTE Confidence: 0.771040846

01:11:56.542 --> 01:11:58.571 use Darragh VCD and then the  
NOTE Confidence: 0.771040846

01:11:58.571 --> 01:11:59.995 question becomes of those  
NOTE Confidence: 0.771040846

01:11:59.995 --> 01:12:02.450 patients who should go on to get  
NOTE Confidence: 0.771040846

01:12:02.450 --> 01:12:04.175 autologous stem cell transplant.  
NOTE Confidence: 0.771040846

01:12:04.175 --> 01:12:06.676 And I think what we and other  
NOTE Confidence: 0.771040846

01:12:06.676 --> 01:12:08.171 centers have adopted is in  
NOTE Confidence: 0.771040846

01:12:08.171 --> 01:12:10.140 patients who have achieved a  
NOTE Confidence: 0.771040846

01:12:10.140 --> 01:12:11.349 hematologic complete response.  
NOTE Confidence: 0.771040846

01:12:11.350 --> 01:12:13.644 The thought is that there may



NOTE Confidence: 0.771040846

01:12:13.644 --> 01:12:15.514 not be additional benefit to

NOTE Confidence: 0.771040846

01:12:15.514 --> 01:12:17.438 to auto transplant and that

NOTE Confidence: 0.771040846

01:12:17.438 --> 01:12:19.034 those patients have transplant

NOTE Confidence: 0.771040846

01:12:19.034 --> 01:12:21.061 available available to them if

NOTE Confidence: 0.771040846

01:12:21.061 --> 01:12:22.896 they were to relapse subsequently.

NOTE Confidence: 0.4249425

01:12:24.090 --> 01:12:27.510 Great and a question for Terry

NOTE Confidence: 0.931962126

01:12:27.510 --> 01:12:28.890 with this in this competing

NOTE Confidence: 0.931962126

01:12:28.890 --> 01:12:31.386 environment of therapies for

NOTE Confidence: 0.931962126

01:12:31.386 --> 01:12:33.680 relapsed refractory myeloma. Where

NOTE Confidence: 0.925460425

01:12:33.690 --> 01:12:35.018 where do you position

NOTE Confidence: 0.672480366666667

01:12:36.250 --> 01:12:38.629 by tone? Approach.

NOTE Confidence: 0.75371771

01:12:41.160 --> 01:12:44.490 Yeah, and that's a good question.

NOTE Confidence: 0.75371771

01:12:44.490 --> 01:12:46.202 So it's you know, a lot of these

NOTE Confidence: 0.75371771

01:12:46.202 --> 01:12:47.727 trials are still in early phase,

NOTE Confidence: 0.75371771

01:12:47.730 --> 01:12:50.410 and they're still in really

NOTE Confidence: 0.75371771

01:12:50.410 --> 01:12:52.018 heavily treated patients.  
NOTE Confidence: 0.75371771

01:12:52.020 --> 01:12:53.424 So I think we don't know  
NOTE Confidence: 0.75371771

01:12:53.424 --> 01:12:54.757 which ones gonna win, right?  
NOTE Confidence: 0.75371771

01:12:54.757 --> 01:12:57.933 All the bispecific seem to have very similar  
NOTE Confidence: 0.75371771

01:12:57.933 --> 01:13:00.457 toxicity profiles as far as CRS minimal.  
NOTE Confidence: 0.75371771

01:13:00.460 --> 01:13:01.968 I can't hematological toxicity.  
NOTE Confidence: 0.75371771

01:13:01.968 --> 01:13:04.987 I do see the by specifics being moved  
NOTE Confidence: 0.75371771

01:13:04.987 --> 01:13:07.739 into that one to three lines of therapy,  
NOTE Confidence: 0.75371771

01:13:07.740 --> 01:13:09.660 especially if we can improve  
NOTE Confidence: 0.75371771

01:13:09.660 --> 01:13:11.580 upon the duration of response.  
NOTE Confidence: 0.75371771

01:13:11.580 --> 01:13:12.744 Similar to kind of what never  
NOTE Confidence: 0.75371771

01:13:12.744 --> 01:13:13.720 was saying with the car.  
NOTE Confidence: 0.75371771

01:13:13.720 --> 01:13:15.672 T and then I believe the question of  
NOTE Confidence: 0.75371771

01:13:15.672 --> 01:13:17.547 car T versus advice specifics really  
NOTE Confidence: 0.75371771

01:13:17.547 --> 01:13:20.180 gonna come up and the vice specifics.  
NOTE Confidence: 0.75371771

01:13:20.180 --> 01:13:22.350 Maybe for those individuals who really can't.

NOTE Confidence: 0.75371771

01:13:22.350 --> 01:13:25.530 Wait for the car tne treatment

NOTE Confidence: 0.75371771

01:13:25.530 --> 01:13:27.650 sooner rather than later,

NOTE Confidence: 0.75371771

01:13:27.650 --> 01:13:29.756 as a majority of their responses

NOTE Confidence: 0.75371771

01:13:29.756 --> 01:13:32.410 were seen within a month of therapy.

NOTE Confidence: 0.75371771

01:13:32.410 --> 01:13:34.018 And so I think it's going to depend

NOTE Confidence: 0.75371771

01:13:34.018 --> 01:13:35.667 on how extensive the disease is,

NOTE Confidence: 0.75371771

01:13:35.670 --> 01:13:37.386 how quickly a patient needs therapy,

NOTE Confidence: 0.75371771

01:13:37.390 --> 01:13:39.134 and how fit they are overall.

NOTE Confidence: 0.75371771

01:13:39.134 --> 01:13:42.410 But I think we have a question in the

NOTE Confidence: 0.75371771

01:13:42.493 --> 01:13:44.666 chat if you see it for Doctor Gore shot.

NOTE Confidence: 0.7808837233333333

01:13:45.470 --> 01:13:49.170 So the question asks outside

NOTE Confidence: 0.7808837233333333

01:13:49.170 --> 01:13:51.920 of the clinical trial context,

NOTE Confidence: 0.855404685

01:13:51.950 --> 01:13:54.476 when would you use Dara?

NOTE Confidence: 0.855404685

01:13:54.476 --> 01:13:56.740 RVD in clinical setting? General

NOTE Confidence: 0.899714886666667

01:13:56.790 --> 01:13:57.600 standard of care.

NOTE Confidence: 0.70899399875

01:14:00.290 --> 01:14:01.984 He said, is that meant to be  
NOTE Confidence: 0.70899399875

01:14:01.984 --> 01:14:04.876 Dara, RVD, or this is our VP.  
NOTE Confidence: 0.742161594

01:14:05.470 --> 01:14:08.340 Well I guess spread needs Prednisone,  
NOTE Confidence: 0.742161594

01:14:08.340 --> 01:14:12.340 Prednisone or dexamethasone platinum.  
NOTE Confidence: 0.949571865

01:14:12.340 --> 01:14:14.716 So I I think that I mean look.  
NOTE Confidence: 0.949571865

01:14:14.720 --> 01:14:16.600 Obviously we have a couple of options here.  
NOTE Confidence: 0.949571865

01:14:16.600 --> 01:14:18.497 You know, like we discuss VRD backbone.  
NOTE Confidence: 0.949571865

01:14:18.500 --> 01:14:19.661 Well established, efficacious.  
NOTE Confidence: 0.949571865

01:14:19.661 --> 01:14:22.839 You know if you're if you're a little  
NOTE Confidence: 0.949571865

01:14:22.839 --> 01:14:24.849 more concerned about high risk,  
NOTE Confidence: 0.949571865

01:14:24.850 --> 01:14:28.794 there are some centers that would go KRd,  
NOTE Confidence: 0.949571865

01:14:28.800 --> 01:14:33.967 but to me I think that the quadruple it we  
NOTE Confidence: 0.949571865

01:14:33.967 --> 01:14:38.076 see the durable improvement in response is,  
NOTE Confidence: 0.949571865

01:14:38.080 --> 01:14:39.800 you know, approaching the 24  
NOTE Confidence: 0.949571865

01:14:39.800 --> 01:14:41.176 month of maintenance therapy.  
NOTE Confidence: 0.949571865

01:14:41.180 --> 01:14:43.180 So if a patient has.

NOTE Confidence: 0.949571865

01:14:43.180 --> 01:14:47.415 If a patient can tolerate a quadruplet.

NOTE Confidence: 0.949571865

01:14:47.420 --> 01:14:48.360 You know whether they're

NOTE Confidence: 0.949571865

01:14:48.360 --> 01:14:49.535 standard risk or high risk.

NOTE Confidence: 0.949571865

01:14:49.540 --> 01:14:51.210 I would strongly consider that.

NOTE Confidence: 0.781034380344828

01:14:53.450 --> 01:14:56.096 Yeah, I agree, I think the quadruplet

NOTE Confidence: 0.781034380344828

01:14:56.096 --> 01:14:57.677 therapies for monoclonal antibody

NOTE Confidence: 0.781034380344828

01:14:57.677 --> 01:14:59.597 backbone are entering the frontline

NOTE Confidence: 0.781034380344828

01:14:59.597 --> 01:15:02.274 care and with more and more data

NOTE Confidence: 0.781034380344828

01:15:02.274 --> 01:15:04.428 accumulating and data maturing to show.

NOTE Confidence: 0.781034380344828

01:15:04.430 --> 01:15:08.160 So far it's the murded superiority.

NOTE Confidence: 0.781034380344828

01:15:08.160 --> 01:15:10.840 But we know from separate trials that

NOTE Confidence: 0.781034380344828

01:15:10.840 --> 01:15:12.965 MRD negativity is associated translates

NOTE Confidence: 0.781034380344828

01:15:12.965 --> 01:15:15.029 into much improved progression,

NOTE Confidence: 0.781034380344828

01:15:15.030 --> 01:15:17.490 free survival and overall survival.

NOTE Confidence: 0.781034380344828

01:15:17.490 --> 01:15:21.044 So I think the field is really evolving and

NOTE Confidence: 0.781034380344828

01:15:21.044 --> 01:15:24.196 which one will emerge as the next favorite.  
NOTE Confidence: 0.781034380344828

01:15:24.200 --> 01:15:26.060 Therapy is a big question.  
NOTE Confidence: 0.781034380344828

01:15:26.060 --> 01:15:28.130 I think one has to consider  
NOTE Confidence: 0.781034380344828

01:15:28.130 --> 01:15:31.198 that high risk patients.  
NOTE Confidence: 0.781034380344828

01:15:31.200 --> 01:15:33.224 You know situation may still not be optimal,  
NOTE Confidence: 0.781034380344828

01:15:33.230 --> 01:15:35.533 so further work needs to be done  
NOTE Confidence: 0.781034380344828

01:15:35.533 --> 01:15:37.770 for the high risk population.  
NOTE Confidence: 0.781034380344828

01:15:37.770 --> 01:15:40.426 Say I think it's hour and 15 minutes,  
NOTE Confidence: 0.781034380344828

01:15:40.430 --> 01:15:42.356 which is the time we provisioned  
NOTE Confidence: 0.781034380344828

01:15:42.356 --> 01:15:43.319 for this seminar.  
NOTE Confidence: 0.781034380344828

01:15:43.320 --> 01:15:44.706 I don't see any other questions.  
NOTE Confidence: 0.781034380344828

01:15:44.710 --> 01:15:46.138 Any other discussion from  
NOTE Confidence: 0.781034380344828

01:15:46.138 --> 01:15:47.990 the from the panelists here?  
NOTE Confidence: 0.9049301275

01:15:51.000 --> 01:15:52.836 If not, we will conclude and thank you very  
NOTE Confidence: 0.9049301275

01:15:52.836 --> 01:15:55.370 much for participation. Everyone, thanks.  
NOTE Confidence: 0.92483282

01:15:56.280 --> 01:15:58.000 Thank you everyone. Thank you.